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Abstract
The aims o f this thesis were to: (i) determine the regulatory properties o f human 
fo llicu lar flu id  (FF) on the activities and expression o f 11(3HSD, (ii)  investigate the 
effects o f  progesterone on llp H S D  activity and expression ( iii)  investigate the 
effects o f  prostaglandins on basal and endocrine-stimulated llp H S D  activity and 
expression (iv) to predict the topology and tertiary structure o f 11 p H S D l. Human FF 
contains hydrophilic and hydrophobic compounds that stimulate and inhibit, 
respectively, the NADP(H)-dependent activities o f 1 lp H S D l. The predominant lipid 
inhibitors o f  11(3HSD1 in FF are unlikely to be steroids or prostaglandins, and the 
effects o f  the FF components on enzyme activities occur without changes in 
lip H S D l protein expression. Inhibition o f progesterone production by 
aminoglutethimide increased 1lpHSD activities, without affecting 1 lpH S D l protein 
expression in human granulosa-lutein cells. Pharmacological inhibitors o f 
prostaglandin-H synthase (PGHS)-2 (meclofenamic acid (M A ) and NS-398) 
decreased cortisol-cortisone inter-conversion by up to 50%, suggesting that 
prostaglandins may stimulate ovarian llp H S D  activities in a paracrine/autocrine 
manner. Furthermore, PGHS-2 inhibitors prevented human chorionic gonadotrophin 
(hCG) and IL - lp  from stimulating llp H S D  activities in human granulosa-lutein 
cells, implicating eicosanoids in the stimulation o f ovarian llp H S D  by 
gonadotrophins and cytokines. Since M A and NS-398 had no effect on 1 lpH SD l 
protein expression, the stimulation o f 11 pHSD activities by eicosanoids occurs at the 
post-translational level. Finally, the structure o f 1 lp H S D l protein was modelled to 
develop molecular mechanisms by which prostaglandins, gonadotrophins and 
cytokines might regulate enzyme activities. Although the primary sequence o f
I lp H S D l, which is highly conserved across 10 mammalian species, contains several 
consensus phosphorylation sites for serine/threonine and tyrosine kinases, models o f
I I  pHSDl topology predict that most phosphorylation sites would lie in the lumen o f 
the endoplasmic reticulum. 1 lpH S D l includes hydrophobic a-helices neighbouring 
the active site, which may provide regions for the allosteric control o f glucocorticoid 
metabolism by progesterone and eicosanoids in ovarian cells.
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‘Research is what I ’m doing when I don’t know what it is I’m doing’
Wemher Von Braun (1912-1977)
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Chapter 1- General Introduction
Approximately 1 in 7 couples o f reproductive age are infertile in the UK [Templeton 
et al., 1991] and w ill require assisted reproductive technology in order to conceive a 
child. It is therefore essential to establish the fundamental mechanisms controlling 
ovarian physiology w ith a view to advancing reproductive technologies. The 
investigations reported in this thesis were designed to enhance our understanding o f 
the regulatory mechanisms controlling ovarian glucocorticoid metabolism at a 
cellular level.
1.1 The Human Ovary
1.1.1 Formation o f the human ovary
Until the 6th week o f human embryo development, the male and female gonads are 
identical. It is at this stage o f human foetal development that the Y  chromosome 
determination o f gonadal sex occurs through the expression o f the SRY gene, which 
initiates Sertoli cell development and proliferation o f male sex cords. The female 
gonads do not express the SRY gene and so remain indifferent to its effects. In the 
absence o f SRY the Mullerian ducts differentiate into the Fallopian tubes/oviducts, 
and the external female genitalia form. About the time o f the second trimester, the 
ovary and ovarian primordial follicles develop, with primordial fo llic le numbers 
equalling approximately 6 m illion. M itotic division o f oogonia ceases before birth, 
and under the control o f  the meiotic initiation factor, the oogonia undergo the first 
meiotic division to become primary oocytes. Oogenesis is arrested at prophase I, at 
the dictyate stage o f the first meiotic division. A t birth the human ovaries contain
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approximately 2 m illion primordial follicles, which by puberty decreases to 
approximately 500,000 primordial follicles [Johnson and Everitt 2000]. Recent 
studies by Johnson et al. [2004] have challenged the model that there is a fixed pool 
o f primordial follicles at birth, and have presented data in adult mice to suggest that 
germ stem cells are able to regenerate themselves in adult life.
1.1.2 The Ovarian cycle: Folliculogenesis. Ovulation and Luteinisation
Before puberty, the ovary is active, with follicles growing and undergoing atresia. A t 
puberty, the process o f folliculogenesis activates ovarian follicles to begin further 
development leading to ovulation o f the oocyte. Each ovarian cycle can be split into 
3 distinct phases, the fo llicular phase, the ovulatory phase, and the luteal phase. This 
cyclic pattern is controlled by interactions between the hypothalamus, (through the 
release o f gonadotrophin-releasing hormone (GnRH)), anterior pituitary, (through 
the release o f gonadotrophins under the control o f  GnRH [Fink, 1979]), and the 
ovaries [reviewed by McGee and Hsueh 2000].
1.1.2.1 The Follicular Phase
Primordial follicles are characterised as containing an oocyte surrounded by a 
flattened layer o f  granulosa cells. As the follic le develops, the granulosa cells start to 
divide and undergo morphological changes forming a cuboidal phenotype. A t this 
stage the fo llic le  is referred to as a primary follicle. The initial recruitment o f 
primordial follicles and subsequent growth to the pre-antral stage is independent o f 
circulating gonadotrophins. Resting follicles are thought to be under the control o f 
inhibitory and stimulatory intra-ovarian factors that are thought to suppress or
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initiate primordial fo llic le  growth respectively. The mechanism o f recruitment o f 
primordial follic les remains unclear. However, the k it ligand has been implicated in 
the in itia l recruitment and formation o f the primary fo llic le [Yoshida et al., 1997]. 
Growth differentiation factor-9 (GDF-9), a peptide secreted by the oocyte, has also 
been implicated in primary fo llic le development. Follicles lacking GDF-9 have been 
shown not to proceed beyond the primary fo llic le stage [Aaltonen et al., 1999].
Development o f  the primary fo llic le into the secondary fo llic le  involves the growth 
o f the oocyte, and further cell growth and differentiation. The undifferentiated cells 
surrounding the granulosa cells differentiate into thecal cells. These cells condense 
around the fo llic le  forming 2 layers, the theca interna and the theca externa, which 
are separated from the granulosa cells by a basement membrane. The vascular supply 
infiltrates the thecal cell layer, but is excluded from the granulosa cells.
Granulosa-oocyte communication has been shown to be essential for oocyte 
development. Gap junctions exist between granulosa cells and the oocyte to mediate 
this communication. For example, connexin 37 is an important gap junction protein, 
essential for oocyte development [Simon et al., 1997]. Paracrine communications 
between granulosa cells and the surrounding theca cell layers have also been shown 
to be important for the growth o f pre-antral follicles. Recent studies have implicated 
fibroblast growth factor-7 as a paracrine factor secreted from theca cells that 
enhances pre-antral fo llicular growth [McGee et al., 1999]. As granulosa cells 
proliferate a viscous liquid forms between the cells in droplet form. These droplets 
coalesce to form a single flu id-filled follicular antrum. A t this stage the follicle can 
be described as an early antral follicle.
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The gonadotrophins, fo llic le stimulating hormone (FSH) and luteinising hormone 
(LH), are important trophic factors that control the proliferation, survival and 
recruitment o f  antral follicles. FSH is important for early antral fo llic le  development, 
inducing expression o f steroidogenic genes such as aromatase (CYP19), P450 
cholesterol side chain cleavage (P450CSCc? CYP11A) and the expression o f LH 
receptors. Moreover, treatment o f early antral follicles w ith FSH has been shown to 
prevent the onset o f  follicular atresia through apoptosis [Chun et al., 1996]. 
Oestrogens are important anti-apoptotic signals in early antral development, the 
production o f which is FSH dependent.
The 2-cell, 2-gonadotrophin model o f oestradiol production reveals a functional 
synergy between LH and FSH. LH stimulates the synthesis o f  androstenedione in 
theca cells, forming the substrate for granulosa cell oestradiol synthesis. FSH 
stimulates aromatisation o f androgens in granulosa cells to form oestrogens. The 
actions o f FSH on granulosa cells are further enhanced by insulin-like growth factor- 
I (IGF-I) [Richards et al., 2002] (this shall be covered more extensively in section 
1.2).
The action o f LH  on the production o f theca cell androgens can be mimicked by 
several paracrine factors. Members o f the IGF subtype and transforming growth 
factor-(3 (TGFP) superfamily have been shown to have important roles in this 
process. In vitro, IGF-1 and insulin can stimulate theca cells androgen synthesis 
[Barbieri et al., 1986]. IGF-II and IGF-binding proteins (IGFBPs) are thought to play 
a modulatory role in androgen production by thecal cells. FSH has been shown to
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stimulate IGF-I production by granulosa cells. Activins and inhibins also regulate 
theca androgen production [H illie r et al., 1991]. Inhibin can inhibit FSH production 
through negative feedback and has been speculated to be important in pre-ovulatory 
fo llic le  development [Adashi et al., 1991]. Activ in predominates in immature 
follicles, promoting FSH-induced mitosis and steroidogenic differentiation.
In mono-ovulatory mammals such as humans, only 1 fo llic le  is selected to achieve 
dominant fo llic le  status, with the other recruited follicles undergoing atresia. Atresia 
is thought to occur due to a number o f metabolic and /or genetic defects in the 
fo llic le  [reviewed by Moley and Schreiber, 1995]. Moreover, anti-apoptotic and pro- 
apopototic proteins have been shown to affect oocyte and primordial follicle 
numbers in the mouse ovary. Bcl2 knockout-mice studies have implicated these anti- 
apoptotic proteins in oocyte and primordial fo llic le survival. Bax knock-out mice 
studies have revealed its importance in ovarian somatic-cell death [reviewed by 
T illy , 1995]. However, the precise cellular mechanisms underlying atresia still 
remain unclear.
1.1.2.2 Ovulation
Following dominant fo llic le selection, the increase in oestradiol production (through 
the acquisition o f LH receptors by the granulosa cells o f  the dominant follicle) leads 
to a decline in FSH secretion. A t this stage, further fo llic le  growth becomes LH 
dependent. The further increase in oestradiol production causes a positive feed­
forward loop on the release o f FSH and LH from the anterior pituitary gland. This 
results in an increased pulsatile frequency o f LH and causes the mid-cycle
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gonadotrophin surge. The resulting increase in release o f  LH is thought to stimulate 
both physical and biochemical changes in the fo llic le through the induction o f gene 
expression [Richards et al., 1994; Tsafriri and Reich 1999, Espey and Richards
2002]. The biochemical changes include the up-regulation o f the progesterone 
receptor gene, and the induction o f prostaglandin H synthase 2 (PGHS2) gene 
expression. These changes in turn induce the expression o f matrix metalloproteinases 
(MMPs), synthesis o f  growth factors, and the recruitment o f inflammatory cells 
[Petrovska et al., 1992; Buksovsky et al., 1995; Brannstrom and Friden 1997], to 
mediate this inflammatory event o f  ovulation [Espey, 1980]. These changes result in 
fo llicular rupture, and expulsion o f the oocyte from the follicle. The expression o f 
glucocorticoid-metabolising 11(3 hydroxysteroid dehydrogenase enzymes are also 
regulated at the time o f ovulation; this w ill be discussed further in section 1.8 
[Tetsuka et al., 1997; 1999a]. Several structural changes are associated with 
ovulation, these include the degradation o f the extracellular matrix at the follicular 
apex, and vascularisation o f the follicle.
1.1.2.3 Follicular Fluid
The antrum o f the ovarian follicle, filled with an aqueous substance termed follicular 
flu id (FF), is formed during early folliculogenesis. FF is comprised o f many lipids, 
proteins, growth factors, respiratory substrates and various as yet undetermined 
factors (Sutton et al., 2003). The components o f FF are derived from serum exudate 
modified by secretions from both the granulosa cells and the oocyte (Sutton et al.,
2003). The basal lamina between the vascularised theca interna and the granulosa 
cells also acts a filtering system o f serum both on molecular weight (e.g. slowing
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entry o f  LD L into the follicular antrum) and on the basis o f  molecular charge 
(Rodgers et al., 2003). Coupled to this, channels exist between the granulosa cells 
which can potentially let in proteins with a molecular weight o f  up to 500 kDa 
(Rodgers et al., 2003).
As the mid-cycle surge o f LH occurs the fo llic le undergoes a number o f structural 
and functional changes, the result o f which lead to a change in follicular fluid 
composition. An increase in the angiogenic factor VEGF has been detected in FF 
follow ing the pre-ovulatory surge o f LH (Anasti et al, 1998). This promotes 
vascularisation coupled with an increase in vascular permeability o f  the follicle, 
resulting in an increase o f plasma influx into the FF. As a consequence, as ovulation 
approaches, the representation o f plasma proteins in FF increases. On the other hand, 
in the final stages o f folliculogenesis, LH and FSH exert the greatest action on the 
local ovarian synthesis o f both steroid and peptide hormones, such that these 
compounds (e.g. oestradiol, progesterone and inhibin) tend to be much more 
concentrated in the FF o f mature pre-ovulatory follicles than in plasma.
In the preovulatory follicle, LH also increases the production o f hyaluronan by the 
cumulus cells o f  the cumulus-oocyte complex. This loosens the hyaluronic acid 
matrix between neighbouring cumulus cells and so is essential for the normal 
expansion o f the cumulus-oocyte complex (Rodgers et al., 2003; Jessen and Odum
2003). Emerging literature has shown that the increase in basal lamina permeability 
is essential for the in flux into FF o f plasma proteins that are essential for hyaluronan 
formation. One such plasma protein, inter a-trypsin inhibitor, is thought to couple to 
hyaluronan and stabilise the extracellular matrix o f the cumulus-occyte complex
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(Jessen and Odum, 2003). Thus revealing the changes in fo llicu lar dynamics and FF 
composition that LH induces in the preovulatory follicle.
1.1.2.4 The Luteal Phase
Following ovulation, the remaining follicular cells undergo extensive remodelling to 
form the corpus luteum (CL). The process o f CL formation involves irreversible 
fo llicu lar remodelling with the theca and granulosa cells differentiating into a luteal 
phenotype. These cells become highly vascularised through proliferation o f 
capillaries from surrounding stromal cells, which penetrate the basal lamina [Duncan
2000]. Vascularisation is controlled by a number o f angiogenic factors including 
vascular endothelial growth factor (VEGF) and basic fibroblast growth factor 
(bFGF) [Gospodarowicz 1985; Reynolds et al., 1998]. These factors also induce 
endothelial cell migration. Many proteases are activated, such as MMPs, which alter 
the shape o f the forming CL.
During luteinisation, the expression o f a number o f genes and proteins associated 
w ith steroidogenesis occurs [Richards et al., 1998]. Examples o f such genes include 
components o f the cholesterol uptake and transport system such as steroidogenic 
acute regulatory (StAR) protein and sterol carrier protein 2 (SCP-2). As luteinisation 
occurs, the primate CL produces progesterone and oestradiol under the influence o f 
LH [Channing 1980]. Progesterone and oestradiol act in concert to inhibit 
gonadotrophin secretion from the pituitary, and therefore control the onset o f the 
next ovarian cycle. In response to progesterone production by the CL, the 
endometrium secretes nutrient factors to support an embryo should fertilisation occur
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[Spencer and Bazer 2002]. In the event o f fertilisation, the CL persists to maintain 
circulating progesterone concentrations until the placenta is established. 
Progesterone also acts to enhance the negative feedback effects o f  oestradiol and 
inhibin on FSH and LH release and to block the positive feedback effects o f 
oestradiol [Schaison and Couzinet 1991; Leung and Peng 1996].
In the absence o f fertilisation the CL regresses. The exact mechanisms controlling 
the lifespan o f  the CL and luteal regression remain unclear. A  number o f structural 
and functional changes are involved in CL regression. These include membrane 
breakdown as indicated by decreased membrane flu id ity  [Carlson et al., 1982; 
Greenhalgh 1990; Riley and Behrman 1991] coupled with an increase in 
phospholipase A 2 (PLA 2) activity [Sawada and Carlson 1991]. There are known 
luteolytic and luteotrophic factors such as prostaglandin (PG)F2a and PGE2 that can 
shorten or prolong the lifespan o f the CL respectively. The synthesis o f such 
eicosanoids are enhanced by the increase in PLA2 activity.
1.2 Ovarian Steroidogenesis
1.2.1 Cholesterol uptake and transport
Cholesterol is the precursor o f steroid biosynthesis. Cholesterol can be obtained from 
4 sources: as free cholesterol or cholesteryl esters from plasma lipoproteins, as 
intracellular cholesteryl esters stored in lipid droplets, as free cholesterol from the 
plasma membrane, or by de novo synthesis.
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Steroidogenic tissues, including the ovary, acquire cholesterol substrate primarily 
through the uptake o f plasma lipoproteins containing cholesteryl esters and free 
cholesterol. Three types o f lipoproteins have been identified: high density lipoprotein 
(HDL), low density lipoprotein (LDL) and very low density lipoprotein (VLDL) 
[Grummer and Carroll, 1988]. In humans, the primary source o f cholesterol is from 
LD L [Gwynne and Strauss, 1982], providing the majority o f  cholesterol for 
steroidogenesis.
Receptor-mediated endocytosis is the predominant mechanism through which LDL- 
derived cholesterol can enter cells [Rhainds and Brissette, 1999]. On internalisation 
in to the cell, the LD L receptor is either recycled to the plasma membrane or 
degraded. The resulting LD L particle is taken up by lysosomes, leading to 
degradation o f LD L and the liberation o f free cholesterol. On entering the cell, 
cholesterol can either be stored in its esterified form, or liberated from stored 
cholesteryl esters depending on the requirement o f the cell. There are 2 enzymes that 
control the equilibrium o f free and esterified cholesterol in the cell: acyl coenzyme A 
cholesterol acyltransferase (ACAT) and cholesterol esterase. AC AT favours the 
storage o f cholesterol in its esterised form converting free cholesterol to cholesteryl 
esters, and cholesterol esterase liberates free cholesterol from cholesteryl esters 
[F lint and Armstrong, 1973].
Once in the cell, in order for the first step o f steroidogenesis to occur, cholesterol 
needs to be transported from the cytoplasm through the outer mitochondrial 
membrane into the inner mitochondrial membrane, where cholesterol is converted to 
pregnenolone by cytochrome P450cscc (CYP11A). To transport cholesterol from the
34
cytosol to the mitochondria, methods o f facilitated transport are required due to the 
hydrophobic properties o f cholesterol. The cytoskeleton and sterol carrier protein 2 
(SCP2) are both thought to play a role in this process. Various constituent parts o f the 
cytoskeleton (e.g. tubulin) have been linked to increased steroidogenesis. It has been 
hypothesised that changes in cell shape can increase steroidogenesis through 
shortening the distance that cholesterol needs to travel to the mitochondria for 
conversion to pregnenolone. Studies in Y1 adrenocortical cells have shown that 
increased steroidogenesis is associated with changes in cell morphology, namely 
rounding o f the cells [Betz and Hall, 1987]. This evidence suggests the possible role 
o f cytoskeletal re-organisation in cholesterol transport.
SCP2 is an aqueous carrier protein that has been speculated to play a role in 
cholesterol transport. Studies have revealed that anti-SCP2 antibodies can decrease 
steroid synthesis [Chanderbhan et al., 1986]. SCP2 transcripts have been localised to 
the ovary, and trophic hormones that increase steroidogenesis have been shown to 
increase SCP2 gene expression [Rennert et al., 1991].
There are two main mechanisms o f cholesterol transport from the outer 
mitochondrial to the inner mitochondrial membrane. The peripheral benzodiazepine 
receptor (PBR) has been shown to be one mechanism that facilitates cholesterol 
transport. PBR expression is abundant in steroidogenic tissue, and in the ovary, the 
expression o f PBR has been shown to vary across the ovarian cycle, with maximal 
expression observed following ovulation [Gavish, 1995]. The ligand for PBR is 
diazepam-binding inhibitor (DBI), the binding o f which to PBR stimulates 
mitochondrial cholesterol transport [Bar-Ami et al., 1991]. Binding o f DBI to the
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PBR is essential for cholesterol transport, such that the depletion o f DBI has been 
shown to inhibit constitutive and hormone stimulated-steroidogenesis in Leydig cells 
[Boujrad et al., 1993].
StAR protein has also been implicated in mitochondrial cholesterol transport. StAR 
was first cloned by Clark et al. [1994] and numerous studies have since investigated 
its role in cholesterol transport. In humans, a mutation in the StAR gene results in a 
potentially lethal phenotype termed congenital lipoid adrenal hyperplasia [Lin et al.,
1995]. This results in a reduction o f gonadal and adrenal steroids. StAR knock-out 
mice studies also reveal a similar phenotype [Caron et al., 1997]. An explanation for 
the mechanisms by which StAR mediates cholesterol transport was provided by 
proposing that StAR targets cholesterol to the PBR, which then mediates cholesterol 
transport to the inner mitochondrial membrane [West et al., 2001].
1.2.2 Ovarian Steroidogenesis
The first step o f steroidogenesis is the conversion o f cholesterol to pregnenolone by 
P450CScc (Figure 1.1). This reaction takes place in the inner mitochondrial membrane 
and involves 3 reactions, the first 2 steps leading to the hydroxylation o f C22 and 
C20 o f cholesterol, and the third resulting in the cleavage o f the C20-C22 bond to 
yield the C21 product pregnenolone, and the C6 molecule, isocaproic acid [Burstein 
and Gut, 1971]. Each reaction utilises nicotinamide adenine dinucleotide phosphate 
(NA DPH) as a co-factor (Figure 1.1).
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Cholesterol 
CYP11Ai
3pHSD2
Pregnenolone ► Progesterone
CYP17 CYP21
*  3|3HSD2 ^
17a-Hydroxypregnenolone ► 17a-hydroxyprogesterone
C Y P 1 7^ CYP21 I
3(3HSD2
Dehydroepiandrosterone ► Androstenedione
C Y P 19^
17pHSD 
Oestrone ^  Oestradiol
F igure 1.1: Principle pathways o f  ovarian steroidogenesis. Blue script- m itochondrial 
reactions, red script- ER reactions.
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Once pregnenolone is formed, it leaves the inner mitochondrial membrane and 
moves to the smooth endoplasmic reticulum (ER) where it is converted to 
progesterone by type 2 3(3 hydroxysteroid dehydrogenase (3J3HSD2) [Mason et al.,
1998]. Progesterone synthesis occurs in two parts, the first involving the oxidation o f 
the 3-hydroxyl group o f pregnenolone, and the second involving the isomerisation o f 
the C5 double bond to yield a C4 double bond [Hall et al., 1984]. This reaction 
utilises nicotinamide adenine dinucleotide (NAD+) as a co-factor.
In the ovary, androgens can be formed from pregnenolone and progesterone. Both 
pregnenolone and progesterone can undergo 17a-hydroxylation, followed by 
cleavage o f the C l7,20 bond to form dehydroepiandrosterone (DHEA) and 
androstenedione respectively. Both the hydroxylations and lyase reactions are 
catalysed by a single enzyme, cytochrome P450cn (CYP17).
From the theca cells, androstenedione is transported to granulosa cells, where it 
undergoes aromatisation to form oestrone: a reaction catalysed by cytochrome 
P450arOm (CYP19). The weak oestrogen, oestrone, is subsequently converted to 
oestradiol by 17pHSDl. The aromatisation o f androgens to oestrogens in granulosa 
cells is controlled by FSH. The process o f thecal cell androgen production, and the 
subsequent conversion to oestrogens by granulosa cells is termed the 2-cell, 2- 
gonadotrophin hypothesis [H illie r et al., 1984; H illie r et al., 1994]. As noted in 
section 1.1.2, many intra-ovarian and paracrine factors have been implicated in the 
control o f this process including TGF-p, and IGFs [H illie r et al., 1994].
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Although the ovary does not express the CYP21 enzyme necessary for de novo 
synthesis o f  cortisol, it can generate cortisol from cortisone. The enzyme required for 
this reaction, an isoform o f 1 lpHSD is known to be expressed in human [Michael et 
al., 1997; Tetsuka et al., 1997; Smith et al., 1997; Ricketts et al., 1998; Smith et al.,
2000], bovine [Tetsuka et al., 2003] and rat [Tetsuka et al., 1999a] ovaries and 
appear to be differentially regulated across the ovarian cycle (see section 1.8).
1.3 Eicosanoids and Ovarian function
Eicosanoids are hydrophobic inflammatory molecules derived from arachidonic acid 
(A A ) and control ovarian function in a paracrine fashion. Eicosanoids have 
established roles in ovulation and in regulating the lifespan o f CL. However, before 
exploring these roles, the biosynthetic pathways o f eicosanoid synthesis w ill be 
outlined.
1.3.1 Prostaglandin Biosynthesis
A ll prostaglandins are comprised o f a prostanoic fatty acid skeleton. The position on 
the fatty acid skeleton at which the oxygen containing moieties occur confer the 
biological activity o f  each prostaglandin, with positions 9, 11, and 15 being the most 
significant positions in terms o f biological function. Three categories o f 
prostaglandins have been identified termed 1-, 2-, and 3- series prostaglandins. Each 
series differs in their degree o f saturation and is formed from different 
polyunsaturated fatty acid precursors.
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The most biologically important precursor for prostaglandins is A A  which is stored 
in cell membranes, esterified at the C2 position o f membrane phospholipids. Three 
alternative pathways control the release o f A A  from the lipid membrane: the 
phospholipase A 2 (PLA2) pathway, the phospholipase C (PLC) pathway, and the 
phospholipase D (PLD) pathway. Each pathway involves hydrolysis o f the 
phospholipid head-group to liberate AA.
The first step o f A A  conversion to prostaglandins is catalysed by isoforms o f the 
enzyme prostaglandin H synthase (PGHS, formerly named cyclo-oxygenase). This 
enzyme is a haem-containing protein that has 2 catalytic activities; a cyclo- 
oxygenase activity, and an endoperoxide synthase activity. The cyclo-oxgenase 
activity catalyses the addition o f 2 oxygen atoms to A A  to form PGG2. The 
endoperoxide synthase activity converts the hydroperoxy moiety o f PGG2 to a 
hydroxyl group, forming PGH2. Hence, PGHS represents the first irreversible step in 
the prostanoid biosynthetic pathway [reviewed by Smith et al., 1996].
To date, there are 3 cloned isoforms o f PGHS. PGHS3 is thought to be a splice 
variant o f PGHS1 and has been isolated from canine and human cerebral cortex, 
although little  is known about its function [Chandrasekharan et al., 2002]. Although 
functionally different, PGHS1 and PGHS2 have very similar structures. Both form 
homodimers, and are haem-containing, glycosylated, integral membrane proteins, 
sharing the same catalytic mechanism. Both PGHS1 and PGHS2 have the same 
affin ity for A A  (K m~ 5pM) [Barnett et al., 1994] with subtle differences in substrate 
fatty acid specificities and peroxide requirements [Laneuville et al., 1995]. Both 
PGHS1 and PGHS2 are anchored to the lumenal face o f the ER, lumenal surfaces o f
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the nuclear envelope and contiguous outer membrane o f the nuclear membrane. 
These enzymes attach to the lumenal leaflet o f  these specific membranes through the 
hydrophobic surfaces o f amphiphatic helices w ithin the protein structures o f the 
enzymes.
PGHS1 is a constitutive enzyme. It is ubiquitously expressed, and is typically 
expressed at constant levels throughout the cell cycle. The function o f PGHS1 
appears to be in maintaining renal functions and platelet function [reviewed by Smith 
et al., 1996]. In contrast PGHS2 is an inducible enzyme that is virtually undetectable 
in most tissues. However, rapid activation o f PGHS2 expression can be induced 
w ithin 2-6 hours o f hormone, growth factor or cytokine stimulation. Following 
induction, PGHS2 mRNA expression has been detected in many tissues including 
ovarian follicles [Sirois et al., 1992]. Moreover, anti-inflammatory agents, such as 
cortisol, have been shown to decrease PGHS2 mRNA and protein expression via 
transcriptional and post-transcriptional mechanisms [reviewed by Smith et al.,
1996].
The functional roles o f PGHS2 are thought to be two fold. It is thought that the 
enzyme co-localises with PGHS1 on the lumenal face o f the ER to augment the 
function o f PGHS 1. The localisation o f PGHS2 to the lumenal face o f the nuclear 
envelope is speculated to operate as a unique nuclear prostanoid biosynthetic 
pathway that forms prostaglandins, which can act via the nuclear membrane, or 
nucleoplasmic targets in association with cell differentiation and replication. Indeed, 
prostaglandins are ligands for the members o f the peroxisome proliferator activated 
receptor (PPAR) fam ily o f nuclear receptors [Helliwell et al., 2004].
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Once PGH2 has been formed, it undergoes various structural changes to form PGD2, 
PGE2, PGF2a, PGI2 or thromboxane A 2 (TX A 2). The resulting prostanoids exert their 
cellular actions through paracrine mechanisms. Each prostaglandin is secreted and 
can bind to G-protein coupled receptor (GPCR) on neighbouring cells, and activate 
various second messenger signalling cascades including cAMP-protein kinase A 
(PKA) (activated by PGE2) and calcium-calcium dependent protein kinase (PKC) 
(stimulated by PGF2tt) [reviewed by Narumiya et al., 1999]. Prostaglandins are also 
thought to signal through intracrine mechanisms, specifically through binding to 
orphan nuclear receptors such as PPARs [reviewed by Helliwell et al., 2004]. A  role 
for the nuclear generation o f prostaglandins has also been speculated. Stimulation o f 
PGHS2 with IL - ip  was shown to re-localise PGHS2 from the nucleus to the nuclear 
envelope and the cytoplasm, with no effect on PGHS1 localisation [Parfenova et al.,
2001], highlighting novel mechanisms through which prostaglandins may exert their 
actions.
1.3.2 Lipoxygenase
The lipoxygenase pathway o f A A  metabolism to leukotrienes involves the oxidation 
o f A A  to form hydroperoxy-eicosatetraenoic acids (HPETEs) and 
hydroxyeicosatetraenoic acids (HETEs). HETEs and HPETEs can be further reduced 
to leukotrienes according to the requirements o f the cell [Ueda et al 1986; 
Samuelsson, 1987].
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1.3.3 Epoxygenase
The actions o f epoxygenase metabolises A A  to generate dihydroxyacids and 
epoxyeicosatrienoic acids [Zeldin, 2001]. The involvement o f  these metabolites in 
phospholipase A 2 intracellular signalling are yet to be elucidated [Van Voorhis et al 
1993].
1.3.4 Role o f Eicosanoids in Ovulation
The administration o f non-selective PGHS inhibitors to human and non-human 
primates has been shown to inhibit ovulation [Wallach et al., 1975a; K illick  and 
Elstein 1987]. Moreover, in non-human primates, ovulation could be restored by 
simulataneous administration o f PGF2a [Wallach et al., 1975b]. Similar studies in 
rodents using non-selective PGHS inhibitors either administered systemically 
[Tsafriri et al., 1972; M ikuni et al., 1998] or into perfused whole ovaries [Hamada 
1978; Sogn et al., 1987; M ikuni et al., 1998] inhibited ovulation. Subsequent co­
administration o f PGE2 or PGF2a was shown to restore the ovulatory process. Taken 
together, these data have supported the hypothesis that ovulation is an inflammatory 
event, mediated, in part, by prostaglandins [Espey 1980].
Further studies into the role o f the PGHS isoform in ovulation have shown that the 
administration o f preferential PGHS2 inhibitors disturbs ovulation in women by 
preventing (or delaying) follicular rupture, despite normal profiles o f oestradiol and 
progesterone [Smith et al., 1996; Mendonca et al., 2000; Pall et al., 2001]. Knock­
out mice studies have shown that PGHS1 null mice exhibit normal ovulation and 
fertilisation [Langenbach et al., 1995], whereas, PGHS2 null mice show a decrease
43
in the number o f ovulation sites [Lim  et al., 1997]. Moreover, administration o f 
PGE2 to PGHS2 knockout mice restores the normal ovulatory pattern.
Studies in the rhesus macaque found that 12 hours post administration o f an 
ovulatory dose o f human chorionic gonadotrophin (hCG), PGHS2 mRNA expression 
was induced in fo llicu lar granulosa cells, and remained elevated through to 36 hours 
post hCG administration [D uffy and Stouffer, 2001]. PGHS1 mRNA did not change 
at 0, 12, and 36 hours post hCG. The concentrations o f PGE2 and PGF2a in follicular 
flu id (FF) did not change over the first 24 hours, but were 100-fold higher by 36 
hours post hCG administration [Duffy and Stouffer, 2001]. These data agree with the 
proposal by Sirois and Dore [1997] that the increase in FF prostaglandins is the 
determining step controlling ovulation in mammals.
Use o f immunohistochemistry in the rhesus macaque fo llic le after administration o f 
an ovulatory dose o f hCG, localised PGHS2 expression to the theca and granulosa 
cells. This was also confirmed in naturally cycling animals [D uffy  and Stouffer,
2001]. In contrast PGHS1 expression was only detected in ovarian surface epithelial 
(OSE) cells [D uffy  and Stouffer, 2001] where PGHS1 is speculated to play a role in 
apoptosis which is essential for follicular rupture. This suggestion has been 
supported through administration o f indomethacin, an inhibitor o f PGHS1 and 
PGHS2, which was shown to inhibit apoptosis in OSE cells [Murdoch, 1996].
Knockout mice studies o f PGE2 (EP) receptors and the PGF2a (FP) receptor have 
yielded different results. EP2 receptor or PGHS2 knock-out mice exhibit defects in 
ovulation rate and cumulus cell expansion, suggesting alternative roles o f
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prostaglandins in the control o f ovarian function [T illey et al., 1999; Hizaki et al.,
1999], However, other studies have shown that EP or FP receptor knockout mice 
show no defect in ovulation [Kobayashi and Narumiya, 2002], highlighting the need 
for further study to elucidate the role for prostaglandins in ovulation. Moreover, 
PGE2 and PGF2a have been shown to play critical roles in oocyte maturation 
[Watanabe et al., 1994], suggesting other mechanisms o f ovarian function that 
prostaglandins are important not only in ovulation, but also in folliculogenesis.
Products o f the lipoxygenase pathway have also been implicated in the ovulatory 
process. The presence o f leukotriene B4  (LTB 4 ) has been detected in human FF, and 
lipoxygenase activity has been detected in human granulosa-lutein cells from women 
undergoing in vitro fertilisation and embryo transfer (IVF-ET) [Feldman et al., 1986; 
Priddy et al., 1989]. Reich et al. [1983] demonstrated that various inhibitors o f 
lipoxygenase could block ovulation in the rat. Further studies revealed the presence 
o f 12-HETE [Espey et al., 1991] and 15-HETE [Tanaka et al, 1989; Espey et al., 
1991; Tanaka et al., 1991] in the rat ovary following hCG administration. Other 
studies have detected increases in LTB 4  following administration o f an ovulatory 
dose hCG to perfused rabbit ovaries [Yoshimura et al., 1991]. Administration o f a 
preferential lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA), to perfused 
rabbit ovaries follow ing an ovulatory dose o f hCG reduced ovulatory efficiency. 
However, co-administration o f LTB 4 reversed the inhibitory effects o f NDGA on 
ovulation [Yoshimura et al., 1991; M ikuni et al., 1998]. Inhibitor studies o f the 
lipoxygenase pathway using indomethacin, NDGA and MK-886 have all been 
shown to decrease the expression o f MMP-1 and MMP-2 in rat ovarian extracts
45
follow ing hCG administration. This indicates a role for lipoxygenase products in 
follicular collagenase stimulation [reviewed by Tsafriri 1995].
Speculated roles for lipoxygenase products in ovulation are similar to those for 
prostaglandins. Lipoxygenase metabolites o f A  A  are speculated to affect vascular 
permeability, vasodilation and collagenolysis.
1.3.3 Role o f eicosanoids in CL function
Luteal cells and tissues have the capacity to synthesise prostaglandins in all 
mammalian species investigated including cows [M ilvae and Hansel 1983; Pate 
1988], pigs [Watson and Patek 1979], rats [Tamura et al., 1991; Olofsson et al.,
1992], non-human primates [Houmard and Ottobre 1989] and women [Challis et al., 
1976]. Coupled to this, PLA2 activity has been shown to increase throughout 
luteolysis in rats [Wu and Carlson 1990] and abrogate steroidogenesis in luteal cells 
[Greenhalgh 1990]. Radioimmunoassays o f tissue from the rat CL throughout 
pseudopregnancy and pregnancy have detected the presence o f PGE2, PGF2a, and 
PGI2 [Olofsson et al., 1990]. In other species, similar findings have been obtained 
[M ille r et al., 1983; Vijayakumar and Walters 1987]. The FP receptor has been 
localised to the CL in all species tested [Reviewed by Anderson et al., 2001]. 
Functional EP1 and EP2 receptors have also been identified in human granulosa- 
lutein cells [Harris et al., 2001].
There are 2 ways in which prostaglandins are thought to control steroidogenesis and 
the functional lifespan o f the CL. PGE2 is thought to act as a luteotrophin,
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functioning to stimulate progesterone synthesis. PGF2a may act in a luteolytic 
manner, to inhib it progesterone synthesis. However, the role o f PGF2« in luteolysis 
in primates remains unclear.
Indomethacin treatment for seven days during the early and mid-luteal phase has 
been shown to decrease both basal and GnRH-stimulated progesterone 
concentrations, indicating a luteotrophic role for prostaglandins and lipoxygenase 
products w ith in the early and mid-luteal phase [Fulghesu et al., 1993].
The luteotrophic role o f PGE2 has been demonstrated in both human [Dennefors et 
al., 1982; Hahlin et al., 1988] and bovine [Shelton et al., 1990; Sharif et al., 1998] 
CL. Moreover, the luteotrophic actions o f PGE2 have been demonstrated in 
luteinised granulosa cells [McNatty et al., 1975], and luteal cells o f the rhesus 
macaque [Stouffer et al., 1979], rat [Thomas et al., 1978] and hamster [Yang et al., 
1998]. In the human [Dennefors et al., 1982; Hahlin et al., 1988] and non-human 
primate CL [Molskness et al., 1987], progesterone production was found to increase 
in response to PGE2 apparently acting via the stimulation o f adenylyl cyclase, and 
increased generation o f cAMP.
In the rat CL, PGF2tt can inhibit LH-stimulated adenylyl cyclase activity, partly due 
to the impairment o f  the Gs-protein [Lahav et al., 1976; Norjavaara and Rosberg 
1986]. This inhibition was shown to increase with luteal age [Khan et al., 1979]. 
Moreover, in human granulosa-lutein cells, PGF2a can inhibit LH-stimulated 
steroidogenesis both prior and subsequent to the elevation o f cAMP [Michael et al.,
1993]. Other studies have also highlighted temporal differences in signalling
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pathways coupled to the FP receptor in luteal cells, one o f which is the calcium- 
dependent PKC signalling pathway [Steele and Leung, 1993].
1.4 Role of LH in Ovarian function
LH is a glycoprotein hormone produced alongside FSH by the gonadotrophs o f the 
anterior pituitary. LH  is a heterodimer consisting o f an a-subunit that is non- 
covalently bonded to a [3-subunit. The pattern o f glycosylation confers the functional 
specificity on LH  [reviewed by Ascoli et al., 2002].
The LH receptor (LHR) is a single polypeptide with an overall structure and 
topology o f members o f the rhodopsin/(3-adrenergic superfamily o f GPCRs [Segaloff 
et al., 1990]. The receptor comprises a large N terminal extracellular region 
consisting o f approximately 340 residues, a 7 transmembrane domain, and a C 
terminal intracellular region.
The LHR couples to the adenylyl cyclase signalling cascade [Richards et al., 1998]. 
Prior to ovulation, LH activates a cAMP-PKA signalling cascade to induce the 
expression o f genes required for cell proliferation and differentiation. As the mid­
cycle LH surge occurs, triggering ovulation, LH dramatically increases cAMP-PKA 
signalling. LH  can also increase inositol lipid-hydrolysis, which results in elevation 
o f the intracellular calcium concentration and activation o f PKC activation. This in 
turn alters the pattern o f gene expression to orchestrate the final stages o f follicular 
development, causing the oocyte to undergo meiotic maturation, and rupture o f the 
follicular wall [Robker and Richards 1998; Espey and Richards 2002]. Genes that
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are up-regulated by LH include interleukin (IL)-1|3, the IL - ip  receptor (IL -lp R ) 
[Adashi, 1997; 1998] and PGHS2 [Morris and Richards 1995]. L ittle  is known about 
the transcription factors and regulators that mediate these responses, however, 
C/EBP is speculated to play a role [Sterneck et al., 1997].
The expression o f the LHR has been localised to various tissue types including the 
ovary, specifically in the thecal cells, interstitial cells, differentiated granulosa cells, 
and luteal cells [reviewed by Ascoli et al., 2002]. In situ hybridisation studies have 
localised LHR mRNA to the thecal and interstitial cells in immature pre-antral 
follicles. In mature antral follicles, LHR mRNA is localised to both thecal and 
granulosa cells [Camp et al., 1991]. Expression o f LHR mRNA in the granulosa is 
increased by FSH administration in vitro and FSH has been shown to directly 
regulate LHR gene transcription [Shi and Segaloff 1995].
LH is an integral factor in the control o f the ovarian cycle. In the follicular phase, LH 
controls thecal cell androgen production with aromatisation o f androstenedione to 
form oestrogens in the neighbouring granulosa cells [H illie r et al., 1994]. The 
increase o f LH pulsatile frequency during the peri-ovulatory phase induces essential 
genes for ovulation [Espey and Richard, 2002]. During the luteal phase, LH is a key 
luteotrophic factor, stimulating progesterone production and supporting CL function 
[Kohen et al., 2003]. LH plays a key role in the regulation o f prostaglandin synthesis 
through regulating the expression o f PGHS2 (reviewed in section 1.3).
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1.5 Role of Interleukin-1 in Ovarian function
Preliminary studies into the role o f IL-1 in ovarian function detected IL-1 activity in 
human FF [Khan et al., 1988]. Subsequent studies localised both IL-1 a  and IL -1 p 
mRNA to the cumulus cells o f women undergoing IVF-ET [Barak et al., 1992; De 
Los Santos et al., 1998]. Recent in vitro studies have confirmed that human 
granulosa cells secrete IL -1 p [Carlberg et al., 2000]. Moreover, studies have 
correlated intrafollicular levels o f IL-1 with oocyte quality in women undergoing 
IVF-ET [Karagouni et al., 1998, Mendoza et al., 1999].
Two receptor subtypes for the IL-1 system have been cloned [reviewed by Gerard et 
al., 2004]. The IL-1R couples to p38 mitogen activated protein kinase (MAPK) and 
Jun N-terminal kinase (JNK) signalling pathways, resulting in the activation o f 
nuclear factor-KB (NF-kB) [O ’Neill, 2000]. The type I IL-1R has been localised to 
human granulosa, cumulus, theca cells [Hurwitz et al., 1992] and the human embryo 
[De Los Santos et al., 1998]. To date, studies to characterise the expression o f the 
type II IL-1R in the ovary have been limited. However, the type II IL-1R has been 
localised to equine cumulus cells and oocytes both before and after in vitro 
maturation. In rat immature ovaries the type II receptor was not detected, although it 
was detected in cultured ovarian cells [reviewed by Gerard et al., 2004].
The naturally occurring IL-1 receptor antagonist (RA), has been shown to regulate 
the bioavailability o f  IL - la  and IL-1 (3 to their receptors. IL-1RA is known to be 
expressed in the human ovary [Hurwitz et al., 1992]. Subsequent studies have 
localised IL-1RA to human granulosa cells, which were devoid o f any
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immunological cells suggesting de novo synthesis o f IL-1 RA by granulosa cells [Kol 
et al., 1999]. The IL-1RA has also been localised to human cumulus cells, with its 
quantity changing throughout follicular maturation [Tsafriri, 1995].
The various components o f the IL-1 system are thought to regulate ovarian function. 
There are hypothesised roles for IL-1 in ovulation, oocyte maturation, cellular 
metabolism, and ovarian steroidogenesis. IL-1 p has been shown to increase 
progesterone production in human granulosa cells. In non-ovarian tissue, IL-1 
promotes many ovulation-associated physiological and biochemical changes 
including collagen activation, increased vascular permeability and prostaglandin 
production [Gerard et al., 2004].
In studies across various species, IL-1 has been shown to stimulate PGE2 and PGF201 
production. Studies by Narko et al. [1997] have revealed that IL-1 (3 can induce 
PGHS2 mRNA expression in human granulosa-lutein cells. Moreover, subsequent 
studies revealed that IL -1P can induce the expression o f mRNA encoding FP, EP2 
and EP4 receptors in hGL cells [Narko et al, 2001]. In human FF the concentration 
o f IL-1 (3 has been correlated with the concentration o f PGE2 and PGF2a [Watanabe 
et al., 1994] providing evidence o f a regulatory link between IL-1 (3 and 
prostaglandin synthesis via PGHS2. Other studies have also shown that IL-1 (3 can 
increase PLA2 activity [Kol et al., 1997], providing AA , the substrate o f 
prostaglandin synthesis.
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Studies into the effect o f  IL -1 (3 on the expression o f PGHS2 in human granulosa- 
lutein cells harvested during different phases o f the ovarian cycle has shown that IL- 
lp  can induce the expression o f PGHS2 mRNA and decrease its degradation [Narko 
et al., 1997], These data highlight the importance o f IL-1 (3 in the induction o f 
PGHS2 for prostaglandin synthesis in the ovary.
1.6 Cortisol Metabolism
1.6.1 Synthesis o f  glucocorticoids
Glucocorticoids are synthesised in the adrenal cortex, specifically in the zona 
fasciculata in response to adrenocorticotrophic hormone (ACTH) stimulation. As for 
all steroids, the substrate for glucocorticoid synthesis is cholesterol (Figure 1.2). As 
outlined in section 1.2.2, cholesterol is converted to pregnenolone by CYP11A 
(P450CSCc), and pregnenolone is oxidised to progesterone by 3pHSD. Once formed, 
progesterone can be converted to cortisol through a 3 step process. Firstly, 
progesterone is converted to 17oc-hydroxyprogesterone by CYP17. This 17a- 
hydroxyprogesterone is then converted to 11-deoxycortisol by CYP 21 (21- 
hydroxylase). The final step in the reaction is catalysed by 11 p-hydroxylase 
(CYP11B 1) converting 11-deoxycortisol to cortisol (Figure 1.2) [reviewed in Brook 
and Marshall 2001].
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Figure 1.2: Principle pathways o f  glucocorticoid biosynthesis. Blue=mitochondrial pathways, red=ER 
reactions, HSD=hydroxysteroid dehydrogenase, CYP= cytochrome P450
1.6.2 Circulation o f glucocorticoids
Glucocorticoids are transported in the plasma by corticosteroid binding globulin 
(CBG), which regulates the availability o f glucocorticoids to target tissues. CBG is a 
glycoprotein that binds C21 steroid hormones with high affinity, and functions to 
transport C21 steroids to their target tissues. The binding o f glucocorticoids to CBG 
regulates their free concentration in blood, and their biological activity [Hammond et 
al., 1991].
CBG is synthesised in the liver, however the mRNA encoding CBG has been 
detected in the human ovary [Misao et al., 1999a], placenta [Misao et al., 1999b] and 
CL [Misao et al., 1999c]. Luteal CBG is thought to be regulated by steroid hormone 
concentrations [Misao et al., 1999c].
1.6.3 Action o f Glucocorticoids
The primary physiological role o f glucocorticoids is to maintain glucose homeostasis 
w ithin the body. Cortisol production is specifically increased in response to chronic 
stress, and functions to maintain glucose homeostasis. Cortisol does this through 
increasing gluconeogenesis by inducing the expression o f enzymes involved in the 
gluconeogenic pathway, stimulating muscle breakdown, and increasing the turnover 
o f peripheral adipose tissue. Other stress responses include suppression o f the 
immune response, suppression o f reproductive function, and in instigating cell 
differentiation [Brook and Marshall 2001]. The genomic actions o f glucocorticoids 
are mediated via the glucocorticoid receptor (GR), which acts as a ligand-dependent 
nuclear transcription factor. There are 2 major isoforms o f the receptors, GRa, which
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is transcriptionally active, and GRp, which acts as a dominant negative regulator o f 
transcription [Charmandari et al., 2004]. Recent publications have suggested that the 
ligand- and tissue- specific effects o f the GR are mediated through translational 
variants o f  the receptor isoforms [Yudt and Cidlowski 2002; Lu and Cidlowski
2004].
1.6.4 Glucocorticoid-metabolising enzymes
There are 2 important glucocorticoid-metabolising systems that regulate the activity 
o f cortisol, namely 11 p-hydroxysteroid dehydrogenase ( llp H S D ), and the 5a/5p- 
reductase pathways. In glucocorticoid target tissues, the active glucocorticoid 
cortisol (corticosterone in mice and rats) can be inter-converted to its inactive 
metabolite cortisone (11-dehydrocorticosterone in mice and rats), by isoforms o f 
llpH S D . The roles for this enzyme shall be fu lly  explored in section 1.8. In the 
liver, the 5a- and 5p-reductase enzymes metabolise cortisol and cortisone through a 
series o f reducing steps, to solubilise cortisol and cortisone for urinary excretion 
[White et al., 1997] (Figure 1.3).
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Figure 1.3: Mechanism by which cortisol and cortisone are metabolised in target 
tissue (red) and in the liver for excretion (blue). DHF=dihydrocortisol, aDHF=allo 
dihydrocortisol, DHE=dihydrocortisone, THF=tetrahydrocortisol, aTHF=allo 
tetrahydocortisol, THE=tetrahydrocortisone. Adapted from  White et a l 1997
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1.7 Short-chain dehydrogenases/reductas
The short-chain dehydrogenases/reductases (SDRs) are a superfamily o f enzymes 
consisting o f approximately 3000 members, o f which 37 are human [Oppermann et 
al., 2001]. The SDRs utilise a wide range o f substrates including alcohols, sugars 
and steroids [Persson et al., 2003]. To date, five SDR families have been identified, 
based on co-enzyme and catalytic site motifs. One such SDR family is termed the 
Classical SDR family. Each o f the enzymes in the Classical fam ily o f SDRs is 
comprised o f approximately 250 residues, and catalyses NAD(P)(H)-dependent 
oxidation/reduction reactions. The co-factor binding site is localised to the N 
terminus, forming a Rossman fold, and the active site is localised to the C terminus 
o f the protein [Persson et al., 2003]. The Classical SDRs have the active site m otif o f 
YxxxK [Oppermann et al., 1997]. Typical members o f this family include steroid 
dehydrogenase/reductase enzymes
Enzymes w ith in the steroid dehydrogenase/reductase subtype o f proteins can be 
divided into 2 sub-categories. The first are enzymes catalysing the steroidogenic 
pathways. Such enzymes include 3p-hydroxysteroid dehydrogenase (HSD), and 
17(3HSD, which are pivotal enzymes in the formation o f ovarian steroids; i.e. the 
synthesis o f  progesterone from pregnenolone (3pHSD) [Mason et al., 1997], and the 
conversion o f oestrone to oestradiol (17[3HSD) [Andersson and Moghrabi, 1997] 
(see Section 1.2.2). Steroid metabolism serves 2 purposes. The first for the excretion 
o f steroid through the generation o f polar and /or charged steroid metabolites e.g., 
the conversion o f progesterone to 20a-dihydroprogesterone by 20aHSD, and in 
metabolism o f steroids within their target organs for regulating the potency o f the
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steroid at it ’ s receptor. This mechanism is integral for local control o f steroid 
hormone activity. Such enzymes include the glucocorticoid metabolising enzyme, 
11 (3HSD which regulates the activity o f cortisol, the active glucocorticoid, through 
interconversion w ith cortisone, its inactive keto-steroid metabolite [Walker and 
Stewart, 2003].
1.8 llpHSD
As previously mentioned in section 1.6.4, in target tissues the active glucocorticoid 
cortisol is inter-converted to its inactive keto-steroid metabolite cortisone by 
isoforms o f the enzyme 1 lpHSD [Blum and Maser 2003; Walker and Stewart, 2003, 
Figure 1.4]. To date, 3 isoforms o f llp H S D  have been cloned. llp H S D l and 
llpH S D 2  have been extensively studied and functionally characterised. However, 
the functional properties o f 1 lpHSD3 are yet to be elucidated.
1.8.1. 11BHSD1
1 lpH S D l was originally isolated from a rat cDNA library [Agarwal et al., 1989]. It 
is a 34kDa protein with 2 hypothesised sites for N-glycosylation. Monder and 
Lakshmi [1990] localised 1 lpH S D l mRNA expression to the liver, lungs, testis, and 
kidney. Subsequent cloning o f human lip H S D l localised the gene to chromosome 
1, with ubiquitous gene expression in most tissues including the ovary [Tannin et al., 
1991]. Kinetic analysis o f lip H S D l has shown that it is predominately a low 
affin ity 11 ketosteroid reductase (11KSR) in vivo, with a micromolar affin ity for 
cortisol (Km=27pM), and a co-factor preference for NADP(H). Functional analysis
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Figure 1.4: Inter-conversion o f cortisol and cortisone by isoforms o f the enzyme 1 lpHSD . Highlighted 
in red is the oxidation o f the C l 1 hydroxyl group o f cortisol to a ketone to form cortisone, and in blue, 
the reduction o f the C l 1 group to a hydroxyl to form cortisol.
revealed that 1 lp H S D l is a bi-directional enzyme in vitro, 11KSR enzyme with a 
basal dehydrogenase activity.
Physiological studies using knockout mice have revealed that mice lacking the 
1 lp H S D l enzyme are fertile and have an unaltered birth weight and litter size. They 
appear to exhibit adrenocortical hyperplasia, caused by increased ACTH stimulation 
o f the adrenal due to decreased negative feedback by corticosterone [Kotelevstev et 
al., 1997]. Moreover, in 1 lpH S D l null mice, the plasma corticosterone levels are 
increased, and lack the circadian rhythm observed in wild-type mice. The 1 lpH S D l 
knockout mice also appear to have aberrations in the gluconeogenic pathway, and 
increased insulin sensitivity [Kotelevstev et al., 1997]. Further analysis o f 1 lp H S D l' 
'' mice revealed that the mice showed a decrease in weight gain in comparison to 
w ild type mice when fed on high fat diets. Atrophy o f the thymus o f the 11 pHSD ''' 
mice was also observed (Holmes et al., 2001]. These phenotypes are consistent with 
the role for cortisol in maintaining metabolic homeostasis, w ith specific functional 
roles in gluconeogenesis. They highlight the role o f 1 lp H S D l in regenerating 
cortisol (and corticosterone) from cortisone (and 11-dehydrocorticosterone) in the 
liver, and the importance o f cortisol in modulating the expression and activity o f key 
enzymes involved in gluconeogenesis.
1.8.2 11BHSD2
1 lpHSD2 activity was originally reported in human fu ll term placenta [Brown et al.,
1993], and rabbit renal cells [Rusvai and Naray-Fejes-Toth, 1993]. The enzyme was 
found to function as an N A D +-dependent 11 p-dehydrogenase converting cortisol to
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cortisone, with a nanomalor affin ity for cortisol (K m=60nM) [Mercer and 
Krozowski, 1992; Brown et al., 1993]. Subsequent studies cloned and characterised 
llpH S D 2  from human and sheep kidney [Albiston et al., 1994; Agarwal et al.,
1994]. Northern blotting revealed expression o f llp H S D 2  in tissues involved in 
water re-absorption including the placenta, distal nephron o f the kidney, colon, 
parotid gland and ovary. As well as binding to the GR, cortisol and corticosterone 
can also bind to the mineralocorticoid receptor which have little inherent specificity 
for binding aldosterone. In these tissues 11J3HSD2 is thought to inactivate cortisol to 
cortisone, thus inhibiting promiscuous occupation o f mineralocorticoid receptor by 
cortisol. Such occupation o f the mineralocorticoid can result in the syndrome o f 
‘apparent mineralocorticoid excess’ (AME) [White, 2001]. 11(3HSD2 is also 
involved in regulating glucocorticoid availability to the foetus serving as a barrier 
mechanism in the placenta oxidising cortisol to cortisone. This mechanism exists to 
prevent foetal exposure to glucocorticoids, which would stimulate premature 
differentiation o f foetal tissue, and result in intra-uterine growth retardation 
[reviewed by Michael et al., 2003].
Phenotypic analysis o f mice bearing a gene deletion for 11 (3HSD2 revealed that 50% 
o f llpH S D 2  null mice died within 48 hours o f birth [Kotelevtsev et al., 1999]. 
Reasons for this included cardiac arrest due to severe hypokalaemia (low potassium) 
caused by hyper-activation o f the mineralocorticoid receptors [Holmes et al., 2001]. 
These symptoms are consistent with that o f  severe AME.
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1.8.3 11BHSD3
Over the past decade, several authors have suggested the existence o f a third isoform 
o f 11(3HSD [Gomez-Sanchez et a l, 1997; Ge et al., 1997; Michael et al., 1997; Ge 
et al., 2000]. Recently the primary sequences for 11(3HSD3 from 6 individual 
species have been deposited in the NCBI protein database by Huang 
[http://www.ncbu.nlm.nih.gov/entrez/query]. To date, nothing is known o f the tissue 
distribution, kinetic, structural and functional properties o f this enzyme. However, 
personal communication with Huang has revealed that each o f the 6 species
I lpHSD3 was isolated from brain, and the gene encoding 11[3HSD3 has also been 
cloned from human brain.
1.8.4 11PHSD enzymes and Ovarian function
1.8.4.1 11BHSD enzymes and their link to in vitro fertilisation-embrvo transfer 
outcome
Publications over the last decade have suggested a possible link between cortisol- 
cortisone conversion in ovarian cells, and the outcome o f in vitro fertilisation- 
embryo transfer (IVF-ET). The net rate o f cortisol oxidation to cortisone has been 
shown to correlate inversely with the probability o f  conception by IVF-ET; a low
I I  pHSD activity reflects a higher probability o f achieving pregnancy in women 
undergoing IVF-ET [Michael et al., 1993; 1995; 1999; Keay et a l, 2002; Thurston et 
al., 2003a; Lewicka et al., 2003].
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There have been conflicting studies that have found no correlation between 11 (3HSD 
activity and IVF-ET outcome [O ’Shaughnessy et al., 1997; Thomas et al, 1998; 
Andersen et al., 1999]. However, differences in granulosa cell culture times, and 
storage o f granulosa cells in human FF, known to contain modulators o f llp H S D  
activity could explain these differences [reviewed by Michael et al., 2003].
Subsequent studies have isolated modulatory compounds o f llp H S D  activity in 
human FF. Studies by Thurston et al. [2002] first reported the presence o f 
hydrophilic stimulators and hydrophobic inhibitors o f 1 lpHSD activity in human FF. 
The relative ratio o f  stimulatory compounds to inhibitory compounds, i.e. the 
presence o f a low stimulatory activity, and a high inhibitory activity, has been related 
to the successful outcome o f IVF-ET [Thurston et al., 2003a].
1.8.4.2 Spatial and temporal expression patterns o f 11BHSD enzymes in the ovary
The expression o f 11PHSD enzyme isoforms has been documented in the human 
ovary. Immuno-histochemical studies have localised 1 lp H S D l expression to the 
oocyte, luteinising granulosa cells, theca cells and ovarian surface epithelial cells. 
The 11 pHSD2 isoform has been localised to theca, mural and cumulus granulosa 
cells from immature follicles [Ricketts et al., 1998; Smith et al., 2000; Yong et al., 
2000]. The pattern o f 1 lpHSD expression in the ovary is dependent on the stage o f 
the ovarian cycle. In rat [Tetsuka et al., 1999a] and human [Tetsuka et al., 1997] 
granulosa cells, isolated from the pre-ovulatory stage o f the ovarian cycle, 1 lpHSD2 
mRNA was detected. In rat and human granulosa cells undergoing luteinisation, an 
increase in 1 lp H S D l mRNA was detected following the administration o f hCG.
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This also coincided with a decrease in llpH S D 2  mRNA expression. These results 
were further confirmed by lip H S D l and 11(3HSD2 mRNA expression and activity 
studies in human granulosa-lutein cells, where only 11 (3HSD1 mRNA was expressed 
[Michael et al., 1997; Tetsuka et al., 1997; Thurston et al., 2003b]. The expression 
pattern o f 11 pHSD isoforms has also been recently reported for the bovine ovary. 
Although the pattern o f 1 lpH S D l expression changes less dramatically over the 
stages o f the ovarian cycle, the follicular phase granulosa cells express 
predominantly 11PHSD2 and luteal phase cells express predominantly 1 lpH S D l 
[Tetsuka et al., 2003]
There are many possible reasons why the pattern o f ovarian 11 PHSD expression 
changes throughout the ovarian cycle. In a wide range o f teleost species, cortisol 
stimulates oocyte maturation [Kime et al., 1992]. Hence, 1 lpH S D l may be required 
at ovulation to increase the local regeneration o f glucocorticoids. In humans there is 
circumstantial evidence o f a role o f cortisol for oocyte maturation. In FF cortisol 
levels peak around the time o f ovulation [Harlow et al., 1997], and in women 
undergoing IVF-ET a positive link was found between oocyte maturity and cortisol 
levels in human FF [Fateh et al., 1989]. It has also been suggested that intrafollicular 
concentrations o f cortisol are important for the final stages o f oogenesis. This is 
supported by immunocytochemical data showing the expression o f high levels o f
I lpH S D l mRNA and protein in the rat oocyte [Benediktsson et al., 1992]. 
Noteworthy is that transcription is blocked between pre-ovulatory meiosis and the 
mitotic division o f the embryo to the 2-cell stage. Therefore high expression o f
I I  pHSDl in the rat oocyte could reflect the need to regenerate active glucocorticoids
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in the oocyte, zygote and/or early embryo stages o f development [reviewed by 
Michael et al., 2003]
As reviewed in sections 1.1 and 1.3, ovulation is an inflammatory event that involves 
an inflammatory cascade, initiated in response to gonadotrophins. These events 
result in fo llicu lar rupture and oocyte expulsion. Following ovulation, the follicular 
tissue undergoes rapid repair and remodelling. Therefore it has been proposed that 
up-regulation o f 1 lp H S D l mRNA in granulosa cells, would facilitate an increase in 
intrafollicular cortisol following gonadotrophin stimulation. Moreover, it has been 
suggested that the increase in cortisol synthesis, provides an anti-inflammatory 
mechanism by which prostaglandin production is suppressed following the inhibition 
o f PLA2 and decreased PGHS-2 expression [H illie r and Tetsuka 1998].
1.8.5 Hormonal regulation o f 11BHSD
To date there are numerous factors that have been shown to regulate the activity and 
expression o f llp H S D  isoforms. These factors are summarised in Table 1.1 and 
include lipids, peptides, growth factors, transcription factors and pharmacological 
agents.
In the ovary, there have been limited studies on the regulation o f 11 PHSD. The 
regulatory factors that have been explored include IL-1 [Tetsuka et al., 1999b; Yong 
et al., 2002], and LH  [Tetsuka et al., 1999b], both o f which stimulate 11 pHSDl gene
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expression. The role o f LH and IL-1 in the regulation o f llp H S D  w ill be fully 
explored in a sections 1.8.5.2 and 1.8.5.3 respectively.
1.8.5.1 Prostaglandins and 11BHSD
As previously described, prostaglandins have numerous regulatory roles in the ovary. 
PGE2 and PGF20C have been shown to increase 11 PHSD 1 activity in cultured 
chorionic trophoblast cells. Moreover, PGF2tt can stimulate the reductase activity o f 
lip H S D l (in a concentration-dependent manner) at parturition in humans [A lfaidy 
et al., 2001], The mechanism is speculated to be via mobilisation o f Ca2+, activation 
o f PKC, and by phosphorylation o f 1 lp H S D l, mediated via the FP receptor [A lfaidy 
et al., 2001]. In turn, cortisol has been shown paradoxically, to increase 
prostaglandin synthesis via the upregulation o f PGHS2 expression and decreased 
prostaglandin metabolism via inhibition o f 15-prostaglandin dehydrogenase (PGDH) 
in chorionic trophoblast cells [A lfa idy et al., 2001; Challis et al., 2002]. These data 
highlight the importance o f the positive feedback loop between prostaglandins and 
cortisol in the onset o f parturition in sheep and humans. In contrast to studies by 
A lfa idy et al., [2001], PGE2 and PGF2tt have been shown to inhibit llpH S D 2 in 
human choriocarcinoma JEG-3 cells [Hardy et al., 2001].
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Table 1.1: Regulatory compounds o f llp H S D  enzyme isoforms. ND = not 
determined by the study, - = inhibited activity or decreased expression, + = 
stimulated activity or increased expression, NS = not specified, NE = no effect.
Compound llpHSD
isoform
Tissue Activity Expression Reference
Lipids
Cholesterol NS Rat kidney - N D Buhler et al., 
1991
Chendeoxycholic
acid
1 lpH SD l Rat kidney - ND Perschel et 
al., 1991
Cortisol 11PHSD1 Human adipocytes ND +  mRNA Engeli et al., 
2004
Dexamethasone 11PHSD1
11PHSD1
Human osteoblasts
Term amnion 
fibroblasts
+
ND
+ mRNA 
+  mRNA
Cooper et al., 
2002 
Sun and 
Myatt, 2003
DHEA 1 lpH SD l Rat liver cDNA ND - Gu et al., 
2003
Glycyrrhetinic acid 11PHSD1 Rat liver 
microsomes
- ND Monder et al., 
1991
Lanosterol NS Rat kidney - ND Buhler et al., 
1991
Leukotriene B4 11PHSD2 JEG3 cells - NE Hardy et al., 
1999
Lithocholic acid 11PHSD1 Rat kidney - N D Perschel et 
al., 1991
Medroxyprogesterone 11PHSD2 Ishikawa cells + N D Darnel et a!., 
1999
Oestradiol llp H S D 2
11PHSD2
11PHSD2
lip H S D l
Human placental 
trophoblast 
Ishikawa cells
Rat kidney
Rat kidney
+
NE
ND
+  mRNA and 
protein 
-  mRNA and 
protein
ND
Sun et al.,
1998 
Darnel et al.,
1999 
Gomez-
Sanchez et 
al., 2003 
Gomez- 
Sanchez et 
al., 2003
p g e 2 11PHSD2 JEG3 cells - NE Hardy et al., 
1999
PGF2q 1 lpHSD2 Human placental 
microsomes +
N D Hardy et al., 
2001
PGF2a 1 lpH SD l Human chorionic 
trophoblast +
N D Alfaidy et al, 
2001
Progesterone 1 lpHSD2 Human placental 
trophoblast
- -  mRNA Sun et al., 
1998
Testosterone lip H S D l Rat Leydig cells - N D Gao et al., 
1997a
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Growth
Factors
EGF lip H S D l 
1 lpH S D l 
11PHSD2
Rat Leydig cells 
Rat Leydig cells 
Ishikawa cells
+
N D
N D
N D
Gao et al., 
1997a 
Gao et al., 
1997a 
Darnel et al., 
1999
IGF-I (GH activated) 11PHSD1 Human omental 
adipose
- N D Moore et al., 
1999
Cytokines
IL-1 p lip H S D l Glomerular 
mesangial cells 
Rat granulosa cells
hOSE cells 
Human adipose 
stromal cells
MG-63 cells
+
N D
+
+
+
ND
+  mRNA
N D  
+  mRNA
+  mRNA
Escher et al., 
1997 
Tetsuka et 
al., 1999b 
Yong et al., 
2002 
Tomlinson et 
al., 2001 
Friedberg et 
al., 2003, 
Cooper et al., 
2001
IL-4 lip H S D l Differentiating
monocytes
+ + Thieringer et 
al., 2001
IL-4 +INFy 1 lpH SD l Human granulosa 
lutein cell
+ ND Evagelatou et 
al.,1997
IL-5 1 lpH SD l Human granulosa 
lutein cell
+ ND Evagelatou et 
al.,1997
IL-6 1 lpH S D l Human granulosa 
lutein cell
+ ND Evagelatou et 
al.,1997
IL-13 11PHSD1 Differentiating
monocytes
+ + Thieringer et 
al., 2001
Leukocytes 11PHSD1 Human granulosa 
lutein cell
+ ND Evagelatou et 
al.,1997
TNFa 1 lpH S D l 
1 lpH SD l 
llp H S D 2
Human adipose 
stromal cells 
Human adipocytes
LLC-PK
+
+
+  mRNA  
+  mRNA  
-  mRNA
Tomlinson et 
al., 2001 
Friedberg et 
al., 2003 
Heiniger et 
al., 2001
Peptide
hormones
ACTH 1 lpH S D l Human adipocytes - NE Freidberg et 
al., 2003
CRH lip H S D l Human adipocytes - NE Freidberg et 
al., 2003
LHRH 1 lp H S D l Rat granulosa cells N D +  mRNA Tetsuka et 
al., 1999b
Noradrenaline 11PHSD2 Placental
trophoblasts
- Sarker et al., 
2001
rhFSH lip H S D l Rat granulosa cells ND + mRNA Tetsuka et 
al., 1999b
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rhLH lip H S D l Rat granulosa cells ND +  mRNA Tetsuka et 
al., 1999b
Modifiers of 
Signalling 
Transduction
Carbenoxolone lip H S D l Human - N D Stewart et al., 
1990
Calcium llp H S D 2 Human placental 
microsomes
- N D Hardy et al., 
2001
C/EBPcc 1 lpH S D l Hepatoma cells ND +  mRNA Williams et 
al., 2000
C/EPBP 11PHSD1 Hepatoma cells ND +  mRNA Williams et 
al., 2000
Forskolin 11PHSD1
11PHSD2
Rat granulosa cells
Human placental 
chorion,
N D
+
+  mRNA  
+  mRNA
Tetsuka et 
al., 1999b 
Sun et al, 
1998
Hypoxia via Erg-1 11PHSD2 LLC-PK1 cells ND - mRNA Heiniger et 
al., 2003
Indomethacin 11PHSD2 JEG3 cells - ND Hardy et al., 
1999
LXR 1 lpH S D l 3T3-L1 cells - - mRNA Stulnig et al., 
2002
MAPK ERK inhibitor 11PHSD2 LLC-PK + N D Heiniger et 
al., 2001
MAPK p38 inhibitor 11PHSD2 LLC-PK + ND Heiniger et 
al., 2001
PMA 11PHSD1
11PHSD2
Rat granulosa cells 
LLC-PK
ND + mRNA 
-  mRNA
Tetsuka et 
al., 1999b 
Heiniger et 
al., 2001
PPARy ligand- 
thiazolidinedione
11PHSD1 3T3-L1 cells - - mRNA Berger et al., 
2001
RU486 11PHSD1 Term amnion 
fibroblasts
ND - mRNA Sun and 
Myatt, 2003
1.8.4.2 LH  and 11BHSD
In reproductive tissues, LH and hCG exert differential effects on 11(3HSD1 activity 
and expression. Studies have shown that in leydig cells increased LH can increase 
11(3HSD activity [Gao et al., 1997]. The role o f corticosterone in the testis is 
speculated to be in suppressing the circulating and local concentrations o f
69
testosterone. Studies comparing the oxidative activity o f 11 PHSD in dominant and 
subordinate male rats have shown that the dominant rat has an increased llp H S D  
oxidative activity. This is thought to be due to an increase in LH, which increases 
11 PHSD oxidative activity, allowing the Leydig cells to produce testosterone, and 
for the dominant rat to maintain its fertility  despite higher levels o f corticosterone 
[Hardy et al., 2002].
Measurements o f free cortisol in follicular flu id following the LH surge have shown 
a dramatic increase in free and total cortisol [Harlow et al., 1997]. 1 lpH S D l mRNA 
expression in the rat ovary has been shown to be regulated LH. Moreover, LH was 
found to act in a concentration-dependent manner to increase 1 lpH S D l mRNA 
expression in rat granulosa cells. This effect was found to be additive when rat 
granulosa cells were co-treated with IL-1 p [Tetsuka et al., 1999b]. Hence, the 
increased expression o f 1 lpH S D l in response to LH could contribute to the increase 
in intrafollicular cortisol concentrations following the LH surge.
1.8.5.3 IL-1 and 11BHSD
The roles for inflammatory cytokines in the regulation o f 11 pHSD activity and 
expression have been demonstrated in several tissue types. In adipose tissue, 
osteoblasts, placenta and the ovary, IL-1 p induces the expression o f 1 lpH SD l 
mRNA. In the rat ovary, Tetsuka et al., [1999b] have shown that IL-1 p can up- 
regulate 1 lp H S D l mRNA expression in a concentration-dependent manner. In other 
studies using human ovarian surface epithelial cells (hOSE), IL-1 a  was shown to
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increase 11 pHSDl mRNA expression and the 11KSR activity o f 11 pHSDl [Yong et 
al., 2002]. A  recent publications by Rae et al., [2004] has also shown that IL-1 a  can 
induce 11 (3HSD1 mRNA expression. Moreover, IL-1 a  also increased the expression 
o f the GRa subtype, highlighting a possible mechanism by which IL-1 a  may 
stimulate the anti-inflammatory activities o f cortisol through the up-regulation o f the 
GRa gene coincident with increased reactivation o f cortisol in target cells [Rae et 
al., 2004].
1.9 Project aims and justification
The cellular mechanisms that control cortisol metabolism in the ovary still remain to 
be elucidated. Prostaglandins have been extensively implicated in the regulation o f 
ovarian function, specifically within ovulation and CL dynamics. However, their 
precise mechanisms o f action within the human ovary still remain unclear. Although 
cortisol metabolism is thought to be regulated by prostaglandins in several 
reproductive tissues, the cellular mechanisms o f control are yet to be investigated in 
the ovary.
Therefore the aims o f this study were:
a) To determine the modulatory properties o f human FF on 1 lpH S D l activity and 
expression, and to determine the identity o f the modulatory compounds
b) To investigate the effect o f progesterone on the activity and expression o f 
1 lpH S D l in human granulosa-lutein cells
c) To elucidate the effects o f prostaglandins on basal 1 lp H S D l activity and 
expression in human granulosa-lutein cells
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d) To elucidate the effects o f hCG and IL-1 (3 on 1lpH S D l activity and expression in 
human granulosa-lutein cells, and the possible mediatory role for eicosanoids in any 
responses to hCG and /or IL-1 (3
e) To predict the topology and tertiary structures o f 1 lp H S D l as these relate to the 
regulation o f enzyme activities by hydrophilic and hydrophobic hormones using 
current literature, and in silico approaches.
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Chapter Two: Materials and M ethods
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Chapter 2- Materials and Methods
2.1 Chemicals and Reagents
PGE2 and PGF2a antibodies were kindly donated by Drs. R.W Kelly and N.L. Poyser 
respectively (University o f Edinburgh, UK). Progesterone antibody was obtained 
from the Central Veterinary Laboratory (Weybridge, Surrey, UK). hCG was a kind 
g ift from the National Hormone and Peptide Program-NIDDK (California, USA).
[7(n)-3H]-cholesterol (8Ci/mmol), [l,2 ,6,7-3H]-cortisol (60Ci/mmol), [l,2 (n )-3H]- 
cortisone (45Ci/mmol), [2,4,6,7-3H]-oestradiol (8 ICi/mmol), [5,6,8,11,12,14,15-3H]- 
PGE2 (164Ci/mmol), [5,6,8,9,1 l,12,14,15-3H]-PGF2a (219Ci/mmol), [1,2,6,7-3H]- 
progesterone (86Ci/mmol), [l,2 ,6,7-3H]-testosterone (70Ci/mmol), Dextran T500, 
ECL™ Western blotting detection reagents, PD-10 columns, and Hyperfilm™ ECL™ 
were each obtained from Amersham Biosciences, UK Ltd (L ittle  Chalfont, Bucks., 
UK). [7-3H]-pregnenolone (14Ci/mmol) was purchased from Perkin Elmer, 
(Beaconsfield, Bucks.,UK).
(3-mercaptoethanol, charcoal, chloroform, di-sodium hydrogen orthophosphate 12- 
hydrate (Na2HP0 4 .1 2 H2 0 ), ethanol, ethyl acetate, gelatin (powder), methanol, 
sodium di-hydrogen orthophosphate dihydrate (NaH2P0 4 .2 H2 0 ), and ultra-pure 
water were supplied by BDH (Poole, Dorset, UK).
1:1 Dulbecco’s modified Eagle’s medium:Hams’s F 12 (DM EM :Ham ’s F12) medium, 
foetal ca lf serum (FCS), L-glutamine, penicillin/streptomycin and Dulbecco’s
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phosphate-buffered saline (PBS) were purchased from Life technologies Ltd (Gibco 
BRL, Paisley, UK). TLC aluminium sheets (20cmx20cm, Silica gel 60) were 
supplied by Merck (Poole, Dorset, UK) and Ultima-Gold scintillant was purchased 
from Packard Biosciences B.V (Pangbourne, Berks, UK).
Bicinchoninic acid (BCA) protein assay reagent A  (Na2C0 3 , NaHCC>3, C4H406Na2 
in 0.2% N NaOH and BCA detection reagent), BCA reagent B (4% (w/v) CuS04) 
and Bovine serum albumin (BSA) protein standard (2mg/ml) were each obtained 
from Pierce Science UK Ltd (Tattenhall, Cheshire, UK). Extra thick filter paper and 
Tris-electrophoresis grade were supplied by Bio-Rad (Hercules, California, USA). 
Polyvinilyidine difluoride (PVDF) (Immobilon™-P transfer) membrane was 
purchased from M illipore (Watford, England). 30% (w/v) polyacrylamide (Ultra 
pure Protogel®) and X10 Tris-glycine-SDS electrophoresis grade running buffer 
were purchased from National diagnostics (Atlanta, Georgia, USA).
Sheep anti-human 1 lp H S D l primary monoclonal antibody (IgG fraction) and mouse 
anti-human GAPDH primary monoclonal antibody (IgG fraction) were both supplied 
by The Binding site Ltd. (Birmingham, UK). Donkey anti-sheep peroxidase 
conjugated IgG and rabbit anti-mouse peroxidase conjugated IgG were purchased 
from Sigma-Aldrich (Poole, Dorset, UK).NS398 was obtained from Cayman 
Chemicals (Alexis Platform, Nottingham, UK). Protease inhibitor Cocktail Set I 
(containing 500pM 4-(2-aminoethyl)-benzene-sulfonyl fluoride (AEBSF), 150nM 
aprotinin, ljuM  E-64, 0.5mM ethylene-diaminetetraacetic acid (EDTA), and lp M  
leupeptin) were obtained from Calbiochem®, c/o Merck Bioscience Ltd (Beeston,
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Nottingham, UK). SeeBlue® Plus 2 Pre-stained Protein standard molecular weight 
markers, range 250-4 kDa were supplied by Invitrogen Life Technologies (Paisley, 
UK). GBX fixer and replenisher, and GBX developer and replenisher were supplied 
by Eastman Kodak Company (Rochester, New York, USA).
A ll other chemicals and solvents were supplied by Sigma-Aldrich (Poole, Dorset, 
UK).
2.2 Collection and storage of follicular aspirates
2.2.1 Patient samples
Ovarian follicular aspirates containing granulosa cells were collected from women 
undergoing assisted conception at the Lister Hospital, Chelsea Bridge Road, London, 
UK. Collections were carried out with approval o f the local ethics committee, with 
informed patient consent, in accordance with the Declaration o f Helsinki and 
following HFEA guidelines.
Pituitary down-regulation was achieved by administration o f a GnRH analogue, 
Suprecur (Shire Pharmaceuticals, Andover, Hants, UK), 500pg per day from day 2 
o f the ovarian cycle for 10-21 days. Administration o f the GnRH analogue was then 
continued in conjunction with purified urinary human menopausal gonadotrophin, 
Menogon (Ferring Pharmaceuticals, Feltham, Middlesex, UK), 2-4 ampoules daily 
for 10-14 days, followed by a single intramuscular injection o f hCG, Profasi 
(Serono, Welwyn Garden City, Herts, UK), 5,000-10,000IU administered 36 hours
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prior to oocyte retrieval. Follicles were subsequently aspirated transvaginally under 
local anaesthesia.
2.2.2 Isolation o f human granulosa cells
Human granulosa cells were isolated following the method previously described by 
Webley et al. [1988]. Granulosa cells and contaminating blood cells from a single 
patient were separated from the supernatant follicular flu id and follicular flushing 
medium by centrifugation at 250g for 10 minutes at 4°C, with no brake, in a 
Beckman GS-6R centrifuge. The supernatant was discarded and the cell pellet 
resuspended in 10ml Dulbecco’s PBS. The cell suspension was overlaid onto 10ml 
60% (v/v) Percoll . The Percoll gradients were centrifuged at lOOOg for 20 minutes 
at 4°C with no brake. This resulted in sedimentation o f erythrocytes at the bottom o f 
the tube, w ith the granulosa cells settling on the Percoll-PBS interface. Granulosa 
cells were aspirated from the interface, resuspended in 10ml PBS, and centrifuged at 
250g for 10 minutes at 4°C. The supernatant was discarded and the pellet 
resuspended in 10ml PBS. This wash step was repeated a total o f  three times, and in 
the final wash step, cells from a single patient were pooled together.
Following the final wash step, the cell pellet was resuspended in 1ml PBS, and a 
lOpl aliquot was mixed with 0.4% (w/v) trypan blue solution to assess cell viability. 
Viable granulosa cells did not take up the trypan blue stain, and were counted under 
the microscope (magnification x200) using a haemocytometer. A fter dilution the 
cells were cultured in 1:1 (v/v) DMEM:Ham’s F i2 medium supplemented with 10% 
(v/v) FCS, penicillin (87,000 IU/L), streptomycin (87 mg/L) and 2mM L-glutamine.
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For studies o f 11 (3HSD activity and progesterone secretion, cells were seeded into 
sterile 24-well plates at a density o f 5x104 cells/ml o f culture medium, with a volume 
o f 1 m l/well. For studies o f prostaglandin secretion, cells were seeded into sterile 24- 
well plates at a density o f lx lO 5 cells/ml o f culture medium, with a volume o f 
1 m l/well. For experiments to determine effects on protein expression, cells were 
seeded into a sterile 6 well plate at a density o f 5x105 cells/ml o f culture medium, 
with a volume o f 2ml/well. Cells were subsequently incubated for 2 days at 37°C in 
a humidified atmosphere o f 5% (v/v) CO2 in air to allow cells to attach to the well o f 
the cell culture plates. A t the end o f the 2 day incubation, the medium was aspirated 
from the wells and discarded. The cells were rinsed with approximately 200fil pre­
warmed serum-free medium to remove any residual serum. The washing medium 
was aspirated, discarded, and serum-free medium and treatments were added to a 
total volume o f 1 or 2ml depending on cell culture plates. When using serum-free 
medium, bovine serum albumin was not added since this binds to cortisol with high 
affin ity and would thus be a confounding factor in quanitifying 11PHSD activities. 
Cells were subsequently incubated at 37°C as described above for a period o f 0 to 24 
hours, depending on the experimental design.
2.3 Radioimmunoassays
2.3.1 Progesterone R IA
Progesterone concentrations were determined by RIA as previously described by 
Pallikaros et al. [1995]. A  progesterone standard curve was prepared from a lpg/m l 
stock solution o f progesterone in ethanol, stored at -20°C. A  volume o f lOpl
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progesterone standard was transferred to a borosilicate tube, and the ethanol was 
evaporated under nitrogen. The progesterone was resuspended in 1ml serum-free 
medium to produce the top standard progesterone concentration o f lOng/ml 
(31.80nM). The top standard was double diluted in medium to produce the following 
standards: 15.90, 7.95, 3.98, 1.99, 0.99, 0.50, and 0.25nM progesterone. Volumes o f 
100p.l o f each standard were aliquoted in triplicate and 1 OOjliI serum-free medium 
were aliquoted into the OnM progesterone (Bo), total and non-specific binding (NSB) 
tubes in triplicate. The unknown samples were serially diluted in serum-free medium 
into a total volume o f lOOpl. The unknown samples were diluted in serum-free 
medium between 1/100 to 1/200 into a total diluted sample volume o f lOOpl per 
tube.
Progesterone antiserum was diluted 1/100 (v/v) in phosphate azide saline-gelatin 
(PAS-gel) buffer and stored in 1 OOjul aliquots at -20°C. Immediately prior to use, a 
lOOpl aliquot was thawed and further diluted 1/100 (v/v) in PAS-gel buffer resulting 
in a working antibody dilution o f 1/10,000 (v/v). A lOOpl volume o f diluted antibody 
was added to each standard and sample tube, excluding those for the determination 
o f total and NSB radioactivity where lOOpl PAS-gel buffer was substituted in place 
o f antibody.
[l,2 ,6 ,7-3H]-progesterone was diluted in PAS-gel buffer to give the required 
10,000cpm per lOOpl. A  volume o f lOOpl o f diluted [l,2 ,6 ,7-3H]-progesterone was 
added to all assay tubes. Each tube was vortexed, covered in aluminium foil, and 
incubated at 4°C overnight.
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The next day, a solution o f 0.025% (w/v) dextran was prepared in PAS-gel buffer. 
A fter the dextran had dissolved, 0.25% (w/v) charcoal was added and mixed for 30 
minutes at 4°C. A  volume o f 500p,l activated dextran-coated charcoal was added to 
each assay tube, w ith the exception o f the total radioactivity tubes, which received 
500p.l PAS-gel buffer. The tubes were vortexed and centrifuged for 10 minutes at 
lOOOg at 4°C w ith no brake to precipitate unbound progesterone. The supernatants 
were decanted into mini-scintillation vials, and 2ml Ultima-Gold scintillant was 
added into each vial, which were subsequently capped and vortexed. Radioactivity in 
cpm was measured on a Beckman Coulter LS 6500 Multipurpose Scintillation 
counter, with a count time o f 1 minute per vial. The counts were analysed using a 
DOS-RIA software program using the logit % B/Bo whereby the data from the 
standard curve was linearised. Intra and inter-assay coefficients o f variation were 9% 
(n=15) and 14% (n=40) respectively at 30% binding.
2.3.2 PGE? RIA
PGE2 concentrations were determined as previously described by Poyser [1987]. A 
PGE2 standard curve was prepared from a lpg/m l stock solution o f PGE2 in ethanol, 
stored at -20°C. A  lOpl volume o f PGE2 stock was transferred to a borosilicate tube, 
evaporated to dryness under nitrogen, and resuspended in 1 OOjlaI serum-free medium 
to produce a stock o f lOOng/ml PGE2 . A  50pl aliquot o f the lOOng/ml stock was 
diluted in serum-free medium to a total volume o f 1ml to generate the top standard 
concentration o f 5ng/ml (14.19nM) PGE2 . The top standard was double diluted in 
serum-free medium to generate the following standards: 7.09, 3.55, 1.77, 0.89, 0.44,
80
0.22, 0.1 InM  PGE2 . Volumes o f lOOfil o f each standard were aliquoted in triplicate 
and lOOp.1 serum-free medium were substituted into the Bo, total radioactivity, and 
NSB tubes. The unknown samples were either diluted 1/5 (v/v) in serum-free 
medium or assayed neat, with a total diluted sample volume o f lOOfil per tube. PGE2 
rabbit antiserum was stored in 50p,l aliquots at -20°C. A  50}il aliquot o f antiserum 
was diluted 1/100 (v/v) in phosphate buffer and stored in 500p.l aliquots at -20°C. 
Immediately prior to assay, a 500p.l aliquot o f 1/100 antibody was thawed and 
further diluted 1/30 (v/v) in phosphate buffer resulting in a working dilution o f 
1/3,000 (v/v). A  100fil volume o f diluted antibody was added to each standard and 
sample tube, excluding those for the determination o f total and NSB radioactivity 
where 100p.l o f Tris buffer was substituted for the antibody. Stock 
[5,6,8,11,12,14,15-3H]-PGE2 was diluted in Tris buffer to give the required 
10,000cpm per lOOjal. A  volume o f 100|il o f the diluted [5,6,8,11,12,14,15-3H]- 
PGE2 was added into all standard and unknown sample tubes. Each tube was 
vortexed, covered in aluminium foil, and incubated at 4°C overnight.
The next day, a solution o f 0.1% (w/v) dextran was prepared in Tris buffer. After the 
dextran had dissolved, 1% (w/v) charcoal was added and mixed for 30 minutes at 
4°C. A volume o f 200pJ activated dextran-coated charcoal was added to each assay 
tube, w ith the exception o f the total radioactivity tubes, which received 200p,l Tris 
buffer. The tubes were vortexed and centrifuged for 10 minutes at lOOOg at 4°C with 
no brake to precipitate unbound PGE2. The supernatants were decanted into m ini­
scintillation vials, and 2ml Ultima-Gold scintillant was added into each vial, which 
were subsequently capped and vortexed. Radioactivity in cpm was measured on a
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Beckman Coulter LS 6500 Multipurpose Scintillation counter, w ith a count time o f 1 
minute per vial. The counts were analysed using a DOS-RIA software program using 
the logit % B/Bo whereby the data from the standard curve was linearised. Intra- and 
inter-assay co-efficients o f variation were 10% (n=15) and 16% (n=28) respectively 
at 40% binding.
2.3.3 PGF?„ RIA
PGF2a concentrations were determined as previously described by Kelly et al., 
[1986]. A  PGF20C standard curve was prepared from a lpg/m l stock solution o f 
PGF201 in ethanol, stored at -20°C. A  lOpl volume o f PGF20C stock was transferred to 
a borosilicate tube, evaporated to dryness under nitrogen, and resuspended in lOOpl 
serum-free medium to produce a stock o f lOOng/ml PGF2a- A 25pl aliquot o f the 
lOOng/ml stock was diluted in serum-free medium to a total volume o f 1ml to 
generate the top standard concentration o f 2.5ng/ml (7.09nM) PGF2tt- The top 
standard was double diluted to generate the following standards: 3.55, 1.77, 0.89, 
0.44, 0.22, 0.11, 0.06nM PGF2a- Volumes o f lOOpl were aliquoted in triplicate and 
100pl o f serum-free medium were aliquoted into Bo, total radioactivity and NSB 
tubes. The unknown samples were either diluted 1/5 (v/v) in serum-free medium or 
assayed neat, with a total diluted sample volume o f lOOpl per tube.
PGF201 rabbit antiserum was stored in lOOpl aliquots at -20°C. A lOOpl aliquot o f 
antiserum was diluted 1/100 (v/v) in Tris buffer and stored in 100pl aliquots at
82
-20°C. Immediately prior to assay, a lOOpl aliquot o f 1/100 antibody was thawed 
and further diluted 1/100 (v/v) in Tris buffer resulting in a working dilution o f 
1/10,000 (v/v). A  lOOpl volume o f diluted antibody was added to each standard and 
sample tube, excluding those for the determination o f total and NSB radioactivity 
where lOOpl o f  Tris buffer was substituted for the antibody. Stock 
[5,8,9,1 l ,1 2 ,1 4 ,1 5 -3H]-PGF2a was diluted in Tris buffer to give the required 
10,000cpm per 100pl. A  volume o f IO O jllI o f the diluted [5 ,8 ,11,12 ,14 ,15-3H]-PGF2« 
was added into all standard and unknown sample tubes. Each tube was vortexed, 
covered in aluminium fo il, and incubated at 4°C overnight.
The next day, a solution o f 0.1% (w/v) dextran was prepared in Tris buffer. After the 
dextran had dissolved, 1% (w/v) charcoal was added and mixed for 30 minutes at 
4°C. A  volume o f 200pl activated dextran-coated charcoal was added to each assay 
tube, with the exception o f the total radioactivity tubes, which received 200pl Tris 
buffer. The tubes were vortexed and centrifuged for 10 minutes at lOOOg at 4°C with 
no brake to precipitate unbound PGF2a- The supernatants were decanted into m ini­
scintillation vials, and 2ml Ultima-Gold scintillant was added into each vial, which 
were subsequently capped and vortexed. Radioactivity in cpm was measured on a 
Beckman Coulter LS 6500 Multipurpose Scintillation counter, with a count time o f 1 
minute per vial. The counts were analysed using a DOS-RIA software program using 
the logit % B/Bo whereby the data from the standard curve was linearised. Intra- and 
inter- assay co-effecients o f variation were 10% (n=15) and 14% (n=15) 
respectively, at 37% binding.
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2.4 11 pHSD Assay
Human granulosa cells were isolated as described in section 2.2 and cultured at a 
density o f 5x l04 cells/ml culture medium, with a volume o f 1ml medium/well in a 24 
well culture plate. Cells were cultured for 2 days in 1:1 (v/v) DMEM:Ham’s F12 
medium supplemented with 10% (v/v) FCS, penicillin (87,000 IU/L), streptomycin 
(87 mg/L) and 2mM L-glutamine, at 37°C in a humidified atmosphere o f 5% (v/v) 
CO2 in air.
A t the end o f the 2 day pre-incubation period, the serum-supplemented medium was 
aspirated from the wells and discarded. The cells were rinsed using approximately 
200pl warmed serum-free medium to remove any residual serum and the washing 
medium was discarded. Cells were then transferred to pre-warmed serum-free 
medium supplemented with penicillin (87,000 IU/L), streptomycin (87 mg/L) and 
2mM L-glutamine and incubation continued for a further 24 hours. When assessing 
the effects o f  chronic exposure to treatments, these treatments were added at 48 
hours and were present throughout the third day o f culture (i.e., from 48 to 72 hours). 
When assessing the effects o f acute exposure to treatments, these treatments were 
added for the final 4 hours o f incubation (i.e., from 68 to 72 hours). Where the 
purpose o f the study was to assess the effects o f treatments on 11 (3HSD activities, 
lOOpl o f serum-free medium containing either lOOpmol o f either [ 1,2,6,7-3H]- 
cortisol (5nCi/pmol) or [l,2 ,(n)-3H]-cortisone (5nCi/pmol) were added to each well, 
with a final substrate concentration o f lOOnM. Cortisol-cortisone inter-conversion 
was measured over final 4 hours o f incubation (i.e., from 68 to 72 hours). The
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rationale to this approach was to ensure that all cells, irrespective o f the treatment 
group and duration o f treatment, were at the same stage o f differentiation.
A t the end o f the 4-hour assay incubation period, the medium from each well was 
transferred into screw cap borosilicate tubes to which 2ml o f ice cold chloroform 
was added. The tubes were then capped, vortexed, and subsequently centrifuged at 
lOOOg for 20 minutes at 4°C. Following centrifugation, the aqueous phase was 
removed immediately and discarded. The samples were then evaporated to dryness 
in a Techne Dri-Block DB-3 sample concentrator at 45°C under nitrogen, before 
being stored at 4°C for up to 7 days pending resolution o f steroids by thin layer 
chromatography (TLC).
Following evaporation to dryness, steroid residues were resuspended in 30|ul ethyl 
acetate containing Im M  cortisol and Im M  cortisone. The tubes were vortexed, and 
20pl volumes from each tube were transferred to individual lanes o f a TLC plate. 
TLC plates were developed in an atmosphere o f 92:8 (v/v) chloroform:95% (v/v) 
ethanol. The bands containing cortisol and cortisone were visualised by absorption o f 
UV light at 254nm. The levels o f radioactivity in the cortisol and cortisone regions 
were quantified using a Bioscan System 200 radiochromatogramme scanner 
(Lablogic, Sheffield, UK), with each lane counted for 5 minutes. The cortisol- 
cortisone inter-conversion was calculated by multiplication o f percentage conversion 
o f [l,2 ,6 ,7-3H]-cortisol to [l,2,6,7-3H]-cortisone (for l i p  dehydrogenase activity) 
and [l,2 ,(n )3'FI]-cortisone to [l,2 ,(n)-3H]-cortisol (for 11-ketosteroid reductase
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activity) by the total amount o f steroid that was present at the beginning o f the assay 
(lOOpmol/well).
2.5 Reverse Phase C18 column chromatography
C l8 column chromatography was carried out as described by Morris et al, [1992] 
using C l8 sepak cartridges. Before use o f each C l8 cartridge, the cartridge was 
primed using 10ml methanol and then rinsed with 10ml distilled H2O. Human 
follicular flu id  (1ml) was then loaded onto a C l8 cartridge and the loading eluent 
collected. Fractions were then sequentially eluted, based on hydrophobicity, using 
increasing concentrations o f methanol in 1ml volumes (0, 10, 20, 30, 40, 45, 50, 55, 
60, 65, 70, 75, 80, 85, 90, 95, 100% (v/v)) methanol in distilled water. Each 
individual fraction generated was collected into a separate borosilicate glass tube. 
With the exception o f 0-20% (v/v) methanol fractions, each tube was evaporated to 
dryness using a Techne Dri-Block DB-3 sample concentrator at 45°C under nitrogen, 
and re-suspended in 1ml volumes o f 20% (v/v) methanol. Each tube was stored at - 
20°C pending analysis.
Pooled follicular fluid from large antral follicles was aliquoted into 8 volumes o f 
lm l. Each aliquot was spiked by the addition o f [7(n)-3H]-cholesterol, [1,2,6,7-3H]- 
cortisol, [l,2 ,(n )-3H]-cortisone, [2,4,6,7-3H]-oestradiol, [5,6,8,11,12,14,15-3H]- 
PGE2, [5,6,8,9,1 l,12,14,15-3H]-PGF2a, [7-3H]-pregnenolone, [ 1,2,6,7-3H]- 
progesterone, or [7(n)-3H]-testosterone. The spiked samples were each loaded onto a 
separate C l8 cartridge for fractionation by a stepwise methanol gradient as described 
above. Triplicate lOOpl aliquots o f each fraction generated were transferred to
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scintillant vials containing 2ml Ultima gold scintillation and the amount o f 
radioactivity quantified using a Beckman Coulter LS 6500 Multipurpose 
Scintillation counter with a count time o f 1 minute per tube.
2.6 Assessment of llpHSD enzyme modulators in FF
Effects o f FF fractions on 11 |3HSD activity were assessed using a rat kidney 
homogenate as a source o f both 1 lf3HSDl and 11(3HSD2 enzymes [Thurston et al., 
2002].
Male Sprague-Dawley rats were sacrificed by terminal phenobarbitone anaesthesia 
[Marks et al., 2003]. Kidneys were dissected and stored at -20°C. 0.5g rat kidney 
was added to 17ml hypotonic Tris-EDTA lysis buffer, and homogenised using a 
glass homogeniser. Restoration o f isotonicity was achieved by the addition o f 2ml 
1.5mM potassium chloride to yield a renal tissue homogenate concentration o f 
25mg/ml lysis buffer [Sewell et al., 1998]. The homogenate was centrifuged at 
lOOOg for 20 minutes at 4°C. The supernatant was removed and from the 
supernatant, 1 OOjliI volumes were transferred to borosilicate screw cap tubes. 
Following this, 600pl PBS were added to each tube. Into each set o f triplicate tubes, 
lOOpl o f each follicular fluid fraction was also added. For control tubes, 100pl o f 
20% (v/v) methanol was added instead o f FF. Samples were pre-incubated for 30 
minutes at 37°C in a shaking water-bath. To assess cortisol-cortisone interconversion 
by the NADP(H)-dependent llp H S D l enzyme, either 100p.l containing lOOpmol 
[l,2 ,6 ,7-3H]-cortisol (5nCi/pmol) and lOOpl 4mM NADP+ were added to each tube, 
or [l,2 ,(n )-3H]-cortisone (5nCi/pmol) and 4mM NADPH. To assess the effects on
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llpH S D 2, this protocol was repeated using 4mM N A D + in place o f NADP+. 
Following this, the tubes were incubated for 1 hour at 37°C in a shaking water-bath. 
After 1 hour, the steroids were chloroform extracted, resolved by TLC and quantified 
using a Bioscan System 200 Radiochromatogramme Scanner as described in section 
2.4.
2.7 Cell isolation and protein assay for Western blot
Cell isolation and protein assays were carried out as previously described by 
Thurston et al [2003c]. Following granulosa cell culture and treatment, spent 
medium was aspirated from the 6 well plates, and the cells were washed with 1ml 
ice-cold PBS. The PBS was aspirated, and cells were lysed in protein lysis buffer 
(119pl per well) containing protease inhibitor cocktail (see section 2.1 for cocktail 
recipe). Cells were freeze-thawed, removed from the 6 well plates by scraping, and 
aliquoted into Eppendorf tubes. The samples were heated for 5 minutes at 100°C 
using a Techne Dri-Block DB-3 and centrifuged using a Biofuge bench-top 
centrifuge at 3000g for 1 minute to precipitate cell debris.
For determination o f granulosa cell protein concentration (mg protein/ml), a standard 
curve was generated from a 2mg/ml stock solution o f BSA. To generate the standard 
curve, the following volumes o f stocks were used and diluted in distilled H2O to 
produce concentrations o f 1.8, 1.5, 1.2, 0.9, 0.6, 0.3, 0.1, and Omg/ml. Volumes o f 
10pl o f each standard were aliquoted into duplicate wells in a 96-well cell culture 
plate. Into each standard well, a further volume o f lOpl lysis buffer containing the 
protease inhibitor cocktail was added (to eliminate any variation caused by the
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samples being in lysis buffer containing protease inhibitor cocktail). The samples 
were diluted 1/2 (v/v) in dH20 to a total volume o f 20pl in duplicate. A reference 
blank was generated using lOpl lysis buffer containing protease inhibitor cocktail, 
and lOpl distilled H 2O.
A total volume o f 10ml was prepared using the Bicinchoninic acid reagents, A  and B 
at a ratio o f 50:1 (v/v) A:B as per the manufacturers’ guidelines (Pierce, UK). The 
reagents were vortexed, and a volume o f 200pl was added to each well. The samples 
were incubated at 37°C for 30 minutes, and the optical density determined using a 
Dynex Technologies micro-plate reader at a wavelength o f 562nm. The Revelation 
3.0 software package was used to determine the unknown sample concentrations 
from the standard curve generated.
Once protein concentrations were determined, 1 j l l I  o f 1% (w/v) bromophenol blue, 
and 5pi p-mercaptoethanol were added to each sample. Samples were heated to 
100°C for 5 minutes using a Techne Dri-Block DB-3 and centrifuged using a 
Biofuge 13 bench-top centrifuge (Heraeus Sepatech) at 10,000g for 1 minute to re­
precipitate cells.
2.8 SDS-PAGE
SDS-PAGE was used for resolution o f llp H S D l protein from granulosa cells and 
rat kidney homogenate samples according to their molecular weights. A  BioRad 
Protean I lx i Gel electrophoresis system was used with reducing polyacrylamide Tris- 
glycine gels composed o f a 4% (w/v) acrylamide stacking gel, and a 10% (w/v)
89
acrylamide resolving gel (for polyacrylamide gel composition see Appendices I- J 
and K). A  running buffer system o f Tris-Gly-SDS was used and the protein samples 
loaded into the stacking gel at a final concentration o f 30pg protein/60pl loading 
buffer. Molecular weight markers were run alongside each protein sample. 
Electrophoresis was carried out at a current o f 15mA per gel overnight until the gel 
front reached the bottom o f the plates.
2.9 Western Blot
2.9.1 Preparation for transfer o f proteins from SDS-PAGE gel to polvvinvlidine 
difluoride (PVDF) membrane
The PVDF membrane and 2 pieces o f filter paper were cut to the appropriate size to 
match the size o f the SDS-PAGE gel. To make the membrane receptive to protein 
transfer, the membrane was saturated in methanol, and transferred to distilled H2O 
for 10 minutes. Following this, the PVDF membrane was transferred to Western 
blotting transfer buffer for 15 minutes. The SDS-PAGE gel was incubated in transfer 
buffer for 15 minutes. For the last 5 minutes o f the incubation, the filter paper was 
incubated in transfer buffer. The filter paper, membrane, gel and filter paper were 
arranged on a Transfer-blot SD semi-dry transfer cell (Biorad) in that order. The blot 
was transferred for 1 hour 45 minutes at 25V, with a current o f 0.8mA per cm2 o f 
gel.
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2.9.2 Blocking o f the membrane
Following the protein transfer to PVDF membrane, the gel and filter paper were 
discarded and the membrane incubated in a blocking solution o f 10% (w/v) BSA, 
0.001% (w/v) sodium azide in Tris-buffered saline Tween (TBST) for 2-4 hours.
2.9.3 11BHSD1 primary antibody probing
The membrane was removed from the blocking solution. Following this the 
membrane was incubated overnight in a 1/100 dilution o f sheep anti-human 
1 lpH S D l monoclonal antibody (in 10% (w/v) BSA, 0.001% (w/v) sodium azide in 
TBST) at maximum agitation on a Rotomax 120 shaker (Heidolph). Following this, 
the membrane was removed from primary antibody and washed for 10 minutes in 
150ml TBST at maximum agitation on the Rotamax 120. The TBST washing buffer 
was discarded and this wash step was repeated a total o f 6 times.
2.9.4 Secondary antibody probing
Following the wash steps, the membrane was incubated in a 1/10,000 dilution o f 
donkey anti-sheep IgG (diluted in TBST containing 0.2% (w/v) BSA) conjugated to 
horseradish peroxidase for 1 hour, at maximum agitation on a Rotamax 120 shaker. 
After 1 hour, the blot was removed from secondary antibody and washed for 10 
minutes in 150ml TBST at maximum agitation. This wash step was repeated a total 
o f 8 times.
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2.9.5 Developing o f the blot
To visualise the binding o f the secondary antibody conjugated to horseradish 
peroxidase, the membrane was incubated in equal quantities o f ECL reagents 1 and 2 
for 1 minute as per the manufacturers’ guidelines (Amersham Biosciences, UK). The 
ECL reagents were aspirated from the membrane, discarded and the PVDF 
membrane was wrapped in saran wrap. The PVDF membrane was placed into a film  
cassette and protein bands visualised through exposure onto Hyperfilm ECL® for 1, 
3 or 5 minutes. The film  was then developed using the ECL detection method as per 
the manufacturers’ guidelines (Amersham Biosciences, UK).
2.9.6 Stripping the membrane o f bound antibody
To re-probe the membrane for GAPDH expression, bound primary antibody was 
stripped from the membrane. To achieve this, the membrane was incubated in 100ml 
o f stripping buffer (see Appendix I L) at 50°C for 20 minutes in a water-bath 
(adapted from the manufacturers’ guidelines, Amersham Biosciences). Following 
incubation, the blot was removed and the stripping buffer discarded. The blot was 
transferred to wash in 150ml TBST at maximum agitation on a Rotamax 120. This 
wash step was repeated 4 times in preparation for re-probing o f the membrane for 
GAPDH.
2.9.7 GAPDH re-probing
GAPDH was probed for using the same protocol that was used to determine 
llp H S D l expression but with different antibodies (see section 2.9.3 to 2.9.5). The
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primary antibody was a murine antibody raised against the human sequence o f 
GAPDH. The secondary antibody was rabbit anti-mouse IgG used at a dilution o f 
1/5,000 in TBST containing 0.2% (w/v) BSA.
2.9.8 Quantification o f protein expression
Densitometric analysis was carried out to quantify protein expression using a BioRad 
Model GS-690 Imaging Densitometer with BioRad Molecular Analyst software, 
version 1.4. A  ratio o f 11 (3HSD1 expression to GAPDH was used to quantify protein 
expression w ithin a given lane o f a Western blot.
2.10 Statistical analyses
A ll experimental data are presented as the mean±SEM o f up to 98 independent 
experiments, performed using cells from individual patients. Due to differences in 
hormonal responses, hormonal synthesis and enzyme activities between patients, the 
results o f each experiment have been standardised and presented as a percentage o f 
the basal control. However, all statistical analyses were performed using absolute 
data and not the internally referenced data.
Statistical evaluations were carried out using GraphPad Prism 3.02 software (San 
Diego, USA). Since data conformed to Gaussian distributions, parametric tests were 
used. When comparing two means in isolation, an unpaired /-Test was used 
treatments (with Welch’s correction where appropriate). When comparing multiple 
treatments, or a change across a single variable (e.g., concentration o f treatment or 
with varying time), a one-way analysis o f variance (ANO VA) with repeated
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measures was performed followed by a Dunnett’ s multiple comparison as the post 
hoc test.
Significance was assessed in all experiments as a probability value o f p<0.05.
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Chapter Three; Effect of human follicular fluid on the activity and expression
of 11BHSP1
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Chapter 3: Effect of human follicular fluid on the activity and expression of 
11BHSD1
3.1 Background
Human fo llicular flu id (FF) is comprised o f many compounds including cortisol 
[Fateh et al., 1989; Jimena et al., 1992]. Several studies have inversely linked the 
activity o f 11 [3HSD in granulosa cells, either measured directly in vitro, reflected by 
the ratio o f cortisol:cortisone in FF, with the clinical outcome o f in vitro fertilisation- 
embryo transfer (IVF-ET) (see section 1.8).
The mammalian body contains a range o f natural 11[3HSD enzyme inhibitors 
including compounds such as bile acids and sterols (Table 1.1). Moreover, studies 
conducted by Morris et al. [1992] first isolated an endogenous inhibitor o f 1 lpHSD 
from human urine. This factor was termed ‘glycyrrhetinic acid like factor’ (GALF) 
due to the fact that, like glycyrrhetinic acid, GALF was able to inhibit both 11 (3HSD 
and 5a-reductase activities. The levels o f GALF are higher in women than men, and 
higher in pregnant women than non-pregnant women [Morris et al., 1992].
Inspired by this work, we have speculated that GALF, or related inhibitors o f 
1 lpHSD, may be produced by the ovary and/or placenta. Initia l studies conducted by 
D.P. Norgate suggested that such factors may indeed exist in FF aspirated from 
women undergoing IVF-ET.
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Little is known about the mechanisms by which the modulatory compounds in 
human FF regulate 1 lpHSD activities, and whether the effect is mediated through a 
change in enzyme expression. Moreover, what the identity o f the compounds within 
human FF are. Therefore the aims o f this chapter were:
(i) To isolate those compounds contained in the hydrophilic and 
hydrophobic fractions o f human FF that acutely modulate llp H S D l 
activity and characterise their effects on NADP(H)- and NAD+ - 
dependent 11 (3HSD activities.
(ii) To investigate possible candidates for the lipid inhibitors o f 11 pHSDl 
activity contained in human FF.
( iii)  To investigate the effects o f the enzyme modulators in the active fractions 
o f human FF on the expression o f 11(3HSD1 in human granulosa-lutein 
cells.
3.2 Experimental protocol
For all experiments, fractions o f human FF, aspirated from the ovaries o f women 
undergoing oocyte retrieval for IVF-ET, were separated by reverse phase C l8 
column chromatography using a stepwise methanol gradient as described in section 
2.6. To assess the effects o f specific fractions o f human FF on 1 lpHSD activities, a 
rat kidney homogenate assay was used as described in section 2.7. Enzyme activities 
were assessed over 1 hour in the presence and absence o f specific fractions o f human 
FF. Control samples were incubated with 20% (v/v) methanol and test samples were 
incubated w ith human FF, or specific fractions thereof, each at a final dilution o f
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10% by volume. Hence, in all samples, the final methanol concentration was < 2% 
by volume. A t the end o f each experiment, the steroids were chloroform extracted, 
resolved by TLC and cortisol-cortisone inter-conversion quantified using a 
radiochromatogramme scanner (see section 2.4).
To assess the effects o f human FF fractions on 1 lpH S D l expression, hGL cells were 
isolated and seeded into 6 well plates at a density o f 1 x 106 cells/2ml o f medium per 
well. Cells were cultured for 2 days in serum-supplemented medium to allow for 
luteinisation and for cell attachment to the plates (see section 2.2). Following this, 
cells were transferred to serum-free media, and individual wells were treated with 
control (20% v/v methanol), human FF that had not been subjected to column 
chromatography, compounds eluted specifically in the hydrophilic fractions o f 
human FF at 0% (v/v) methanol or the hydrophobic fraction o f human FF eluted at 
80% (v/v) methanol respectively. A ll fractions (both the control and experimental 
fractions o f human FF) were diluted to a final concentration o f 10% (v/v) and hGL 
cells were treated for 24 hours. Effects on lip H S D l protein expression were 
determined by SDS-PAGE and Western blot analysis with internal standardisation to 
GAPDH expression (see sections 2.8, 2.9 and 2.10).
To investigate whether PGF2a, PGE2 and specific steroids could be the compounds 
contained in any fractions o f human FF found to modulate the activity o f 11 pHSD, 
aliquots o f human FF were spiked with each tritiated radiochemical as described in 
section 2.6. To assess the retention o f each compound on the C l8 column, each 
compound was eluted by stepwise methanol gradient fractionation using reverse
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phase C l8 column chromatography (see section 2.6). To confirm the concentration 
o f methanol required to elute each radiochemical, lOOpl o f each fraction was placed 
into a scintillation vial, along with 2ml Ultima-gold scintillant. The radioactivity o f 
each fraction was assessed using a liquid scintillation counter and the data 
standardised relative to the total amount o f radioactivity recovered from the C l8 
column for that specific radiochemical (to 100% as the total compound concentration 
per column).
It should be noted that the studies o f the effects o f human FF on enzyme activities 
and the candidate compound elution profiles in this chapter were conducted in 
collaboration with L.M . Thurston and D.P. Norgate and have been published in 
Reproduction, (Thurston et al., 2002).
3.3 Results
3.3.1 Effects o f  human FF on NADP(TO-dependent 11BHSD activities
The component fractions o f human FF were resolved using reverse phase C l8 
column chromatography and the effects o f each component fraction o f human FF on 
NADP(H)-dependent 1 lpHSD activities were tested. Hydrophilic compounds eluted 
by 0% (v/v) and 10% (v/v) methanol significantly increased NADP+-dependent 
cortisol oxidation to 155.0 ± 4.5% and 128.5 ± 3.3% o f control enzyme activities 
respectively (p<0.01, Figure 3.1). In contrast, hydrophobic compounds eluted at 75% 
(v/v), 80% (v/v) and 85% (v/v) methanol inhibited NADP+-dependent cortisol 
oxidation. Maximum enzyme inhibition was achieved by those hydrophobic 
fractions o f human FF eluted at 80% (v/v) methanol. This fraction o f human FF
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inhibited cortisol oxidation by 63.1 ± 3.7% (p<0.01) in comparison to control. The 
effects o f  each component fraction o f human FF on NADPH-dependent cortisone 
reduction mirrored those on cortisol oxidation. Hydrophilic compounds eluted by 0% 
(v/v) methanol increased cortisone reduction to 185.7 ± 2.2% o f control (p<0.01), 
whereas, hydrophobic compounds eluted at 75% (v/v), 80% (v/v) and 85% (v/v) 
methanol inhibited NADPH-dependent cortisone reduction by up to 73.8 ± 1.5% o f 
control enzyme activity (p<0.01, Figure 3.2).
To assess whether the active compounds contained in human FF were lipids, 6 
randomised human FF samples were subjected to charcoal-stripping before being 
applied to a C l 8 cartridge for methanol resolution. Charcoal-stripping o f the human 
FF had no effect on compounds eluted at 0% (v/v) methanol, which continued to 
stimulate NADP+-dependent cortisol oxidation. However, charcoal-stripping o f 
human FF effectively removed the hydrophobic inhibitors o f NADP(H)-dependent 
11(3HSD activities eluted at 75 % (v/v) to 85% (v/v) methanol (Figure 3.3).
3.3.2 Effects o f human FF on NAD+-dependent cortisol oxidation
Fractions resolved from human FF using reverse phase C l 8 column chromatography 
had no affect on N A D +-dependent cortisol oxidation when assessed at a Final dilution 
o f 10% by volume (p>0.05, Figure 3.4).
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3.3.3. Elution profiles o f 3H lipids from C18 cartridges
Using the same reverse phase C l8 chromatography profile, cortisol and cortisone 
eluted at 45% (v/v) and 50% (v/v) methanol, respectively, while oestradiol, 
testosterone, progesterone and pregnenolone eluted over the range o f 60% (v/v) to 
75% (v/v) methanol. Cholesterol was eluted in the 100% (v/v) methanol fraction, 
whereas PGE2 and PGF201 eluted in the range o f 20-40% (v/v) methanol (Figure 3.5).
3.3.4 Effect o f  human FF fractions on 11BHSD1 expression in hGL cells
To assess the effect o f human FF fractions on 1 lpH S D l protein expression in hGL 
cells, 9 human FF samples were chosen from the cohort o f human FF assessed in 
section 3.3.1 and fractionated using a methanol gradient. Human FF that had not 
been subjected to C l8 column chromatography (whole human FF) and the active 
fractions o f human FF eluted at 0% and 80% (v/v) methanol had no effect on 
1 lpH S D l protein expression in hGL cells (p>0.05, Figure 3.6).
3.4 Discussion
Previous work conducted in the laboratory by D.P. Norgate had indicated that human 
FF might contain hydrophilic and hydrophobic compounds that could modulate the 
inter-conversion o f cortisol and cortisone by 11(3HSD. Work conducted in 
collaboration with Thurston et al. [2002] has revealed that the modulators in human 
FF can be resolved by reverse phase C l8 column chromatography using stepwise
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Figure 3.1: Effects o f  compounds in human FF eluted by reverse-phase C l8 
chromatography using a stepwise methanol gradient fractionation on NADP+- 
dependent oxidation o f  lOOnM cortisol over 1 hour in a rat kidney homogenate 
bioassay. Data represent the mean ± SEM for 98 samples o f  human FF, ( * *  p<0.01 
versus no human FF fraction). Data subjected to one-way A N O V A  w ith  repeated 
measures fo llowed by Dunnett’ s m ultip le comparison
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F igure  3.2: Effect o f  compounds in human FF eluted by reverse-phase C l8 
chromatography and stepwise methanol gradient fractionation on NADPH-dependent 
reduction o f  1 OOnM cortisone over 1 hour in a rat kidney homogenate bioassay. Data 
represent the mean ±  SEM for 6 samples o f  human FF, ( * *  p<0.01, versus no human 
FF). Data subjected to one-way A N O V A  w ith  repeated measures fo llowed by 
Dunnett’ s m ultip le  comparison
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Figure 3.3: Effect o f  compounds in human FF before (p ink line) and after (blue line) 
incubation w ith  dextran-coated charcoal. Fractions were eluted eluted by reverse- 
phase C l8 chromatography using a stepwise methanol gradient fractionation on 
N A D P +-dependent oxidation o f  lOOnM cortisol over 1 hour. Data represent the mean 
± SEM fo r 6 samples o f  human FF, (*p<0.05, **p<0.01 versus no human FF). Data 
subjected to one-way A N O V A  w ith  repeated measures fo llowed by Dunnett’ s 
m ultip le  comparison
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F igure  3.4: E ffect o f  compounds in human FF eluted by reverse-phase C l8 
chromatography and stepwise methanol gradient fractionation on N A D +-dependent 
oxidation o f  1 OOnM cortisol over 1 hour in a rat kidney homogenate bioassay. Data 
represent the mean ± SEM for 58 samples o f  human FF, (p>0.05 versus human FF). 
Data subjected to one-way A N O V A  w ith  repeated measures fo llowed by Dunnett’ s 
m ultip le  comparison
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Figure 3.5: Elution profiles o f  exogenously added prostaglandins and steroids in 
human FF eluted by reverse-phase C l8 chromatography and stepwise methanol 
gradient fractionation. Y e llow  triangle=cholesterol, purple cross=pregnenolone, 
Brown circle=progesterone, Blue line=testosterone, Blue cross=oestradiol, Pink 
square=cortisone, Blue circle=cortisol, Green cross=PGE2 , L igh t Blue line=PGF2a 
Data represent the mean ±  SEM for 3 samples o f  human FF
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Figure 3.6: (a) Representative Western blot o f  effect o f  whole non-fractionated hFF 
(W ), and those fractions o f  human FF eluted at 0% (v /v) and 80% (v/v) methanol on 
expression o f  11HSD1 (and G APDH) in hGL cells. W = whole non-fractionated hFF, 
C=control, 0= compounds eluted w ith  0% (v /v) methanol, 80= compounds in hFF 
eluted w ith  80% (v/v) methanol, R=positive control o f  rat kidney (b) Densitometric 
representation o f  effect o f  hFF and specific fractions thereof on 1 lp H S D l protein 
expression standardised to GAPDH. Data represent the mean ±  SEM for 9 independent 
samples (n=9). Means compared at each condition using paired T-test.
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methanol gradient fractionation. Using this technique, the hydrophilic 
stimulus/stimuli to 11 pHSD activities elute at 0% (v/v) methanol, and the 
hydrophobic inhibitor(s) elutes at 80% (v/v) methanol. Under the defined assay 
conditions, the modulators only affect NADP(H)-dependent cortisol-cortisone inter­
conversion in a rat kidney homogenate. Moreover, the modulators exert their effects 
on llp H S D  activities, without affecting the protein expression o f llp H S D l in 
human granulosa-lutein cells. Components o f human FF had no effect on NAD+- 
dependent cortisol oxidation. Since the rat kidney is known to express both 
1 lpH S D l and 1 lpHSD2 [Roland et al., 1995], the modulatory compounds in human 
FF appear to selectively regulate the activities o f the llp H S D l isoform, without 
affecting the oxidative activity o f 11 pHSD2.
When trying to elucidate the possible identity o f candidate modulators o f 1 lpH SD l 
activity in human FF, the simplest explanation could be that the modulators are 
artifacts o f the fractionation process. To investigate this possibility D.P Norgate and 
L.M. Thurston fractionated both PBS and DMEM:Ham’s F I2 media using reverse- 
phase C l8 column chromatography with a stepwise methanol gradient. The 
generated fractions assayed for NADP and NAD dependent-11 pHSD activities. 
Neither PBS or DMEM:Ham’s F12 had any modulatory effect on 1 lpHSD activities. 
Thus the modulatory compounds o f llp H S D l activity resolved by reverse-phase 
C l8 column fractionation do appear to originate from human FF.
Although outside the remit o f the work reported in this Chapter, studies to 
investigate whether the modulators o f llp H S D l activity in human FF were GALF
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have been conducted [Thurston et al., 2002]. Urine samples from the same cohort o f 
patients from which the FF was obtained was taken 2 hours prior to FF collection, 
and subjected to reverse phase C l8 column fractionation using a stepwise methanol 
gradient. No correlation was seen between the fractionation profile o f the modulators 
in human FF and the modulators in human urine, or GALF. Therefore the 
modulators in human FF were not those previously identified by Morris et al., 
[1992].
Possible identities for the hydrophilic stimuli o f 11(3HSD1 include proteins and 
water-soluble metabolites. Approximately 97% o f the total protein content o f human 
FF is eluted from a C l 8 column in the loading eluent o f whole human FF and the 0% 
(v/v) methanol fraction o f human FF [Thurston et al., 2002], A  possible water- 
soluble metabolite that could stimulate the activities o f llp H S D l is glucose-6- 
phosphate. Recent publications have linked the activities o f llp H S D l with the 
metabolism o f glucose-6-phosphate/fructose-6-phosphate by hexose-6-phosphate 
dehydrogenase (H6PDH) [Banhegyi et al., 2004], Moreover, it has been speculated 
that functional co-operativity exists between the two enzymes both localised to the 
lumen o f the ER, suggesting a link between the regulation o f glucose metabolism, 
and the functionality o f 1 lpH S D l [Atanasov et al., 2004].
Charcoal-stripping to remove lipids from human FF has shown that the hydrophobic 
enzyme inhibitors o f 11 pHSD in FF are lipids. The addition o f exogenous tritiated 
prostaglandins, steroids and cholesterol to human FF has eliminated these 
compounds as candidates contained in the hydrophobic fraction o f human FF eluted
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at 80% (v/v) methanol, since these candidate lipids eluted at 30-40% (v/v), 50-75% 
(v/v) and 100% (v/v) methanol respectively.
Recent studies have shown that 7-oxysterols can act as substrates for 11 (3HSD1 [Hult 
et al., 2004]. Studies have shown that human, rat and mouse llp H S D l can inter­
convert 7-ketocholesterol and 7p-hydroxycholesterol with similar kcat values as 
observed w ith glucocorticoids [Hult et al., 2004; Schweizer et al., 2004]. These 
studies suggest that 7-oxysterols could be modulatory components o f human FF that 
could compete for the active site o f llp H S D l, and competitively inhibit cortisol- 
cortisone inter-conversion. The structural properties o f the oxysterols would render 
them less hydrophobic than cholesterol, but more hydrophobic than known steroids. 
Hence, they might be expected to elute from a C l8 column at 80% (v/v) methanol.
Another possible candidate for the intrafollicular 1 lpHSD inhibitor eluted with 80% 
(v/v) methanol could be meiosis activating sterol (MAS). This sterol has been 
isolated from pre-ovulatory human FF [Byskov et al., 1995] and the concentration o f 
MAS has been linked to the ability o f the human oocyte to fertilise and cleave 
[Byskov et al., 1998]. Other candidates for the hydrophobic inhibitors o f 1 lpHSD l 
could be bile acids and their derivatives. Bile acids are also derived from cholesterol, 
are comprised o f 24 carbons and are hydroxylated. These structural properties render 
bile acids (like the oxysterols) less hydrophobic than cholesterol, but more 
hydrophobic than steroids. Bile acids such as chenodeoxycholic acid, have also been 
shown to inhibit the activity o f 1 lpH S D l [Perschel et al., 1991: Buhler et al., 1994; 
Morris and Souness., 1996; Diederich et al., 2000; Morris et al., 2004]. However,
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bile acids also inhibit N AD +-dependent cortisol oxidation by 11J3HSD2 such that 
they are unlikely to be the main inhibitory compound that specifically inhibits 
1 lpH S D l activities in human FF.
Chronic exposure o f hGL cells to whole human FF (not subjected to C l 8 cartridge 
chromatography) and human FF fractions eluted at 0% (v/v) or 80% (v/v) methanol 
had no significant effect on 11PHSD1 protein expression. These data suggest that the 
components o f human FF affect llp H S D l activities without affecting 11 PHSD 1 
enzyme expression, instead acting via a post-translational mechanism. Since 
1 lpH S D l binds cortisol and cortisone in a hydrophobic binding cleft [Tsigelny and 
Baker, 1995b], it is possible that lipids from human FF could inhibit llp H S D l 
activities by competing with cortisol and cortisone for binding to the active site o f 
the enzyme. Published hydropathy plots also indicate that the human 11 PHSD 1 
protein contains hydrophobic regions outside the active site, which could bind 
hydrophobic allosteric regulators o f 11 PHSD 1 (The structural and functional 
significance o f the hydrophobic regions in human 1 lpH S D l are investigated by the 
studies reported in Chapter 7).
Limitations to this study are that (i) concentration-dependent effects and (ii) kinetic 
analysis o f the stimulatory and inhibitory compounds were not determined. I f  
additional research time were permitted the concentration dependent effects o f 
human FF could be tested in the rat kidney homogenate radiometric conversion assay 
to determine effects o f each eluted fraction on llp H S D  enzyme activities. A 
concentration range o f 0% (v/v), 2% (v/v), 5% (v/v), 10% (v/v) and 20% (v/v) would
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be used for each reverse phase C l8 column eluted fraction o f human FF. A 
maximum concentration o f 20% (v/v) o f each fraction would be used in this assay to 
avoid methanol toxicity.
Kinetic analysis o f the stimulatory and inhibitory fractions o f human FF could be 
assessed using the rat kidney homogenate radiometric conversion assay. However, 
due to the crude nature o f the purification method for isolating these modulatory 
compounds, it is possible that each fraction is comprised o f multiple modulatory 
factors. Therefore, in order to determine the kinetic properties o f a specific 
modulator within these fractions, further purification o f the components o f each FF 
fraction would first be needed. Techniques that could be employed to do this are gas- 
chromatography followed by mass spectrometry. Furthermore, following purification 
the individual compounds from each modulatory fraction would need to be isolated 
in sufficient quantities before kinetic analysis could be carried out.
The human FF used in these studies was obtained from women undergoing 
controlled ovarian hyperstimulation for IVF-ET. Therefore the presence o f the 
enzyme modulators could be the result o f pituitary down-regulation and ovarian 
hyperstimulation, as opposed to a natural phenomenon in the human ovary. In 
subsequent studies conducted by Thurston et al. [2003c], it has been established that 
bovine and porcine FF also contain compounds that can stimulate and inhibit the 
NADP(H)-dependent activities o f 11(3HSD1. Moreover, these compounds isolated 
from bovine and porcine FF have biophysical properties comparable to the enzyme 
modulators isolated from human FF. Since these modulatory compounds in bovine 
and porcine FF were isolated from animals that have not been subjected to any
112
endocrine therapy, it is likely that the modulators o f llp H S D l activities in human 
FF are a natural phenomenon and not an artefact o f IVF-ET.
In conclusion, endogenous modulators in human FF regulate both the oxidative and 
reductive activities o f llp H S D l, but do not affect enzyme expression, suggesting 
possible post-translation mechanisms for the regulation o f 1 lpH S D l by compounds 
present in the human ovary. Possible candidates for these stimulatory and inhibitory 
modulators are likely to be hydrophilic proteins/metabolites and hydrophobic sterols 
respectively. Although steroids and prostaglandins were not found to be in the active 
fractions o f human FF that regulate 11 PHSD 1 activity, these lipids have 
characterised functions in the regulation and control o f the ovarian cycle. Therefore 
the next 3 chapters w ill address the modulatory roles for progesterone and 
prostaglandins in the regulation o f 1 lpH S D l activities and expression in hGL cells.
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Chapter Four: The autocrine/paracrine effects of progesterone on the activities 
and expression of 11BHSD1 in human granulosa-lutein cells
114
Chapter 4-The autocrine/paracrine effects of progesterone on the activities and
expression of 11BHSD1 in human granulosa-lutein cells
4.1 Introduction
The expression o f 11 pHSD isoforms in the ovary has been well documented. Rat 
[Tetsuka et al., 1999a], bovine [Tetsuka et al., 2003] and human [Michael et al 1997; 
Tetsuka et al., 1997; Ricketts et al., 1998] ovaries have all been shown to express 
11 pHSD isoforms differentially dependent on the stage o f the ovarian cycle. In the 
follicular phase, granulosa cells co-express mRNA encoding 11|3HSD2 and 
mineralocorticoid receptors [Tetsuka et al., 1999a]. In contrast, following the 
administration o f an ovulatory dose o f LH/hCG, 11|3HSD2 mRNA is down- 
regulated and 1 lpH S D l mRNA expression is up-regulated (see section 1.8.4).
There are numerous endocrine and paracrine regulators o f llp H S D  (see Table 1.1 
for summary). In the ovary, there are many secretory hormones that regulate the 
ovarian cycle. Progesterone is the major secretory product o f the corpus luteum, 
synthesised by the luteinising granulosa and theca cells. In other cell types, including 
the kidney, progesterone and its metabolites have been shown to regulate the activity 
o f 1 lpHSD [Quinkler et al., 1999; Burton and Waddell 2002; Quinkler et al., 2003]. 
However, the potential autocrine/paracrine effects o f progesterone on llpH S D  
activity and expression in luteinising human granulosa cells have yet to be 
elucidated. Therefore the aims o f this study were:
(i) To determine whether aminoglutethimide (AG) can inhibit progesterone 
synthesis in human granulosa-lutein (hGL) cells.
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(ii) To investigate the effects o f inhibition o f progesterone synthesis on 
1 ipHSD activities in human granulosa lutein-cells.
( iii)  To determine i f  any effect observed as a result o f progesterone inhibition 
on llp H S D  enzyme activity is dependent on changes in llp H S D l 
protein expression in human granulosa lutein-cells.
4.2 Experimental Design
To investigate the effects o f AG on llp H S D l activities and expression in human 
granulosa lutein-cells, cells were isolated from follicular aspirates from women 
undergoing IVF-ET (section 2.2). Cells were seeded at a density o f 5 x 104 cells/ml 
medium in 24 well plates for activity studies and progesterone secretion studies or at 
1 x 106 cells/2ml medium in 6 well plates for expression studies. The cells were 
cultured for 2 days in serum-supplemented medium to allow for luteinisation and 
attachment to the plates, and transferred to serum-free medium to assess the effect o f 
AG on the activities and expression o f 1 IpHSD (section 2.2).
To assess acute chronic affects o f AG exposure, human granulosa-lutein cells were 
incubated with increasing concentrations o f AG (OpM, 0.0 lp M , 0.1 pM, lpM , 
lOpM, lOOpM) for 4 and 24 hours respectively. 4 and 24 hour time points were used 
to assess whether any effects o f AG were via signalling mediated events (typically 
carried out over minutes to hours) or via changes in gene expression, leading to 
changes in protein expression (typically carried out over hours to days). The vehicle 
to solubilise AG was dimethyl sulphoxide (DMSO). Each concentration o f AG was 
prepared in a final concentration o f 0.1% (v/v) DMSO, and control wells contained
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0.1% (v/v) DMSO as vehicle. The acute effects o f AG were determined for 4 hours, 
coinciding with the last 4 hours o f the 24 hour treatment incubation.
To verify that AG inhibited progesterone production, parallel cultures were set up 
and treated as for the enzyme activity studies. Progesterone concentrations were 
resolved measured in the spent serum-free medium following 4 or 24 hours treatment 
at each concentration o f AG using a radioimmunoassay (section 2.3.1).
11 pHSD activities were assessed over 4 hours in the presence o f each concentration 
o f AG using a radiometric conversion assay (section 2.4). In the case o f cells 
exposed to AG for 24 hours, enzyme activities were assessed in the final 4 hour time 
period (i.e. the same time point as for cells treated acutely with AG). Both 11(3- 
dehydrogenase ( l lp D H )  and 11-ketosteroid reductase (11KSR) activities were 
assessed, steroids extracted and cortisol-cortisone conversion quantified as described 
in section 2.4.
For the assessment o f changes in llp H S D l protein expression, human granulosa- 
lutein cells were incubated for either 4 or 24 hours with that concentration o f AG 
shown to have the greatest effect on llp H S D  activities (lOOpM). As for activity 
studies, the 4 hour time period coincided with the last 4 hours o f the 24 hour 
treatment incubation. Cell proteins were prepared and separated by SDS-PAGE, and 
llp H S D l protein expression was assessed using Western blot, quantified by 
densitometric analysis, and standardised to GAPDH protein expression (see sections 
2.8 to 2.10).
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4.3 Results
4.3.1 Concentration-dependent effects o f exposure to AG on progesterone 
production in human granulosa-lutein cells
In human granulosa-lutein cells acutely treated for 4 hours, AG inhibited 
progesterone production in a concentration-dependent manner (Figure 4.1). 
Maximum inhibition o f progesterone production was observed in cells treated with 
lOOpM AG which inhibited progesterone production by 61.5 ± 3.4% o f control 
(p<0.01). Incubation o f human granulosa-lutein cells with AG for 24 hours also 
inhibited progesterone production in a concentration-dependent manner, with lOOpM 
AG inhibiting progesterone production by up to 95.5 ± 1.2% o f control (p<0.01, 
Figure 4.1).
4.3.2 Concentration dependent effects o f AG on 11BHSD activities in human 
granulosa-lutein cells
Acute treatment o f human granulosa-lutein cells with AG for 4 hours increased both 
the 1 lp D H  and 11KSR activities in a concentration-dependent manner (Figure 4.2). 
11 pDH activity was significantly increased to 150.2 ± 22.2% o f control (p<0.05) and 
11KSR activity was significantly increased to 228.3 ± 60.0% o f control (p<0.05) by 
IOOjjM  AG.
Chronic exposure o f human granulosa-lutein cells to AG for 24 hours revealed a 
similar trend as with acutely treated cells, increasing both llp D H  and 11KSR 
activities (Figure 4.3). Treatment o f human granulosa-lutein cells with 100pM AG
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Figure 4.1: Concentration-dependent effects treatment w ith  A G  for 4 hours (blue 
line) or 24 hours (p ink line) by human granulosa-lutein cells on day 3 o f  culture Both 
data sets represent the mean ±  SEM for 3 independent experiments, (*p<0.05, 
**p<0.01 verses OpM AG ). Data were analysed by one-way A N O V A  w ith  repeated 
measures fo llowed by Dunnett’ s m ultip le comparison for each duration o f treatment.
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Figure 4.2: Concentration-dependent effects o f  A G  on l lp H S D  activities over 4 
hours on day 3 o f  culture in human granulosa-lutein cells. The blue line represents 
l lp D H  activity. A ll data points represent mean ±  SEM for six independent 
experiments, (*p<0.05 verses OpM AG ). The pink line represents experiments 
11KSR activ ity. A ll data points represent the mean ± SEM for five independent 
experiments, (**p<0.01 verses OpM AG). Data were analysed by one-way A N O V A  
w ith  repeated measures fo llowed by Dunnett’ s m ultip le  comparison for each enzyme.
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Figure 4.3: Concentration dependent effects o f  A G  on llp H S D  activities over 24 
hours on day 3 o f  culture in human granulosa-lutein cells. The blue line represents 
11 |3DH activity. The pink line represents experiments 11KSR activity. Both data sets 
represent the mean ±SEM  for 3 independent experiments (**p<0.01 verses OpM 
AG). Data were analysed by one-way A N O V A  w ith  repeated measures fo llowed by 
Dunnett’ s m ultip le  comparison fo r each enzyme activity.
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Figure 4.4: Effects o f  AG  on 11HSD1 protein expression (a) Western b lot showing 
effect o f  AG  on 11 pH SD l protein expression relative to G APDH on day 3 o f  culture 
in human granulosa lutein cells. H represents HEK293 cells stably transfected w ith  
1 lp H S D l as a positive control, C represents control conditions o f  just vehicle (0.1% 
DMSO), AG  represents treatment w ith  lOOpM AG , and B represents a blank well.
(b) Densitometric representation o f  the effect o f  AG  on 1 lp H S D l protein expression 
relative to G APDH on day 3 o f  culture in human granulosa lutein cells The blue bars 
represent experiments carried out over 4 hours. The pink bars represents experiments 
carried out over 24 hours. Hatched bars represent control, and solid bars represent 
hGL cells treated w ith  lOOpM AG. A ll data points represent mean ±SEM  for 10 
independent experiments p>0.05. Meak&compared at each time point using unpaired 
T-t^st.
GAPDH
stimulated lip D H  activity to 132.4 ± 14.6% o f control (p<0.01) and increased 
11KSR activity to 235.3 ±48.9% o f control (p<0.01).
4.3.3 Effect o f AG on 11BHSD1 expression in human granulosa-lutein cells
Over both 4 and 24 hours, treatment with lOOpM AG had no significant effect on 
lip H S D l protein expression when standardised to GAPDH protein expression 
(p>0.05, Figure 4.4).
4.4 Discussion
This study has investigated the effects o f inhibiting progesterone synthesis with AG 
on the activities and expression o f 1 lpH SD l in human granulosa-lutein cells. It has 
been confirmed that AG can inhibit progesterone production in human granulosa- 
lutein cells, consistent with a previous report by Fowkes et al, [2001]. Moreover, 
inhibition o f progesterone synthesis with AG increased both the 11(3DH and 11KSR 
activities o f llp H S D  in human granulosa-lutein cells. When progesterone 
production was significantly inhibited, a significant increase in both the oxidative 
and reductive activities o f 1 lpHSD was observed. Previous studies have highlighted 
the ability o f progesterone and hydroxylated progesterone metabolites to inhibit 
1 lpHSD activities [Lopez-Bernal, 1980]. Hence the positive effect o f AG on the bi­
directional activities o f llp H S D l in human granulosa-lutein cells could reflect 
decreased paracrine inhibition o f enzyme activities by progesterone.
Studies conducted on successive days o f cell culture found that as the granulosa cells 
luteinise, the activities o f llp H S D  decrease with a concomitant increase in the
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expression o f lip H S D l [Thurston et al., 2003b]. Progesterone production also 
increases as human granulosa cells luteinise in vitro [Fowkes et al., 2001]. These 
data are also consistent with progesterone inhibiting 11 pHSD activities in human 
granulosa-lutein cells.
A  limitation o f this study was the use o f only 2 time points. 4 and 24 hour time 
points were used in this study to determine the acute and chronic effects o f AG 
respectively on llp H S D  activity and protein expression. With the benefit o f 
hindsight and with the subsequent publication o f a manuscript by Rae et al., in 
October 2004, it would have been beneficial to extend this time course to 48 hours as 
maximum changes in lip H S D l mRNA expression, when stimulated with IL - la , 
were detected at this time point. The studies in this Chapter have shown that the 
effect o f AG on lip H S D l activities was independent o f lip H S D l protein 
expression. Rae et al., [2004] have also shown that progesterone had no effect on 
lip H S D l mRNA synthesis. These findings suggest that the regulation o f 1lpHSD 
activities by progesterone appears to be at a post-transcriptional and at a post- 
translational level. There are many possible post-translational mechanisms through 
which progesterone could affect 11 pHSD activities. Progesterone could be 
competing with cortisol/cortisone for the active site o f 11(3HSD1. This would 
decrease the availability o f active sites for cortisol/cortisone to bind to, competitively 
inhibiting 1 lpH S D l activities within human granulosa-lutein cells. Progesterone has 
been shown to competitively inhibit cortisol/cortisone metabolism in the rat 
myometrium [Burton and Waddell, 2002], providing one possible mechanism 
through which progesterone could inhibit the activities o f 11 pHSD.
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Another mechanism by which progesterone could decrease 11 pHSD activities could 
be through allosteric regulation. Progesterone could act as an allosteric effector to 
non-competitively inhibit lip H S D l activities through binding to a hydrophobic 
pocket within the structure o f lip H S D l. Structural studies have revealed that there 
are 2 hydrophobic regions flanking the active site o f the lip H S D l protein. Binding 
o f lipids such as progesterone to these clefts could result in a conformational change 
o f the enzyme structure, that could result in inhibition o f 1 lpHSD (see Chapter 7).
The third mechanism by which progesterone could affect the activities o f 1 lpHSD is 
through transmembrane signalling events. There are a number o f receptors that 
progesterone has been shown to signal through. As well as signalling through the 
classical nuclear receptor, there has been evidence for progesterone acting through 
the cell surface gamma amino-butyric acid (GABAa) receptor. Progesterone, its 
metabolites and deoxycorticosterone at physiological (low nM) concentrations have 
all been shown to enhance the interaction o f GAB A with GABAa receptors, 
facilitating the open state o f the GABA-gated ion channel. A t higher concentrations, 
the steroids have been shown to directly activate the G ABAa receptor-channel 
complex [Lambert et al., 2003]. However, studies by Peluso et al. [2002] have found 
that progesterone activation o f calcium in granulosa cells is not due to the binding o f 
GABAa receptor channels. Moreover, they have isolated a 60kDa plasma membrane 
protein that binds progesterone, the binding o f which is thought to mobilise 
intracellular calcium [Peluso et al., 2002]. This could be an alternative method 
through which progesterone is regulating the activities o f llpH S D . There has also
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been evidence o f progesterone binding to a membrane receptor that activates a 
number o f signalling pathways including cAMP, calcium mobilisation and mitogen 
activated protein kinase (MAPK) [reviewed by Bramley 2003]. A ll o f these 
signalling events could lead to the phosphorylation o f lip H S D l,  and change the 
activity o f 11 (3HSD.
The observed changes in 11 PHSD activities in human granulosa-lutein cells might 
also reflect direct effect o f AG on cell survival or direct stimulation o f 11 pHSD. It 
has been documented that AG can inhibit other cytochrome P450 enzymes o f the 
steroidogenic pathway such as aromatase [Santen and Misbin, 1981], but has been 
shown to stimulate 11 pHSD activity. This could be due to AG inhibiting the 
synthesis o f a regulator o f 11 PHSD activity, rather than a direct effect o f AG itself. 
To investigate this, studies could be carried out using a non-steroidogenic cell line 
(e.g. HEK293 cells) stably transfected with HSD11BJ. The same experimental 
design as for human granulosa-lutein cells could be conducted using increasing 
concentrations o f AG and investigating cortisol-cortisone conversion. This would 
reveal any direct stimulation inhibition o f lip H S D l by AG. To investigate cell 
survival, human granulosa-lutein cells could be stained with vital dyes such as trypan 
blue to assess the impact o f AG on cell viability (previous attempts at this in our 
laboratory have excluded any significant effect o f AG on cell viability). Moreover, 
AG has been shown to have no effect on agents which control steroidogenesis (i.e. 
cAMP generation and PKA activity) [D.R.E. Abayasekara, personal 
communication], or 3pHSD activity in human granulosa-lutein cells Therefore the
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effects o f AG on 1 lpHSD activity are likely to be through the inhibition o f P450CSCc 
and not through other non-specific mechanisms, or through effects on cell viability.
Progesterone replacement experiments could be carried out in the presence o f AG to 
determine i f  the speculated effects o f AG were via inhibiting progesterone synthesis. 
Progesterone has been shown to inhibit llp H S D  activity in several cell types 
[Lopez-Bernal, 1980; Burton and Waddell, 2002] therefore it would be difficu lt to 
ascertain whether the results obtained were via endogenous progesterone synthesis 
being inhibited, and the addition o f exogenous progesterone mimicking the 
speculated inhibitory effect, or through the addition o f exogenous progesterone 
simply inhibiting 1 lpHSD activity independent o f its speculated effects.
RU486, a progesterone receptor antagonist [Bardon et al., 1985] could be used to 
determine whether the effects o f AG on 1 lpHSD activity were via the inhibition o f 
progesterone synthesis and hence its actions. However, a confounding factor o f this 
study is that RU486 is also a glucocorticoid receptor antagonist [Bardon et al., 1985; 
Rae et al., 2004], therefore the results o f this experiment would need to be 
interpreted with caution. Also, the use o f a progesterone receptor antagonist pre­
supposes that progesterone is exerting its inhibitory effects on llp H S D  activity 
through intracellular mediated mechanisms, and not through possible allosteric 
binding to lip H S D l,  competitive inhibition o f lip H S D l activity, or through the 
speculated membrane bound progesterone receptor. Therefore any data obtained 
using RU486 could be used only to complement experimental data obtained using 
AG and/or progesterone replacement.
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A more specific mechanism o f inhibiting progesterone production would be through 
the inhibition o f 3pHSD (which converts pregnenolone to progesterone). Inhibitors 
such as trilostane or cyanoketone could be used to inhibit 3J3HSD activity. However, 
pregnenolone has been shown to inhibit llp H S D  activity [A.E. Michael, personal 
communication]. Therefore the accumulation o f pregnenolone in human granulosa- 
lutein cells is likely to exert inhibitory effects on 11 pHSD activity. It cannot be ruled 
out that pregnenolone is also inhibiting llp H S D  activity in human granulosa-lutein 
cells, and the addition o f AG could be stopping the inhibitory effects o f both 
pregnenolone and progesterone. One way to test this would be to use a 
radioimmunoassay to determine the basal concentration o f pregnenolone, and assess 
the concentration and time dependent effects o f AG on pregnenolone production. 
That said, progesterone is the major secretary hormone o f the CL, so it is likely that 
inhibition o f 11 PHSD activity is mediated predominately by progesterone.
In this study it was notable that suppression o f progesterone synthesis using lOOpM 
AG had a greater effect on the reduction o f cortisone than on the oxidation o f 
cortisol, irrespective o f the duration o f exposure to AG. Intuitively, i f  the effects o f 
AG are solely due to removing progesterone as a competitive inhibitor o f 11PHSD1 
the suppression o f progesterone synthesis might have been expected to have a greater 
effect on the low affin ity 1 lpD H  activity than on the high affin ity 11KSR activity o f 
the 1 lpH S D l enzyme. However the reasons for this counterintuitive finding are not 
clear at the present time.
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In conclusion, this study has revealed that inhibition o f progesterone synthesis using 
AG can affect the bi-directional activities o f lip H S D l but not expression o f 
lip H S D l protein in human granulosa-lutein cells on day 3 o f culture. The 
mechanisms by which progesterone affects the activities o f llp H S D  could be 
through competitive or non-competitive inhibition o f 11 PHSD, or through a 
signalling event to change the phosphorylation state o f the enzyme and hence its 
activities. Given the findings o f this study, all subsequent studies investigating the 
endocrine regulation o f 11 pHSD activities and expression were conducted in the 
presence o f lOOpM AG to circumvent the potential inhibition o f 1 lpH S D l activities 
by progesterone.
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Chapter 5: Paracrine roles for eicosanoids in determining the basal activities
and protein expression of 11BHSD1 in human granulosa-lutein cells
5.1 Introduction
The roles o f prostaglandins in the regulation o f female reproduction are well 
documented. In the ovary, at the time o f ovulation, prostaglandins are increased in 
the follicle, and a role for prostaglandins in luteal function has been postulated (see 
section 1.3). In several reproductive tissue types, prostaglandins have differential 
effects on the activity and expression o f 1 lpHSD isoforms. Hardy et al. [1999] have 
reported that in JEG-3 placental cells, PGE2 and PGF2« can inhibit llpH S D 2 
activity. In contrast, studies by Alfaidy et al. [2001; 2003] have shown that PGE2 
and PGF2a can increase cortisone reduction by 1 lpH S D l within foetal membranes, 
instigating a positive loop between prostaglandin synthesis and cortisol regeneration 
from cortisone for the onset o f parturition.
Although prostaglandins are known to regulate ovarian function, the role for 
prostaglandins in the regulation o f 11 pHSD activities and expression in human 
granulosa-lutein cells has yet to be established. Therefore the aims o f this study 
were:
1) To establish whether preferential inhibitors o f PGHS2 (meclofenamic acid 
(M A) and NS-398) affect the activities and expression o f 11 pHSDl in human 
granulosa-lutein cells
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2) To investigate the effects o f exogenous prostaglandins on cortisol oxidation 
in human granulosa-lutein cells.
5.2 Experimental design
5.2.1 Effects o f M A  and NS-398 on prostaglandin production. 11BHSD activities 
and 11BHSD1 expression
To investigate the effects o f M A and NS-398 on prostaglandin synthesis and on the 
lip H S D l enzyme, human granulosa-lutein cells were isolated from follicular 
aspirates o f women undergoing IVF-ET (section 2.2). Cells were seeded into 24 well 
cell culture plates at densities o f 5 x 104 cells/ml media for enzyme activity studies, 
and 1 x 105 cells/ml for prostaglandin secretion studies. For lip H S D l protein 
expression studies, cells were seeded into 6 well plates at a density o f 1 x 106/2ml 
media. Cells were cultured for 2 days to allow for luteinisation and attachment o f the 
cells to the plates. In order to assess the effects o f M A  and NS-398, cells were 
transferred to serum-free medium.
To assess the acute and chronic effects o f M A exposure on prostaglandin secretion 
and 1 lpHSD activities, human granulosa-lutein cells were incubated with increasing 
concentrations o f M A (OpM, 0.01 pM, 0.1 pM, lp M , lOpM, lOOpM) for 4 and 24 
hours respectively on day 3 o f culture. Since M A  was soluble in serum-free medium, 
no organic solvent was used. Where cells were treated with M A  for only 4 hours, 
this 4 hour incubation period coincided with the final 4 hours o f the 24 hours
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treatment point (i.e. cells were treated either from 48-72 hours in culture, or from 68- 
72 hours in culture).
To assess the acute and chronic effects o f NS-398 exposure on prostaglandin 
secretion and 11(3HSD activities, human granulosa-lutein cells were similarly 
incubated with increasing concentrations o f NS-398 (OpM, 0.0 lp M , 0.1 pM, lpM , 
lOpM, lOOpM) following the same experimental protocol as for M A. The organic 
solvent used to solubilise NS-398 was 1% (v/v) DMSO.
To assess the ability o f both M A and NS-398 to inhibit prostaglandin production, 
radioimmunoassays were conducted to measure the concentrations o f PGE2 and 
PGF2a following acute and chronic treatment with either M A  or NS-398. 1 lpHSD 
activities were assessed over 4 hours, coinciding with the last 4 hours o f the 24 hour 
time treatment period, using a radiometric conversion assay. The steroids were 
chloroform extracted, resolved by TLC and cortisol-cortisone inter-conversion was 
quantified using a radiochromatogramme scanner (see section 2.4).
To assess changes in lip H S D l protein expression, human granulosa-lutein cells 
were incubated for either 4 or 24 hours with the concentration o f either M A or NS- 
398 shown to exert the maximum effects on 11 PHSD activities (lOOpM for both 
compounds). The effects o f treatment for 4 hours coincided with the last 4 hours o f 
the parallel 24 hour treatment incubation. Cells were extracted and proteins were 
separated by SDS-PAGE. lip H S D l protein expression was quantified by Western 
blotting and densitometric analysis. Following stripping o f the Western blot,
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GAPDH protein expression was quantified by densitometry, and lip H S D l protein 
expression was standardised to GAPDH expression (see sections 2.7, 2.8 and 2.9).
5.2.2 Effects o f exogenous prostaglandins on cortisol oxidation 
To assess whether exogenous administration o f individual prostaglandins could 
reverse any effects o f M A  and NS-389 on llp H S D  activities, human granulosa- 
lutein cells were incubated in itially with lOOpM M A  in the presence and absence o f 
1 jlxM  PGD2, PGE2, PGF2a and PGI2 . A  control was incubated without M A or 
exogenous prostaglandins for the measurement o f basal llp H S D  activity. This 
experimental design was subsequently repeated with the following modifications. 
Each prostaglandin was tested at 2 concentrations ( lp M  and lOpM) in the presence 
o f either lOOpM M A or NS-398 and in the presence o f lOOpM AG (to control for 
any confounding effects via changes in progesterone synthesis).
5.3 Results
5.3.1. Effect o f M A  on basal prostaglandin production
Treatment o f human granulosa-lutein cells with M A for 4 hours inhibited both PGE2 
and PGF2a production in a concentration-dependent manner (Figure 5.1 A). 
Maximum inhibition o f prostaglandin production was observed with lOOpM MA, 
inhibiting PGE2 and PGF2a production by 64.5 ± 17.2% (p<0.01) and 60.1 ± 11.3% 
(p<0.05), respectively. Treatment with M A for 24 hours also inhibited prostaglandin 
synthesis in a concentration-dependent manner (Figure 5.IB). lOOpM M A
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maximally inhibited both PGE2 and PGF2« production, by approximately 50% 
(p>0.05 and p<0.01, respectively).
5.3.2. Effect o f M A  on 11BHSD activities in human granulosa-lutein cells
Treatment o f  human granulosa-lutein for 4 hours with M A  inhibited llp H S D  
activities. The effects o f M A were more pronounced on cortisone reduction, with 
M A inhibiting 11KSR activity in a concentration-dependent manner (Figure 5.2A). 
Cortisol oxidation was significantly inhibited with lp M  M A  by 31.9 ± 5.3% 
(p<0.05) and treatment with lOOpM M A maximally inhibited cortisone reduction by 
approximately 50% o f the control (p<0.01).
Treatment with M A  for 24 hours also resulted in a significant inhibition o f 1 lpHSD 
activities (Figure 5.2B). Following the same trend as acutely treated human 
granulosa-lutein cells, lOOpM M A significantly inhibited cortisol oxidation over 24 
hours by approximately 20% (p<0.01). Likewise, 11KSR activity was inhibited in a 
concentration-dependent manner, with 0.1 pM M A maximally inhibiting cortisone 
reduction by approximately 50% (p<0.01).
Irrespective o f the duration o f treatment, M A appeared to more potently inhibit 
11KSR activity than the oxidative activity o f 1 lpHSD. A t the maximal concentration 
o f lOOpM, M A  inhibited 11 KSR activity to a greater extent that llp D H  activity. 
Moreover, the concentration o f M A  required to significantly inhibit the reduction o f 
cortisone was several orders o f magnitude lower than that required to inhibit cortisol 
oxidation.
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5.3.3. Effects o f  M A  on 11BHSD1 protein expression
Over both 4 and 24 hours, treatment with lOOpM M A had no significant effect on 
1 lpH S D l protein expression when standardised to GAPDH (p>0.05, Figure 5.3).
5.3.4. Effects o f NS-398 on basal prostaglandin production
The acute effects o f NS-398 on PGE2 and PGF2« were assessed over 4 hours. 
Treatment w ith increasing concentrations o f NS-398 showed a trend for inhibiting 
prostaglandin synthesis (Figure 5.4A). Treatment with lOOpM NS-398 inhibited both 
PGE2 and PGF20C production by 50% (p>0.05 and p>0.05 respectively). Chronic 
treatment o f human granulosa-lutein cells with NS-398 yielded similar results as 
acutely treated cells. PGE2 production was maximally inhibited with lOOpM NS-398 
by 64.2 ± 15.9% (p>0.05, Figure 5.4B). PGF2« production was significantly 
inhibited with lOpM NS-398 by 42.7 ± 12.8% (p<0.05).
5.3.5 Effect o f NS-398 on 11BHSD activities in human granulosa-lutein cells
The acute treatment o f human granulosa-lutein cells with NS-398 inhibited cortisol- 
cortisone inter-conversion in a concentration-dependent manner (Figure 5.5A). 
Cortisol oxidation was significantly inhibited with lOOpM NS-398 by 38.3 ± 5.8% 
(p<0.05). Maximum inhibition o f cortisone reduction was achieved with IOOjliM  NS- 
398, which inhibited cortisone reduction by 53.3 ± 4.5% (p<0.01).
The chronic treatment o f human granulosa-lutein cells with NS-398 revealed a 
similar trend as acute treatment. Again, the inhibitory effects o f NS-398 were less
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marked on cortisol oxidation. lOOpM NS-398 maximally inhibited cortisol oxidation 
by 36.3 ± 4.6% (p<0.05) and cortisone reduction by 46.9 ± 3.7% (p<0.001, Figure 
5.5B).
5.3.6 Effect o f NS-398 on 1K3HSD1 protein expression
Both acute and chronic treatment o f human granulosa-lutein cells with lOOpM NS- 
389 had no effect on 1 lpH S D l protein expression (p>0.05, Figure 5.6).
5.3.7 Effect o f exogenous prostaglandins on cortisol oxidation
Treatment o f human granulosa-lutein cells with lOOpM M A inhibited cortisol 
oxidation by approximately 50% (p<0.001, Figure 5.7). Co-treatment with lp M  
PGD2, PGE2, PGF2C and PGI2 did not alter the inhibitory effects o f M A on cortisol 
oxidation.
This same experiment was repeated using each prostaglandin at a concentration o f 
lOpM and in the presence and absence o f lOOpM AG. In the absence o f AG, lOOpM 
M A significantly inhibited cortisol oxidation (p<0.05, Figure 5.8A). Even at the 
higher concentration o f 10pM, the addition o f exogenous prostaglandins could not 
overcome the inhibitory effects o f lOOpM M A on cortisol oxidation in the absence 
o f AG (p>0.05). In the presence o f lOOpM AG, the inhibitory effect o f M A on 
cortisol oxidation was highly significant (p<0.001, Figure 5.8B) and addition o f 
exogenous prostaglandins did not overcome the inhibitory effects o f MA.
137
160 -|
140 -
120 -
100
80 -
40 -
20 -
0.01 100
[M A ] (pM )
F igure  5.1 A : Concentration-dependent effects o f  treatment w ith  M A  for 4 hours on 
PGE2 and PGF2a production in human granulosa-lutein cells on day 3 o f  culture. 
PGE2= blue line, w ith  each data point representing the mean ± SEM fo r 3 
independent experiment (**p<0.01 versus OpM M A ), PGF2a=pink line, w ith  each 
data point representing the mean ± SEM for 4 independent experiments (*p<0.05 
versus OpM M A ). Data analysed w ith  repeated measures one-way A N O V A  followed 
by Dunnett’ s m ultip le comparison test for each prostaglandin.
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F igure  5.1 B: Concentration-dependent effects o f  treatment w ith  M A  for 24 hours on 
PGE2 and PGF2a production in human granulosa-lutein cells on day 3 o f  culture. 
PGE2=blue line, w ith  each data point representing the mean ± SEM for 5 
independent experiments (p>0.05 versus OpM M A ). PGF2«=pink line, w ith  each data 
point representing the mean ± SEM for 3 independent experiments (**p<0.01 versus 
OpM M A ). Data analysed w ith  repeated measures one-way A N O V A  fo llowed by 
Dunnett’ s m ultip le comparison test.
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F igure  5.2A: Concentration-dependent effects o f  treatment w ith  M A  for 4 hours on 
11(3HSD activities in human granulosa-lutein cells on day 3 o f  culture. l lp D H  
activity=blue line, w ith  each data point representing the mean ± SEM for 5 
independent experiments (*p<0.05 versus OpM M A ), and 11KSR activ ity=p ink line, 
w ith  each data point representing the mean ±  SEM fo r 6 independent experiments 
(**p<0.01 versus OpM M A ). Data analysed w ith  repeated measures one-way 
A N O V A  fo llowed by Dunnett’ s m ultip le comparison test
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F igure  5.2B: Concentration-dependent effects o f  treatment w ith  M A  for 24 hours on 
11 pHSD activities in human granulosa-lutein cells on day 3 o f  culture. 11 pDH 
activity=blue line, w ith  each data point representing the mean ± SEM for 5 
independent experiments (**p<0.01 versus OpM M A ) and 11KSR activ ity=p ink line, 
w ith  each data point representing mean ±SEM for 6 independent experiments 
(**p<0.01 versus OpM M A ). Data analysed w ith  repeated measures one-way 
A N O V A  fo llowed by Dunnett’ s m ultip le comparison test
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F igure 5.3: Effect o f  M A  on expression o f  1 lp H S D l protein. (A ) Western blot 
showing effect o f  M A  on 1 lp H S D l protein expression and GAPDH protein 
expression on day 3 o f  culture in human granulosa lutein cells. C represents control 
conditions, M  represents treatment w ith  lOOpM M A . (B) Densitometric representation 
o f  effect o f  M A  on 11 pH SD l protein expression relative to GAPDH. The blue bars 
represent experiments carried out over 4 hours. The pink bars represents experiments 
carried out over 24 hours. Hatched bars represent control, and solid bars represent 
hGL cells treated w ith  lOOpM M A  Each data point represents the mean ±  SEM for 3 
independent experiments, (p>0.05 versus OpM M A ). Means compared at each time 
point using unpaired T-test.
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Figure 5.4A: Concentration-dependent effects o f  treatment w ith  NS-398 for 4 hours 
on PGE2 and PGF201 production in human granulosa-lutein cells on day 3 o f  culture. 
PGE2=blue line, w ith  each data point representing the mean ± SEM for 3 
independent experiment (p>0.05 versus OpM NS-398), and PGF2a=pink line, w ith  
each data point representing the mean ± SEM for 6 independent experiments (p>0.05 
versus OpM NS-398). Data analysed w ith  repeated measures one-way A N O V A  
followed by Dunnett’ s m ultip le comparison test
0.1 1 
[NS-398] (pM )
143
180 -i
160
140
120
'os—-4—>a
0 100
0
vo
0^
80
0
60
40
20
0
• H
L i t
0.01 0.1 1 
[NS-398] (pM )
“T“
10
—I
100
Figure 5.4B: Concentration-dependent effects o f  treatment w ith  NS-398 for 24 hours 
on PGE2 and PGF2a production in human granulosa-lutein cells on day 3 o f  culture. 
PGE2=blue line, w ith  each data point representing the mean ± SEM for 5 
independent experiments (p>0.05 versus OpM NS-398) and PGF2a=pink line, w ith  
each data point representing the mean ±  SEM fo r 5 independent experiments 
(*p<0.05 versus OpM NS-398). Data analysed w ith  repeated measures one-way 
A N O V A  fo llowed by Dunnett’ s m ultip le comparison test
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Figure 5.5A: Concentration-dependent effects o f  treatment w ith  NS-389 for 4 hours 
on 11 pHSD activities in human granulosa-lutein cells on day 3 o f  culture. 11PDH 
activity=blue line, w ith  each data point representing the mean ±SEM  for 4 
independent experiments (*p<0.05 versus OpM NS-398) and 11 KSR activ ity=pink 
line, w ith  each data point representing the mean ±SEM  for 3 independent 
experiments (**p<0.01 versus OpM NS-398). Data analysed w ith  repeated measures 
one-way A N O V A  followed by Dunnett’ s m ultip le comparison test
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F igure 5.5B: Concentration-dependent effects o f  NS-389 on 11(3HSD activities in 
human granulosa-lutein cells on day 3 o f  culture over 24 hours. 11 (3DH activity=blue 
line, w ith  each data point representing mean ±SEM  fo r 4 independent experiments 
(*p<0.05 versus OpM NS-398), and 11 KSR activ ity=pink line, w ith  each data point 
representing the mean ± SEM for 3 independent experiments (***p<0.001 versus 
OpM NS-398). Data analysed w ith  repeated measures one-way A N O V A  fo llowed by 
Dunnett’ s m ultip le comparison test
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F igure  5.6: Effect o f  NS-398 on expression o f  11 pH S D l protein expression. (A ) 
Western b lot showing effect o f  NS-398 on 1 lp H S D l protein expression relative to 
G APDH on day 3 o f  culture in human granulosa lutein cells. C represents control 
conditions, N represents treatment w ith  lOOpM NS-398. (B) Densitometric 
representation o f  effect o f  NS-398 on 1 lp H S D l protein expression relative to 
GAPDH. The blue bars represent experiments carried out over 4 hours. The pink bars 
represents experiments carried out over 24 hours. Hatched bars represent control, and 
solid bars represent hGL cells treated w ith  lOOpM NS-398. Each data point represents 
the mean ± SEM o f  3 independent experiments (p>0.05 versus OpM NS-398). Means 
compared at each time point using unpaired T-test.
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F igure 5.7: Effect o f  treatment w ith  lOOpM M A  ±  lp M  PGD2 , PGE2 , PGF2« and 
PGI2 on cortisol oxidation over 4 hours in human granulosa-lutein cells, on day 3 o f 
culture. Solid panel represents control w ith  lOOpM M A . Hatched lines represent the 
absence o f  lOOpM M A . Each data point represents the mean ± SEM for 4 
independent experiments (***p<0.001 versus C +M A). Data analysed w ith  repeated 
measures one-way A N O V A  followed by Dunnett’ s m ultip le comparison test
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F igure 5.8A: Effect o f  treatment w ith  lOOpM M A  ± 10pM PGD2 , PGE2 , PGF2« and 
PGI2 on cortisol oxidation over 4 hours in human granulosa-lutein cells, on day 3 o f  
culture in the absence o f  AG. Solid panel represents control in the presence o f 
lOOpM M A . Hatched lines represent the absence o f  lOOpM M A . Each data point 
represents the mean ± SEM for 4 independent experiments (*p<0.05 versus C+M A). 
Data analysed w ith  repeated measures one-way A N O V A  followed by Dunnett’ s 
m ultiple comparison test
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F igure 5.8B: Effect treatment w ith  lOOjaM M A  ± lO pM  PGD2 , PGE2, PGF2a and 
PGI2 on cortisol oxidation over 4 hours in human granulosa-lutein cells, on day 3 o f 
culture in the presence o f  AG. Solid panel represents control w ith  lOOpM M A. 
Hatched lines represent the absence o f  lOOpM M A . Each data point represents the 
mean ±  SEM for 4 independent experiments (***p<0.001 versus C +M A). Data 
analysed w ith  repeated measures one-way A N O V A  followed by Dunnett’ s m ultiple 
comparison test
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F igure 5.9: Effect o f  treatment w ith  lOOpM NS-398 ± lO pM  PGD2, PGE2 , PGF2a 
and PGI2 on cortisol oxidation over 4 hours in human granulosa-lutein cells, on day 3 
o f  culture. Experiments were conducted in the presence o f  AG. Solid panel 
represents control w ithout lOOpM NS-398. Hatched lines represent the presence o f  
lOOpM NS-398. Each data point represents the mean ±  SEM for 4 independent 
experiments (*p<0.05 versus C+NS-398). Data analysed w ith  repeated measures 
one-way A N O V A  followed by Dunnett’ s m ultip le comparison test
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This same experimental design was repeated using lOOpM NS-398 in place o f MA. 
In the presence o f AG, NS-398 inhibited cortisol oxidation by 27.8 ± 1.2% (p<0.05, 
Figure 5.9). Co-treatment with exogenous prostaglandins could not overcome the 
inhibitory effects o f NS-398 on cortisol oxidation.
5.4. Discussion
This study has investigated the effects o f preferential PGHS-2 inhibitors on 
prostaglandin production, llp H S D  activities and llp H S D l protein expression in 
human granulosa-lutein cells. Both M A and NS-398 inhibited PGE2 and PGF2« 
production, and decreased llpH S D  activities without affecting llp H S D l protein 
expression. Having suppressed endogenous prostaglandin production with M A and 
NS-398, exogenous prostaglandins were unable to return the rate o f cortisol 
oxidation to control levels.
Differences were observed in the potencies o f M A and NS-398 for inhibiting 
prostaglandin production. There are several explanations for these differences. 
Firstly the solubility o f M A and NS-398 is different due to structural differences 
between the 2 compounds (Figure 5.10). M A is more hydrophilic and is soluble in 
aqueous media, whereas NS-398 is less hydrophilic and insoluble in aqueous 
solution such that it requires an organic solvent to increase its solubility in medium. 
These structural differences could affect the rate o f uptake o f the compounds into the 
cell. Moreover, once entering the cell these structural differences could result in a 
difference in the solubility o f the compounds within the cytosol, which would also
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Figure 5.10: Structures o f Meclofenamic acid and NS-398. Adapted from Cayman Chemicals, USA
affect the rate at which the compounds are transported out o f the cell. These physical 
factors could result in differential effects o f M A  and NS-398 on prostaglandin 
synthesis and possibly on 11 (3HSD activities.
Another difference could be the specificity o f M A and NS-398 for PGHS2. M A has 
a Kj o f 1.5pM for PGHS2, and a Kj o f 9.7pM for PGHS1 [Laneuville et a l , 1994]. 
Hence at concentrations o f lOpM or lOOpM, the effects o f M A  could reflect 
inhibition o f PGHS1 as well as inhibiting PGHS2. NS-398 is a more selective 
inhibitor o f PGHS2, with a K* for PGHS2 o f 1.77pM and a Ki for PGHS1 o f 75pM 
[Kargman et al., 1996]. These differences in inhibitory constants could explain why 
M A is more effective at suppressing prostaglandin production since it inhibits both 
PGHS2- and PGHS1 -mediated prostaglandin synthesis with near equal affinity.
M A and NS-398 also display different potencies in inhibiting the activities o f 
llpH S D . The simplest explanation o f this finding is that M A and NS-398 could 
have direct inhibitory effects on the activities o f 11 pHSD. However, previous studies 
by a former graduate student in the laboratory had established that 11 pHSD activities 
in human granulosa-lutein cells could also be inhibited by indomethacin: a PGHS1 
and PGHS2 inhibitor which has a notably different chemical structure to M A and 
NS-398. The capacity o f structurally dissimilar inhibitors o f the PGHS enzymes to 
inhibit llp H S D  activities in human granulosa-lutein cells makes it unlikely that 
these compounds act by direct effects on the 11 pHSD enzymes.
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Were the effects o f M A and/or NS-398 on cortisol-cortisone inter-conversion to 
reflect direct actions, one would expect equivalent effects on bi-directional enzyme 
activities. I f  anything, a given drug should be more effective at non-specifically 
inhibiting the low affin ity oxidative activity o f llp H S D l versus the high affinity 
reductase activity o f this enzyme. However, M A was more potent in inhibiting the 
11KSR activity o f human granulosa-lutein cells than the l lp D H  activity, both in 
terms o f the degree o f maximum inhibition o f enzyme activity achieved at lOOpM 
MA, and the concentration o f M A required to achieve significant inhibition (0.1- 
lp M  M A for 11 KSR activity versus lOOpM M A for l lp D H  activity). Hence it 
seems highly unlikely that the decrease in the lip D H  and 11 KSR activities in 
human granulosa-lutein cells reflect non-specific, direct inhibition o f llp H S D l by 
M A or NS-398.
The suppression o f local prostaglandin synthesis with M A and NS-398 had 
differential effects on cortisol oxidation and cortisone reduction. Cortisone reduction 
was more sensitive to inhibition at lower concentrations o f M A  and NS-398 than 
cortisol oxidation. This could reflect differences in the substrate rates o f cortisol 
oxidation versus cortisone reduction. Control rates o f cortisol oxidation were more 
than double the control rate o f cortisone reduction (8-10 pmol cortisol oxidised/5 x 
104 cells.4h versus 3-4 pmol cortisone reduced/5 x 104 cells.4h). Due to this 
difference in absolute substrate conversion, it may be easier to detect a change in 
11 KSR activities than a change in lip D H  activity. E.g., a decrease in the level o f 
substrate metabolism by the same unit o f lpmole/5 x 104 cells.4h would represent a
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25% decrease for 11 KSR activity, but only around a 10% decrease in llp D H  
activity.
The more likely explanation o f these findings is that the effect o f M A and NS398 
(and o f indomethacin) on 11 (3HSD activities reflected changes in the pattern o f AA 
metabolism to eicosanoids following inhibition o f PGHS1/2. Since the 
concentrations o f M A  and NS-398 required to inhibit 11 PHSD activities coincides 
with the concentrations o f M A and NS-398 required to significantly inhibit 
prostaglandin synthesis, the decrease in cortisol-cortisone inter-conversion by human 
granulosa-lutein cells could reflect a positive autocrine/paracrine role for 
prostaglandins in stimulating 1 lpH SD l activities in human granulosa-lutein cells.
The addition o f exogenous prostaglandins to human granulosa-lutein cells in the 
presence o f either M A  or NS-398 failed to restore the rate o f cortisol oxidation to 
control levels even when prostaglandins were added at concentrations o f lOpM. 
There are several explanations for this finding. Firstly, addition o f exogenous 
extracellular prostaglandins may not replicate the effects o f prostaglandins 
endogenously produced within cells. In ovarian cells, multiple prostanoids are 
synthesised, and multiple receptor subtypes are expressed [Narumiya et al., 1999]. 
Hence the addition o f individual specific prostaglandins may not be able to fully 
overcome the effects o f inhibiting the synthesis o f all prostaglandins.
Secondly, the failure o f exogenous prostaglandins to restore rates o f cortisol 
oxidation could reflect the abilities o f M A and NS-398 to inhibit other pathways o f
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AA metabolism. M A  is known to inhibit the 5- and -15 lipoxygenase pathway 
[Stadler et al., 1994] and other non-steroidal anti-inflammatory drugs (NSAIDs), 
such as indomethacin, have also been shown to inhibit other pathways o f AA 
metabolism in the ovary [Downey et al., 1998]. The inhibition o f 5- and 15- 
lipoxygenase by M A  could account for M A more potently inhibiting llpH S D  
activities than NS-398, i f  lipoxygenase products (e.g. leukotriene B4) elevate the 
basal levels o f cortisol-cortisone inter-conversion in human granulosa-lutein cells. 
To confirm the specificity o f M A and NS-398 for inhibiting just prostaglandin 
production, enzyme linked immunoassays (ELISAs) could be conducted to monitor 
products o f the lipoxygenase pathway such a leukotrienes and HETEs in the 
presence o f M A  and NS-398.
Finally the effects o f M A and NS-398 on 11 PHSD activities in human granulosa- 
lutein cells could involve the re-direction o f the flux o f AA  metabolism through 
other associated pathways. The inhibition o f the PGHS enzymes by M A and/or NS- 
398 w ill increase the flux o f A A  through the lipoxygenase and epoxygenase 
pathways. Hence, the decrease o f cortisol oxidation or cortisone reduction achieved 
by M A and NS-398 could implicate lipoxygenase and /or epoxygenase products as 
inhibitors o f 11PHSD1 in human granulosa-lutein cells.
In conclusion, the findings reported in this Chapter has implied a role for eicosanoids 
in regulating the basal activities o f 11 PHSD in human granulosa-lutein cells without 
affecting 1 lpH S D l protein expression. Hence, the studies reported in Chapter 6  w ill
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explore the potential mediatory roles for prostaglandins in the stimulation of ovarian
11 (3HSD activities by hCG and IL-1 p.
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on the activity and expression of 11BHSD1 in human granulosa-lutein cells
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Chapter 6: Role of prostaglandins in mediating the effects of hCG and IL-1B on
the activity and expression of 1113HSD1 in human granulosa-lutein cells
6.1 Introduction
As previously described in section 1.3 and 5.1, prostaglandins play a key role in 
ovarian function and have been shown to regulate the activity and expression o f 
llp H S D  in various tissue types. Inflammatory cytokines have also been implicated 
in the regulation o f llp H S D l activity and expression in several tissue types. Both 
TNF-a and IL - lp  can increase llp H S D l activity and mRNA expression in human 
amnion [Sun and Myatt 2003], pre-adipocytes [Friedberg et al., 2003], osteoblasts 
[Cooper et al., 2001], glomerular mesangial cells [Escher et al., 1997], and in the 
ovary [Tetsuka et al., 1999 Yong et al., 2002; Rae et al., 2004]. Gonadotrophins 
have also been shown to regulate the activity and expression o f 11 pHSD isoforms in 
rat Leydig cells [Gao et al., 1997] and granulosa cells [Tetsuka et al., 1999b].
It has been long established that ovulation is an inflammatory cascade that is 
orchestrated and modulated by inflammatory prostaglandins and cytokines, initiated 
by the gonadotrophin surge [Espey 1980]. Therefore the aims o f this study were:
1) To determine the effects hCG and IL - lp  on prostaglandin production, 
11 PHSD 1 activities and llp H S D l protein expression in human granulosa- 
lutein cells
2) To establish the effects o f co-treatment with M A  and NS-398 on hCG and 
IL-1 p control o f 1 lpHSD activities and expression
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6.2 Experimental design
6.2.1 Acute and chronic effects o f hCG and IL-1B on prostaglandin production and 
11BHSD activities
Human granulosa-lutein cells, isolated from follicular aspirates o f women 
undergoing IVF-ET, were seeded into 24 well cell culture plates at a density o f 1 x 
105 cells/ml for prostaglandin production studies, and 5 x 104 cells/ml for llpH S D  
activity studies, into serum-supplemented medium (see section 2.2). Cells were 
cultured for 2 days to allow for luteinisation and for attachment to the cell culture 
plates. Cells were then transferred to serum-free medium to assess the effects o f hCG 
and IL - ip  on prostaglandin production, and the bi-directional activities o f 1 lpH S D l.
To assess the acute and chronic effects o f hCG and IL - ip  exposure, human 
granulosa-lutein cells were incubated with medium alone (control), lOOng/ml hCG 
or lOng/ml IL - lp  for 4 and 24 hours. The acute effects o f hCG and IL - lp  were 
determined over 4 hours, coinciding with the last 4 hours o f the 24 hour treatment 
incubations. These studies were conducted in the presence and absence o f lOOpM 
AG (to inhibit progesterone responses to hCG and/or IL -lp ).
To determine the effects o f hCG and IL - ip  on prostaglandin production, PGE2 and 
PGF2« concentrations were assessed by RIA (see section 2.3). In parallel cell culture 
plates, 11 pHSD activities were assessed by radiometric conversion assayed during 
the final 4 hours o f each experiment. Cortisol-cortisone inter-conversion was 
determined by radiometric conversion assay. To terminate the reaction, spent 
medium was transferred to borosilicate glass tubes, the steroids were chloroform
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extracted, and resolved by TLC. Cortisol-cortisone conversion was quantified using 
a radiochromatogramme scanner (see section 2.4).
6.2.2 Concentration-dependent effects o f IL-1B and hCG on prostaglandin synthesis 
and 11BHSD1 activities
To investigate the concentration-dependent effects o f hCG, cells were incubated with 
increasing concentrations o f hCG (0, 1, 3, 10, 30, lOOng/ml) in the presence and 
absence o f lOOpM M A or lOOpM NS-398 for 24 hours. To minimise the 
confounding effects o f progesterone, these experiments were conducted in the 
presence o f lOOpM AG. The concentration-dependent effects o f IL - lp  were 
investigated using increasing concentrations o f IL - lp  (0, 3, 1, 3, lOng/ml) in the 
presence and absence o f lOOpM M A or lOOpM NS-398, and in the presence o f 
1 OOpM AG for 24 hours.
The concentration dependent effects o f hCG and IL - lp  on prostaglandin production 
were assessed by RIA o f PGE2 and PGF2a. Cortisol-cortisone inter-conversion was 
assessed over the last 4 hours o f the 24 hour treatment period using a radiometric 
conversion assay. Steroids were chloroform extracted, resolved by TLC and 
quantified using a radiochromatogramme scanner.
6.2.3 Effects o f hCG and IL-1B on 11BHSD1 protein expression
For the assessment o f changes in llp H S D l protein expression, human granulosa- 
lutein cells were seeded into 6 well plates at a density o f 1 x 106 cells/ml in serum-
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supplemented medium. Cells were transferred into serum-free medium and incubated 
for 24 hours with those concentrations o f hCG (lOOng/ml) and IL - ip  (lOng/ml) 
shown to exert the greatest effects on 11 PHSD activities. Cells were treated in the 
presence or absence o f lOOpM M A and in the presence o f lOOpM AG. Cells were 
extracted and proteins separated by SDS-PAGE. llp H S D l protein expression was 
quantified through Western blot and densitometric analysis. Following stripping o f 
the Western blot, GAPDH protein expression was quantified by densitometry. 
llp H S D l protein expression was standardised to GAPDH expression (see sections 
2.7, 2.8 and 2.9).
6.3 Results
6.3.1 Effects o f hCG and IL-1B on PGE? and PGF^ production
In absence o f AG, treatment o f human granulosa-lutein cells with either hCG 
(lOOng/ml) or IL - lp  (lOng/ml) for 4 hours had no significant effect on PGE2 (Figure
6.1 A) and PGF2a (Figure 6.IB ) production (p>0.05) irrespective o f the presence or 
absence o f M A. Likewise, in the presence o f lOOpM AG, acute treatment with either 
hCG or IL - lp  again had no significant effect on PGE2 (Figure 6.2A) and PGF2ot 
(Figure 6.2B) production, irrespective o f the presence o f absence o f M A (p>0.05).
In the absence o f AG, treatment o f human granulosa-lutein cells for 24 hours with 
lOng/ml IL - lp  tended to increase PGE2 production, (p>0.05, Figure 6.3A) and 
significantly increased PGF2a production to 166.7 ± 6.5% o f control (p<0.05, Figure 
6.3B). Co-treatment with M A abolished both o f the prostaglandin responses.
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Treatment o f human granulosa-lutein for 24 hours cells with lOOng/ml hCG had no 
effect on either PGE2 or PGF2a production, irrespective o f the presence or absence o f 
MA.
In the presence o f AG, treatment o f human granulosa-lutein cells for 24 hour with 
hCG tended to increase PGE2 production, and IL - lp  significantly increased PGE2 
production to 144.2 ± 3.4% o f control (p<0.05, Figure 6.4A). IL - ip  also tended to 
increase PGF2tt production by up to 186.5 ± 46.7% o f control (p>0.05, Figure 6.4B). 
Co-treatment with M A  was shown to inhibit these responses. Treatment with 
lOOng/ml hCG for 24 hours had no effect on PGF2tt production by human granulosa- 
lutein cells (p>0.05, Figure 6.4B).
6.3.2 Acute effects o f hCG and IL-1 (3 on 11BHSD activities
In the absence o f AG and in the absence o f MA, treatment o f human granulosa-lutein 
cells for 4 hours with either lOOng/ml hCG or lOng/ml IL - lp  stimulated cortisol 
oxidation to 146.6 ± 23.5% (p<0.05) and 147.3 ± 16.0% (p<0.01, Figure 6.5A) o f 
control enzyme activity respectively. Co-treatment with lOOpM M A abolished the 
stimulation o f 11 p-dehydrogenase activity by both hCG and IL-1 p.
In contrast, hCG and IL - lp  had no acute effect on cortisone reduction irrespective o f 
the presence or absence o f M A (Figure 6.5B). Co-treatment with M A inhibited 
11 KSR activity by approximately 50% (p<0.05) irrespective o f the presence or 
absence o f hCG or IL -lp .
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In the presence o f AG, in human granulosa-lutein cells treated for 4 hours with hCG 
and IL-1 (3, cortisol oxidation was increased to 132.2 ± 9.4% (p>0.05) and 128.8 ± 
4.5% (p<0.05, Figure 6.6A) o f control enzyme activity, respectively. Co-treatment 
with M A for 4 hours significantly decreased cortisol oxidation and prevented both 
hCG and IL - lp  from stimulating 1 lpD H  activity.
In the presence o f AG, hCG and IL - lp  had no acute effect on cortisone reduction 
irrespective o f the presence o f absence o f M A (Figure 6.6B).
6.3.3 Chronic effects o f hCG and IL-113 on 11BHSD activities 
In the absence o f AG and in the absence o f MA, hCG and IL - lp  tended to increase 
cortisol oxidation (p>0.05, Figure 6.7A). However, co-treatment with MA 
significantly inhibited the rate o f cortisol oxidation in the presence o f hCG and IL-1 p 
(p<0.05). As with acutely treated cells, in the absence o f AG, hCG and IL-1 p had no 
significant effect on cortisone reduction (p>0.05, Figure 6.7B) irrespective o f the 
presence o f M A, which inhibited cortisone reduction by approximately 70% in 
control, hCG- and IL-lp-treated cells.
In the presence o f AG, hCG tended to increase cortisol oxidation by over 50% and 
IL - lp  significantly increased llp D H  activity to 170.0 ± 24.9% (p<0.05, Figure 
6.8A) o f control 1 lpD H  activity. Co-treatment with M A abolished the stimulation o f 
1 lpD H  activity by both hCG and IL -lp . As with acutely treated cells, both hCG and 
IL - lp  had no effect on 11KSR activity and co-treatment with M A  inhibited cortisone 
reduction by approximately 50% (Figure 6.8B).
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6.3.4 Concentration-dependent effects of hCG on PGE? and PGF?„ production
In the presence o f AG, increasing concentrations o f hCG had no effect on PGE2 
(p>0.05, Figure 6.9A), irrespective o f the presence or absence o f MA.
Treatment with increasing concentrations o f hCG tended to increase PGF2« 
production. The maximum effective concentration o f lOOng/ml hCG increased 
PGF2a production to 133.8 ± 3.7% o f control values (p>0.05, Figure 6.9B). 
Treatment with M A  abolished this stimulation.
6.3.5 Concentration-dependent effects o f IL-1 B on PGE? and PGF?^ production 
IL - lp  increased PGE2 production in a concentration-dependent manner, with 
lOng/ml IL - lp  maximally increasing PGE2 production to 154.9 ± 21.0% o f control 
(p<0.05, Figure 6.10A). Co-treatment with M A abolished the stimulation o f PGE2 
production by IL-1 p.
IL - ip  also tended to increase PGF2a production (p>0.05, Figure 6.1 OB) and this 
stimulatory trend was abolished by co-incubation with MA.
6.3.6 Concentration-dependent effects o f hCG on 11BHSD activities: effects o f 
preferential-PGHS2 inhibitors
In the absence o f MA, hCG exerted a concentration-dependent stimulation o f 11 pDH 
activity, with lOOng/ml hCG increasing l ip D H  activity to 130.7 ± 8.5% o f control 
enzyme activity (p>0.05, Figure 6.11 A). In the presence o f lOOpM MA, these effects
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o f hCG on l lp D H  activity were abolished. Furthermore, M A  inhibited 11(3DH 
activities by approximately 35 to 50% at each concentration o f hCG. Treatment o f 
human granulosa-lutein cells with hCG also tended to increase 11 KSR activity 
(p>0.05, Figure 6.1 IB). Co-treatment with M A  abolished this effect, decreasing 
11KSR activity by 20 to 60% at each concentration o f hCG.
In the absence o f NS-398, increasing concentrations o f hCG also tended to increase 
cortisol oxidation. Co-treatment with NS-398 inhibited the stimulation o f 11(3DH 
activity by hCG (Figure 6.12).
6.3.7 Concentration-dependent effects o f IL-1B on 11BHSD activities: effects o f 
preferential PGHS2 inhibitors
Treatment o f human granulosa-lutein cells with IL-1 (3 increased 1 lpD H  activity in a 
concentration-dependent manner. The maximum effective concentration o f lOng/ml 
IL-1 (3 increased 11|3DH activity to 140.8 ± 5.5% o f control activity (p<0.05, Figure
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F igure  6.1 A : Effects o f  hCG and IL - lp  on PGE2 production over 4 hours in the 
absence o f  AG. Blue outlines represent 4 hour time point, Blue f i l l  to graphs and 
brackets represent conditions minus M A , Pink f i l l  o f  graphs and brackets represent 
conditions plus M A . C =control, hCG=100ng/ml, IL -lB = 10ng /m l. Each data point 
represents the mean ± SEM for 3 independent experiments (p>0.05 versus control 
minus M A ). Data were analysed by one-way A N O V A  w ith  repeated measures 
followed by D unnetf s m ultip le comparison.
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F igure 6.1 B: Effects o f  hCG and IL-1 (3 on PGF2« production over 4 hours in the 
absence o f  AG. Blue outlines represent 4 hour time point, Blue f i l l  to graphs and 
brackets represent conditions minus M A , Pink f i l l  o f  graphs and brackets represent 
conditions plus M A . C =control, hCG=100ng/ml, !L -lB = 10ng /m l. Each data point 
represents the mean ± fo r 3 independent experiments (p>0.05 versus control minus 
M A ). Data were analysed by one-way A N O V A  w ith  repeated measures fo llowed by 
Dunnett’ s m ultip le comparison
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F igure 6.2A : Effects o f  hCG and IL-1 P on PGE2 production over 4 hours in the 
presence o f  AG. Blue outlines represent 4 hour time point, Blue f i l l  to graphs and 
brackets represent conditions minus M A , Pink f i l l  o f  graphs and brackets represent 
conditions plus M A . C =control, hCG=100ng/ml, IL -lB = 10n g /m l. Each data point 
represents the mean ± SEM for 3 independent experiments (p>0.05 versus control 
minus M A ). Data were analysed by one-way A N O V A  w ith  repeated measures 
followed by D unnetf s m ultip le comparison
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F igure 6.2B: Effects o f  hCG and IL - lp  on PGF2« production over 4 hours in the 
presence o f  AG. Blue outlines represent 4 hour time point, Blue f i l l  to graphs and 
brackets represent conditions minus M A , Pink f i l l  o f  graphs and brackets represent 
conditions plus M A . C =control, hCG=100ng/ml, IL -lB = 10ng /m l. Each data point 
represents the mean ±  SEM for 3 independent experiments (p>0.05 versus control 
minus M A ). Data were analysed by one-way A N O V A  w ith  repeated measures 
followed by D unnetf s m ultip le comparison
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Figure 6.3A: Effects o f  hCG and IL - lp  on PGE2 production over 24 hours in the 
absence o f  AG. Pink outlines to bars represent 24 hour time point, Blue f i l l  to graphs 
and brackets represent conditions minus M A , Pink f i l l  o f  graphs and brackets 
represent conditions plus M A . C =control, hCG=100ng/ml, IL -lB = 10ng /m l. Each 
data point represents the mean ± SEM for 3 independent experiments (p>0.05 versus 
controll). Data were analysed by one-way A N O V A  w ith  repeated measures fo llowed 
by D unnetf s m ultip le comparison
172
200
180
160
140
120
o
a
GOO
pS 100
<NPh
OOh
80
60
40
20
0
-MA
_A_
+MA
_A_
A
i  ■ ■
hCG IL-1B
Treatment
Figure 6.3B: Effects o f  hCG and IL - ip  on PGF2tt production over 24 hours in the 
absence o f  AG. Pink outlines to bars represent 24 hour time point, Blue f i l l  to graphs 
and brackets represent conditions minus M A , Pink f i l l  o f  graphs and brackets 
represent conditions plus M A . C =control, hCG=100ng/ml, IL -lB = 10ng /m l. Each 
data point represents the mean ± SEM for 3 independent experiments (*p<0.05 
versus control). Data were analysed by one-way A N O V A  w ith  repeated measures 
fo llowed by D unnetf s m ultip le comparison
173
160 -I C
140 
120 \
1 100
Oo
(N
W
opH
80 - 
60 - 
40 - 
20 
0
I-:-:-:-:-:-:-:-:
Z-Z-Z-Z-Z-Z-Z-Z-Zz-z-z-zz-z-z-z
z>z>zz>>
>5zS?S
-M A
_ A .
+MA
_A_
hCG IL-1B
!v/IvIvX
;lvlvlvlv
ivlvlvlv'
c
A
hCG IL-1B
Treatment
Figure 6.4A: Effects o f  hCG and IL - ip  on PGE2 production over 24 hours in the 
presence o f  AG. Pink outlines to bars represent 24 hour time point, Blue f i l l  to 
graphs and brackets represent conditions minus M A , Pink f i l l  o f  graphs and brackets 
represent conditions plus M A . C =control, hCG=100ng/ml, IL -lB = 10n g /m l. Each 
data point represents the mean ± SEM for 3 independent experiments (*p<0.05 
versus control). Data were analysed by one-way A N O V A  w ith  repeated measures 
fo llowed by D unnetf s m ultip le comparison
174
250 r
■MA
r
+MA
_A_
oUaoo
200
150 -
^  100 
oDh
50
g S g g :
; y.
: : : : : : : :
? W v
■ X v X v I v
? x x S \ X
•
X-I-M-M-M
:
hCG IL-1B hCG IL-1B
Treatment
F igure 6.4B: Effects o f  hCG and IL - lp  on PGF2a production over 24 hours in the 
presence o f  AG. Pink outlines to bars represent 24 hour time point, Blue f i l l  to 
graphs and brackets represent conditions minus M A , Pink f i l l  o f  graphs and brackets 
represent conditions plus M A . C =control, hCG=100ng/ml, IL -lB = 10ng /m l. Each 
data point represents the mean ± SEM for 3 independent experiments (p>0.05 versus 
control minus M A ). Data were analysed by one-way A N O V A  w ith  repeated 
measures followed by Dunnett’ s m ultip le comparison
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F igure 6.5A: Effects o f  hCG and IL - ip  on cortisol oxidation over 4 hours in the 
absence o f  AG. Blue outlines represent 4 hour time point. Blue f i l l  to graphs and 
brackets represent conditions minus M A , Pink f i l l  o f  graphs and brackets represent 
conditions plus M A . C =control, hCG=100ng/ml, IL-1 B=10ng/ml. Each data point 
represents the mean ± SEM for 8 independent experiments (**p<0.01 versus control 
minus M A ). Data were analysed by one-way A N O V A  w ith  repeated measures 
fo llowed by D unnetf s m ultip le comparison
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F igure 6.5B: Effects o f  hCG and IL - lp  on cortisone reduction over 4 hours in the 
absence o f  AG . Blue outlines represent 4 hour time point, Blue f i l l  to graphs and 
brackets represent conditions minus M A , Pink f i l l  o f  graphs and brackets represent 
conditions plus M A . C =control, hCG=100ng/ml, IL -lB = 10ng /m l. Each data point 
represents the mean ±  SEM for 5 independent experiments (p>0.05 versus control 
minus M A ). Data were analysed by one-way A N O V A  w ith  repeated measures 
followed by D unnetf s m ultip le comparison
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F igure 6.6A : Effects o f  hCG and IL - lp  on cortisol oxidation over 4 hours in the 
presence o f  AG. Blue outlines represent 4 hour time point. Blue f i l l  to graphs and 
brackets represent conditions minus M A , Pink f i l l  o f  graphs and brackets represent 
conditions plus M A . C =control, hCG=100ng/ml, IL-1 B=10ng/ml. Each data point 
represents the mean ± SEM for 8 independent experiments (**p<0.01 versus control 
minus M A ). Data were analysed by one-way A N O V A  w ith  repeated measures 
fo llowed by D unnetf s m ultip le comparison
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F igure 6.6B: Effects o f  hCG and IL - ip  on cortisone reduction over 4 hours in the 
presence o f  AG. Blue outlines represent 4 hour tim e point. Blue f i l l  to graphs and 
brackets represent conditions minus M A , Pink f i l l  o f  graphs and brackets represent 
conditions plus M A . C =control, hCG=100ng/ml, IL-1 B=10ng/ml. Each data point 
represents the mean ± SEM for 3 independent experiments (p>0.05 versus control 
minus M A ). Data were analysed by one-way A N O V A  w ith  repeated measures 
followed by Dunnett’ s m ultip le comparison
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F igure 6.7A: Effects o f  hCG and IL-1(3 on cortisol oxidation over 24 hours in the 
presence o f  AG. Pink outlines represent 24 hour tim e point, Blue f i l l  to graphs and 
brackets represent conditions minus M A , Pink f i l l  o f  graphs and brackets represent 
conditions plus M A . C =control, hCG=100ng/ml, IL -lB = 10n g /m l. Each data point 
represents the mean ± SEM for 3 independent experiments (*p<0.05 versus control 
minus M A ). Data were analysed by one-way A N O V A  w ith  repeated measures 
fo llowed by D unnetf s m ultip le comparison
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F igure 6.7B: Effects o f  hCG and IL - lp  on cortisone reduction over 24 hours in the 
presence o f  AG. Pink outlines represent 24 hour time point, Blue f i l l  to graphs and 
brackets represent conditions minus M A , Pink f i l l  o f  graphs and brackets represent 
conditions plus M A . C ^contro l, hCG=100ng/ml, IL -lB = 10n g /m l. Each data point 
represents the mean ±  SEM for 3 independent experiments (p>0.05 versus control 
minus M A ). Data were analysed by one-way A N O V A  w ith  repeated measures 
followed by D unnetf s m ultip le comparison
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F igure 6.8A : Effects o f  hCG and IL - lp  on cortisol oxidation over 24 hours in the 
presence o f  AG. Pink outlines represent 24 hour tim e point, Blue f i l l  to graphs and 
brackets represent conditions minus M A , Pink f i l l  o f  graphs and brackets represent 
conditions plus M A . C =control, hCG=100ng/ml, IL -lB = 10n g /m l. Each data point 
represents the mean ±  SEM for 3 independent experiments (*p<0.05 versus control 
minus M A ). Data were analysed by one-way A N O V A  w ith  repeated measures 
fo llowed by D unnetf s m ultip le comparison
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F igure 6.8B: Effects o f  hCG and IL - lp  on cortisone reduction over 24 hours in the 
presence o f  AG. Pink outlines represent 24 hour time point, Blue f i l l  to graphs and 
brackets represent conditions minus M A , Pink f i l l  o f  graphs and brackets represent 
conditions plus M A . C =control, hCG=100ng/ml, IL -lB = 10n g /m l. Each data point 
represents the mean ± SEM for 3 independent experiments (p>0.05 versus control 
minus M A ). Data were analysed by one-way A N O V A  w ith  repeated measures 
followed by Dunnett’ s m ultip le comparison
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F igure 6.9A: Concentration dependent effects o f  hCG on PGE2 over 24 hours in the 
presence o f  AG. Blue lines represent conditions minus M A , Pink lines represent 
conditions plus M A . Each data point represents the mean ± SEM for 5 independent 
experiments (p>0.05 versus OpM M A ). Data were analysed by one-way A N O V A  
w ith  repeated measures followed by Dunnett’ s m ultip le comparison versus control 
minus M A
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F igure 6.9B: Concentration dependent effects o f  hCG on PGF201 over 24 hours in the 
presence o f  AG. Blue lines represent conditions minus M A , Pink lines represent 
conditions plus M A . Each data point represents the mean ±  SEM for 4 independent 
experiments (p>0.05 versus OpM M A ). Data were analysed by one-way A N O V A  
w ith  repeated measures followed by Dunnett’ s m ultip le  comparison versus control 
minus M A
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F igu re  6.10A : Concentration dependent effects o f  IL - lp  on PGE2 over 24 hours in 
the presence o f  AG . Blue lines represent conditions m inus M A , Pink lines represent 
conditions plus M A . Each data point represents the mean ±  SEM for 5 independent 
experiments (p>0.05 versus OpM M A ). Data were analysed by one-way A N O V A  
w ith  repeated measures fo llow ed by Dunnett’ s m u ltip le  comparison versus control 
minus M A
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F igu re  6.10B: Concentration dependent effects o f  IL-1(3 on PGF2a over 24 hours in 
the presence o f  AG . Blue lines represent conditions m inus M A , Pink lines represent 
conditions plus M A . Each data point represents the mean ±  SEM fo r 4 independent 
experiments (p>0.05 versus OpM M A ). Data were analysed by one-way A N O V A  
w ith  repeated measures fo llow ed by Dunnett’ s m u ltip le  comparison versus control 
m inus M A
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F igu re  6.11 A : Concentration dependent effects o f  hCG on cortisol oxidation over 24 
hours in  the presence o f  AG . Blue lines represent conditions minus M A , P ink lines 
represent conditions plus M A . Each data point represents the mean ±  SEM fo r 3 
independent experiments (p>0.05 versus OpM M A ). Data were analysed by one-way 
A N O V A  w ith  repeated measures fo llow ed by Dunnett’ s m u ltip le  comparison versus 
control m inus M A
188
180
160
140
o
S-H
CoCJ
100
[hCG ] (ng/m l)
Figure 6.1 IB: Concentration dependent effects o f  hCG on cortisone reduction over 
24 hours in the presence o f  AG . Blue lines represent conditions minus M A , Pink 
lines represent conditions plus M A . Each data point represents the mean ±  SEM fo r 3 
independent experiments (p>0.05 versus OpM M A ). Data were analysed by one-way 
A N O V A  w ith  repeated measures fo llow ed by Dunnett’ s m u ltip le  comparison versus 
control m inus M A
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F igu re  6.12: Concentration dependent effects o f  hCG on cortisol oxidation over 24 
hours in the presence o f  AG . Blue lines represent conditions minus NS-398, Pink 
lines represent conditions plus NS-398. Experiments conducted in presence o f  
vehicle (1%  (v /v ) DM SO ). Each data po in t represents the mean ±  SEM fo r 3 
independent experiments (p>0.05 versus OpM NS-398). Data were analysed by one­
way A N O V A  w ith  repeated measures fo llow ed by Dunnett’ s m u ltip le  comparison 
versus control minus NS-398
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F igu re  6.13A: Concentration dependent effects o f  I L - lp  on cortisol oxidation over 
24 hours in the presence o f  AG . Blue lines represent conditions m inus M A , Pink 
lines represent conditions plus M A . Each data point represents the mean ±  SEM fo r 3 
independent experiments (*p<0.05 versus OpM M A ). Data were analysed by one­
way A N O V A  w ith  repeated measures fo llow ed by Dunnett’ s m u ltip le  comparison 
versus control m inus M A
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F igu re  6.13B: Concentration dependent effects o f  I L - lp  on cortisone reduction over 
24 hours in the presence o f  AG . B lue lines represent conditions m inus M A , Pink 
lines represent conditions plus M A . Each data po in t represents the mean ±  SEM fo r 3 
independent experiments (*p<0.05 versus OpM M A ). Data were analysed by one­
way A N O V A  w ith  repeated measures fo llow ed by Dunnett’ s m u ltip le  comparison 
versus control m inus M A
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F igu re  6.14: Concentration dependent effects o f  I L - lp  on cortisol oxidation over 24 
hours in  the presence o f  AG . B lue lines represent conditions m inus NS-398, P ink 
lines represent conditions plus NS-398. Experiments conducted in presence o f  
vehicle (1%  (v /v) D M  SO). Each data point represents the mean ±  SEM fo r 3 
independent experiments (p>0.05 versus OpM NS-398). Data were analysed by one­
way A N O V A  w ith  repeated measures fo llow ed by Dunnett’ s m u ltip le  comparison 
versus control m inus NS-398
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Figure 6.15: Effect o f  hCG and IL - lp  on 1 lp H S D l protein expression o f  1 lp H S D l 
standardised to G APD H  protein expression in  the presence o f  AG . (a) Western b lo t 
showing effect o f  hCG and IL - lp  on 1 lp H S D l protein expression relative to G APD H  
on day 3 o f  culture in  human granulosa lu te in  cells. C represents control conditions, 
hCG represents treatment w ith  lOOng/ml hCG, and lOng/m l I L - lp  (b) Densitometric 
representation o f  effect o f  hCG and IL-1 p on 1 lp H S D l protein expression re lative to 
G APDH. The blue bars represent experiments carried out in the absence o f  1 OOpM 
M A . The p ink bars represents experiments carried out in  the presence o f  lOOpM M A . 
Data represents the mean ±  SEM  fo r 3 independent experiments p>0.05. Data 
analysed by one-way A N O V A  w ith  Dunnett’ s m u ltip le  comparison fo r each treatment
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6.13A). Co-treatment with M A abolished this stimulation decreasing 1lpD H  activity 
by approximately 30-50% at each IL-1(3 concentration. IL - lp  also increased 11KSR 
activity in a concentration-dependent manner, with lOng/ml IL - lp  maximally 
increasing 11KSR activity to 153.4 ± 3.8% o f control (p<0.05, Figure 6.13B). Co­
treatment with M A  abolished the response to IL - ip . Moreover, co-treatment with 
M A also decreased 11KSR activity by over 70% at each concentration o f IL -lp .
Treatment o f human granulosa-lutein cells with increasing concentrations o f IL - lp  in 
the absence o f NS398 tended to increase cortisol oxidation. Co-treatment with 
reproducibly decreased the rate cortisol oxidation at each concentration o f IL -1 p 
(Figure 6.14). However, from 3 independent experiments, this suppressive effect did 
not achieve statistical significance.
6.3.8 Effect o f hCG and IL-1B on 11BHSD1 protein expression 
In the presence o f AG, neither hCG nor IL - ip  had any effect on the expression o f 
1 lpH S D l protein in human granulosa-lutein cells irrespective o f the presence or 
absence o f M A (p>0.05, Figure 6.15).
6.4 Discussion
This study has shown that hCG and IL - lp  can increase llp H S D  activities in a 
concentration-dependent manner without changes in 1 lpH S D l protein expression. 
Co-treatment with 2 preferential inhibitors o f PGHS2, M A  and NS-398, attenuated 
the stimulation o f llp H S D  activities by hCG and IL - lp . hCG and IL - lp  were
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confirmed to increase PGE2 and PGF2a production by human granulosa-lutein cells, 
and co-treatment with M A was shown to block this stimulation o f prostaglandin 
production.
A difference in the ability o f hCG and IL-1J3 to affect cortisol oxidation has been 
observed. IL - lp  was more effective at stimulating cortisol oxidation than hCG, with 
IL - lp  significantly stimulating cortisol oxidation in all experiments. In the absence 
o f AG, the differences in potencies o f hCG and IL - lp  could be due to hCG 
stimulating progesterone production by human granulosa-lutein cells. Studies in 
Chapter 4 indicated that progesterone production can inhibit basal llpH S D  
activities. Therefore this stimulation o f progesterone production by hCG could be 
attenuating any stimulatory effects o f hCG on cortisol oxidation. However, the 
addition o f AG (to inhibit progesterone production) did not alter the lack o f effect o f 
hCG on 11 pDH activities. On the basis o f these data alone, it is not possible to 
exclude a role for progesterone in limiting the llp H S D  response to hCG since 
lOOpM AG is only partially successful in suppressing progesterone synthesis.
It is noteworthy that in preliminary single concentration experiments, hCG and IL -1 p 
did not stimulate cortisone reduction in either acutely or chronically treated human 
granulosa-lutein cells. However, in concentration-dependent experiments carried out 
in the presence o f AG, hCG tended to increase cortisone reduction, and IL - lp  
significantly increased cortisone reduction. On balance, the data reported in this 
Chapter indicate that hCG and IL - ip  exert more reproducible, consistent stimulation
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o f cortisol oxidation than on cortisone reduction in human granulosa-lutein cells 
treated for either 4 or 24 hours.
A  difference in potency was observed between M A and NS-398 in attenuating 
hormone-stimulated llp H S D  activities was observed. In the presence o f increasing 
concentrations o f either hCG or IL - lp , M A  inhibited llp H S D  activities by 
approximately 30-40% in comparison to around 20% inhibition by NS-398. These 
findings were consistent the data reported in Chapter 5. Moreover, under basal 
conditions, M A inhibited prostaglandin production to a greater extent than NS-398. 
This reflects the different properties o f the 2 compounds reviewed in Chapter 5. In 
brief the different properties o f the inhibitors could reflect differences in solubility. 
Other possible explanations for the differences include the selectivity o f M A and 
NS-398 for inhibiting PGHS-2 and not PGHS-1, or indeed for inhibiting other 
pathways o f A A  metabolism. These hypotheses have been reviewed in more detail in 
section 5.4.
Small increases in PGE2 and PGF2a were observed in cells incubated with hCG or 
IL - lp . These data are consistent with several reports that have documented the 
stimulation o f PGE2 and PGF201 by IL - lp  in the rat [Carnovale et al., 2001], bovine 
[Del Vecchio and Sutherland 1997] and primate ovary [Young et al., 1997]. hCG 
has been documented previously to increase PGHS2 expression and PGE2 
production in mucosal cells from human fallopian tubes [Han et al., 1996]
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IL - ip  could be increasing prostaglandin production through a number o f 
mechanisms. Studies by Brown et al. [1998] in intact foetal membranes have shown 
that IL - lp  can increase PGE2 production by increasing PGHS2 mRNA levels and 
inducing the translocation o f cytoplasmic phospholipase A 2 (CPLA2) from the 
cytosol to the membrane. In bovine luteal cells, the addition o f a PLA2 inhibitor and 
an inhibitor o f protein kinase C (PKC) was shown to abolish IL - lp  stimulated PGF2« 
production [Townson and Pate 1994]. Studies using the phorbol ester 4-P-phorbol 
12-myristate 13-acetate (PMA), to activate PKC, have shown that PMA is able to 
activate PGHS2 gene transcription. This is thought to be via the kinase pathways 
leading to the activation o f activating protein-1 (AP-1) and activating transcription 
factor (ATF), and through the induction o f PGHS2 gene transcription through 
binding to the CRE/ATF binding sites o f the PGHS2 gene [Catley et al., 2003]. 
Other studies have implicated nuclear factor-kappaB (NF-kB) as a transcription 
factor mediating the stimulation o f prostaglandin synthesis by IL - ip  through up- 
regulating PGHS2 mRNA expression [Catley et al., 2003]. N F-kB transcriptional 
binding sites have been located on the PGHS2 gene, and the binding o f NF-kB to 
these sites are thought to activate the PGHS2 promoter to induce gene transcription 
[Catley et al., 2003].
Studies have revealed that the mechanism by which hCG up-regulates PGHS2 
mRNA levels is not through increasing the transcription o f the gene, but through 
increasing the stability o f the transcript [Han et al., 1996a: 1996b]. In addition to 
this, in rat ovarian cells, soluble PLA2 expression was shown to be hCG dependent 
[Ben-Shlomo et al., 1997]. Other studies have revealed that ovarian PLA2 activity
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was stimulated by hCG administration in rats [Bonney and Wilson 1993]. These data 
together reveal that hCG/LH can increase prostaglandin production through 
increasing the expression and activity o f PLA2 and through increasing the stability o f 
PGHS2 mRNA. Indirect effects o f hCG on stimulating prostaglandin production 
have also been documented, with NS-398 and indomethacin administration shown to 
reduce the number o f ovulations in the rat [M ikuni et al., 1998].
The data presented in this Chapter could be interpreted to suggest that prostaglandins 
play a mediatory role in the stimulation o f llp H S D  activities by hCG and IL -lp . 
There are a number o f studies that have documented the role o f prostaglandins in 
increasing the activity and expression o f lip H S D l in different tissue types. In 
human chorionic trophoblast cells, studies by Alfa idy et al. [2001] have documented 
that PGF2a can increase 1 lpH S D l activity. This stimulation was speculated to occur 
via FP receptor activation and subsequent mobilisation o f calcium stores. This is 
thought to activate calcium dependent protein kinase (PKC), which has been shown 
to increase the phosphorylation o f 1 lpH S D l, speculated to account for the increase 
in 1 lpH S D l activity. Consensus sites for PKC phosphorylation are present in the 
primary sequence o f 1 lpH S D l, such that this pathway could mediate the effects o f 
prostaglandins on regulating the activity (but not expression) o f 1 lpH S D l in human 
granulosa-lutein cells. However, subsequent studies in this thesis question the ability 
o f PKC to access 1 lpH S D l (see Chapter 7).
Other mechanisms by which prostaglandins could be regulating 1 lpH S D l activity 
are via perixisome proliferator-gamma receptors (PPARs) subtype. Prostaglandins
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are naturally occurring ligands o f PPARs [Helliwell et al., 2004]. 15deoxy-PGJ2, the 
suggested ligand for PPARy has been shown to increase 1 lpH S D l activity in 
omental and subcutaneous adipocyte stromal cells. Moreover, inhibitors o f PPARy 
have been shown to inhibit 1 lpH S D l activity, and Tomlinson et al. [2001] have 
speculated that the effects o f PGJ2 on increasing 1 lpH S D l activity could be 
mediated by PPARy. However, as PPARs are nuclear receptors, they would be 
expected to influence the activity o f 1 lpHSD through changing 1 lpHSD expression. 
Studies reported in chapters 5 and 6 o f this thesis do not fin d  any changes o f protein 
expression, but do not exclude changes in expression o f 1 lpH S D l mRNA.
One possible mechanism o f regulation that cannot be over-looked is that M A and 
NS-398 could be decreasing the stimulation o f 1 lpHSD activities by increasing the 
metabolism o f AA  to epoxygenase and lipoxygenase products. The inhibition o f 
PGHS by M A  and NS-398 would increase the flux o f A A  through the epoxygenase 
and lipoxygenase pathways, the products o f which could be inhibiting hCG- and IL- 
1 p- stimulated 11 pHSD activities.
In conclusion, this study has found that hCG and IL-1P can increase 11 pHSD 
activities independent o f changes in 1 lpH S D l protein expression. Co-treatment with 
NS-398 and M A abolishes the increase in the oxidative activities o f 1 lpH S D l in 
response to both hCG and IL -lp , both o f which were confirmed to increase PGE2 
and PGF2a production. Taken together, these data suggest a possible role for 
eicosanoids in mediating hCG and IL - lp  stimulation o f 1 lpHSD activities in human 
granulosa-lutein cells.
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Chapter Seven: Elucidation of structural topology, regulatory domains, and
tertiary structure of 11BHSD1
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Chapter 7: Elucidation of structural topology, regulatory domains, and tertiary
structure of 11BHSD1
7.1 Introduction
A number o f studies have investigated the structure, localisation and topology o f 
1 lpH S D l. In the early 1990’s, Tsigelny and Baker [1995a; 1995b] generated the 
first structural domain prediction for 1 lpH S D l based on evolutionary links o f 
1 lpH S D l with other members o f the short-chain alcohol dehydrogenase (SCAD) 
family o f enzymes. In order to predict the structure o f 1 lp H S D l, bacterial 20pHSD 
was selected as a template protein. By analogy, these authors concluded that (i) 
1 lpH S D l dimerises, (ii) the active sites o f 1 lpH S D l would be located within a 
bundle o f 4 hydrophobic helices, and (iii) 1 lpH S D l contained an NADPH co-factor 
binding site within a Rossman fold [Tsigelny and Baker 1995a; 1995b].
Following on from these studies, Ozols generated the first topology predictions o f 
1 lpH S D l orientation within the smooth endoplasmic reticulum (ER) [Ozols 1995; 
Mziaut et al, 1999]. These predictions were based on several factors: the homology 
o f the N terminus o f 11 pHSDl to the N terminus o f the 50kDa esterase enzyme, the 
presence o f 3 N-linked glycosylation sites that were presumed to be orientated 
towards the lumen o f the ER, the presence o f 2 cysteine residues for the formation o f 
an intramolecular disulphide bond, (also assumed to adopt a lumenal orientation), 
and that 1 lpH S D l was resistant to protease digestion unless the smooth ER 
membrane was disrupted using detergents. Based on homology to 50kDa esterase,
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1 lpH S D l was predicted to have a very small cytosolic N terminus (Metj-Lyss), a 
single transmembrane domain (Lys6-Glu25), with the majority o f the C terminus 
(Glu26-Lys292) inside the lumen o f the ER with a hydrophobic core [Ozols 1995].
Subsequent biochemical studies further refined the models generated by Tsigelny 
and Baker, and by Ozols. Studies were conducted using FLAG epitopes at the 
extreme N and C termini o f 1 lpH S D l, in combination with detergents that 
selectively permeabilise only the plasma membrane, or both the plasma membrane 
and the ER membrane. These studies confirmed that the extreme N terminus o f 
1 lpH S D l does indeed reside in the cytosol and that the extreme C terminus is 
located in the lumen o f the smooth ER. Investigations using site-directed 
mutagenesis revealed that Lyss was essential to maintain lumenal orientation o f the 
C terminus, as when this Lys was mutated to a Ser residue, the topology o f 
1 lpH S D l was reversed [Odermatt et al., 1999].
Subsequent studies used site-directed mutagenesis to truncate the N terminus o f 
1 lpH S D l. Mutants lacking either the N-terminal amino acids (aa) 1-15 or aa 1-30 
revealed that these residues, encoded by exon 1 o f the HSD11B1 gene, are not 
essential to anchor 1 lpH S D l to the smooth ER membrane. However, when the 
truncated 1 lpH S D l proteins were also mutated at V a li49 to Arg, the truncated 
protein was partially released from the smooth ER membrane. On mutation o f V a li49 
to Glu, the truncated 1 lpH S D l was fu lly  released from the ER membrane, localising 
exclusively to the cytosolic supernatant fraction. The hydropathy plot for 1 lpH S D l, 
using the thermal modelling and analysis programme (TMAP), revealed that there
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are 3 possible hydrophobic domains in human 1 lp H S D l, the first being the 
predicted transmembrane domain (Met4-Tyr2i), with a second hydrophobic domain 
just prior to the catalytic site (V a li36-Leui58), and the third just after the catalytic site 
(lie i97-Thr22o). Site-directed mutagenesis o f Valng to Glu would reduce the 
hydrophobicity o f the region prior to the active site, rendering it unable to penetrate 
the membrane as a transmembrane domain [Blum and Maser 2003].
Although the biochemical and in silico models o f 1 lpH S D l topology appear to 
favour 1 lpH S D l as comprised o f a single transmembrane domain with a short 
cytosolic N terminus and a large globular C terminal domain within the lumen o f the 
ER, there are several problems with this model. The first is that when a mutant form 
o f 1 lpH S D l was generated that lacked the ‘ first’ transmembrane domain, the 
enzyme still co-precipitated with the smooth ER membrane. The second is that the 
co-factor binding site for NADPH is predicted to reside within the lumen o f the ER, 
but the enzyme is known to respond to addition o f exogenous pyridine nucleotides 
on the cytosolic side o f microsomes. Therefore, the aims o f the studies described in 
this chapter were to use multiple, complementary sequence analysis programs to 
develop alternative models for the 1 lpH S D l enzyme based on:
i) Secondary structure prediction
ii) Hydropathy plots (+/- topology predictions)
iii) Predicted protein folds and domains
Since the primary sequence o f bovine 11PHSD3 has recently been deposited in the 
Entrez-Protein database, the sequence identities between lip H S D l,  llpH S D 2 and
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1 lpHSD3 have been compared in the cow (the only species in which all 3 1 lpHSD 
enzymes have been cloned to date).
7. 2 Experimental Design
For all results obtained, the primary sequences for 1 lpH S D l were used. The 
complete primary amino acid sequences for 1 lpH S D l were obtained from NCBI 
Entrez Protein database
(http://www.ncbi. nlm.nih.gov/entrez/querv.fcgi?db=Protein).
7.2.1 Primary sequence alignment
Primary sequences for 1 lpH S D l were obtained for the following species: human 
{Homo sapiens), squirrel monkey (Samiri sciureus), pig (Sus scrofa), cow {Bos 
taurus), sheep {Ovis aries), rabbit {Oryctolagus cuniculus), guinea pig {Cavia 
porcellus), hamster {Mesocricetus auratus), rat {Rattus norvegicus) and mouse {Mus 
musculus), and the partial sequence to date for cat {Felis catus). A ll sequences were 
converted to FASTA format, and sequence alignments were performed. Two 
different methods for alignment were used, the first being based on manual sequence 
alignments to the human 1 lpH S D l sequence by visual inspection and the second 
using the CLUSTALW  v l.4  database (obtained from 
http://pir.georgetown.edu/pirwww/search/multaln.htmn. CLUSTALW  is a 
progressive alignment method that builds up a multiple sequence alignment starting 
with the most related sequences, and then by adding the less related sequences to the 
original alignment. The order in which the sequences are added is based on an initial
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all by all pairwise alignment, therefore generating an un-biased alignment o f the 
sequences.
This methodology was also used to determine the sequence homology between the 
bovine 1 lp H S D l, llpH S D 2  and 11PHSD3 proteins.
7.2.2 Functional site characterisation o f the 11BHSD1 primary sequence
Potential candidates for functional sites within the 1 lpH S D l sequence were 
identified on the basis o f the presence o f consensus sequences for such domains 
using the Prosite database (http://ca,expasv.org/prosite).
7.2.3 Secondary structure predictions
Secondary structure predictions were made using PsiPred version 2.0 
(http://bioinf.cs.ucl.ac.uk/psipred/) [Jones 1999; McGuffm et al., 2000].
7.2.4 Localisation o f TM  domains
Once sequence alignments were complete, hydrophobicity plots were generated for 
the aligned proteins in itially using Kyte-Doolittle scores. When deriving the 
hydropathy plots the window size was set to 9 amino acids, this being the optimal 
size when looking for surface regions in a globular protein. The window size is the 
number o f amino acids whose hydrophobicity scores are averaged and assigned to 
the middle amino acid in the window. Since the hydrophobicity plots for all 11 
species were very similar, all subsequent studies were performed using only the 
primary and secondary structure predictions for human 1 lp H S D l.
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The human sequence for 1 lpH S D l was analysed using five transmembrane 
prediction tools. Five different predictive tools were used: TMAP [Persson and 
Argos, 1997], Topology Predictor (TopPred) [Claros and von Heijne, 1994] using 
Kyte Doolittle (KD) scores, TopPred using Goldman Engelman Steitz (GES) scores, 
model recognition (MEMSAT 2) [Jones 1998; Jones 1994] and transmembrane 
helical model (TM H M M ) [Krogh et al., 2001]. Transmembrane domains were 
predicted based on the hydrophobicity o f each amino acid residue within the 
sequence and the hydrophobicity o f surrounding residues.
7.2.5. Tertiary structure prediction- Fold recognition
Using the output from the database combined with topology predictions, 3 
alternative models for the tertiary structure o f human 1 lpH S D l were generated. 
Modified genomic threading (mGenTHREADER)
(http://bioinf.cs.ucl.ac.uk/psipred/) [McGuffin and Jones 2003; Jones 1999] was 
used to predict functional folds within the protein based on homology to other 
protein folds within the mGenTHREADER database. The best templates for fold 
homology to 1 lpH S D l were predicted based on homology to 1 lpH S D l without the 
first predicted transmembrane domain. Criteria that were used to assess the templates 
were low energy scores (solvation energy, pairwise energy, and the net energy) 
which provide a co-efficient (E scores) to predict the probability o f fold homology to 
1 lpH S D l.
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7.3 Results
7.3.1. Alignment o f 11BHSD1 primary sequences
Primary sequence alignments for all published 1 lp H S D l sequences were conducted 
by visual inspection (Figure 7.1 A) and using CLUSTALW  (Figure 7.IB ) and 
subsequently aligned in terms o f identity to the human sequence o f 1 lpH S D l. 
Analysis o f percentage sequence homology across species revealed that the 
1 lpH S D l has remained highly homologous. The N terminal sequence upstream o f 
the active site exhibits greater than 80% sequence identity across the mammalian 
species. The C terminal region downstream o f the active site was less homologous, 
with a minimum matching sequence identity o f 66.4% when comparing the mouse or 
rabbit sequences to the human 1 lpH S D l sequence (Table 7.1).
7.3.2. Alignment o f bovine 11BHSDL 11BHSD2 and 11BHSD3 primary sequences
Primary sequence alignments for bovine 1 lp H S D l, 11PHSD2 and llpH SD 3 
sequences were carried out using CLUSTALW  (Figure 7.2). Bovine llpH S D 3 was 
found to share 44% residue identity when compared to bovine 1 lp H S D l. 1 lpHSD2 
shared less identity, with 26% o f residues identical to bovine 1 lpH S D l.
7.3.2 Analysis o f functional sites and regulatory regions in all sequences aligned o f 
11BHSD1
In all 11 species, the consensus sequence for SCAD enzymes (YxxxK) was 
conserved (Figure 7.3). In human 1 lp H S D l, this consensus sequence lies at amino
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acid positions 183-187 (YSASK), with the catalytic region spanning Val/A la i66 to 
Phe 1 9 4 . The NADP(H) co-factor binding site (spanning residues VaU7 to Leugi in
I lp H S D l) was also highly conserved (>83% identity) between species. Three 
conserved sites for N-linked glycosylation were predicted across species (Figure 
7.3). In human 1 lp H S D l, two cysteine residues (Cys78-Cys2 n) were conserved, and 
are thought to take part in intramolecular disulphide bond formation. Possible sites 
for myristoylation o f the enzyme were also identified. Several consensus sequences 
were located for regulation by kinases including PKC, Casein Kinase-2 (CK2) and 
tyrosine kinase. These possible phosphorylation sites were generally located 
downstream (C terminally) with respect to GIU25.
7.3.3. Secondary Structure prediction for human 11BHSD1
The secondary structure o f human 1 lpH S D l was predicted by PsiPred to consist o f
I I  a  helices and 6  p strands interlinked by random coils (Figure 7.4).
7.3.4. Topology predictions for 11BHSD1
A hydropathy plot o f the aligned 11 pHSDl sequences, using the KD scores, revealed 
that across all species the topology o f the protein is highly conserved (Figure 7.5). 
A ll species contain 5 regions o f hydrophobicity, with 3 o f sufficient hydrophobicity 
and sequence length to span the membrane: The first o f the three putative 
transmembrane domains is located at the N terminus o f the protein, and regions 2 
and 3  flank the enzyme’s active site.
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To assess the re liability o f  the topology as predicted by a hydropathy plot conducted 
using KD scores, further predictions were carried out using a total o f 5 different 
programs. Each program used presented different models for the topology o f 
1 lpH S D l (Figure 7.6). TM AP predicted that 1 lp H S D l contains 3 transmembrane 
domains at Met4 to Tyr2 i, V a f 36-Leuisg and I le i97-Thr22o. I f  Goldman Engelman 
Steitz (GES) hydrophobic scores were used, TopPred also predicted 1 lpH S D l to 
contain 3 transmembrane domains although at positions Met4 -  Asn24, V a li36 -  
Leuisg, and G Iui63 -  Tyrm - Further analysis using TopPred with the KD scale o f 
hydrophobicity predicted 5 transmembrane domains at M eti-Tyr2 i, Pheio2-Thri22, 
Sern9-Lysi59, Asn i62~Alai82 , and Tyr2oi-Thr22o. Both MEMSAT2 and TM HM M  
programs predicted only a single membrane spanning region at Tyr7-Tyr2i or Tyr7- 
Ser22, respectively.
To elucidate the role o f V a li49 in stabilising the hydrophobic domains as shown by 
Odermatt et al [2001], TM AP-KD  was used, but with V a li49 replaced with either Arg 
or Glu. Replacing the hydrophobic Val at position 149 with Arg or Glu decreased the 
hydrophobicity scores o f the surrounding regions. A  decrease in overall 
hydrophobicity o f  the protein was observed with this mutation, specifically the 
affected region spanned from Leui45 to A la i5 3 .
7.3.5. Tertiary structure models
Combining the results o f  the secondary structure and topology predictions, 3 
possible models for the tertiary structure o f human 1 lpH S D l were generated. The 
models generated make the assumption that the in vitro studies carried out by
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Odermatt et al, [2001] to determine the orientation o f the extreme N and C terminus 
o f 11 PHSD 1 in the smooth ER membrane were correct. Therefore all models are 
generated on the assumption that the extreme N terminus o f 1 lpH S D l is localised to 
the cytoplasm, and the extreme C terminus is localised to the lumen o f the ER. 
Model 1 predicts a single transmembrane protein, that is able to form a dimerisation 
interface through a  helixE, w ith  a potential inter-molecular disulphide bond at Cys272 
(Figure 7.7a). The N terminus o f the protein is localised to the cytosol, with a-helixA 
forming a membrane spanning region, and the C terminus w ithin the lumen o f the 
ER. Both the catalytic site (P standE and a  helixF) and the Rossman fold that 
constitutes the NADP(H) co-factor binding site (p strandA to a  helixc) are localised 
to the lumen o f  the ER.
Model 2 predicts a protein w ith 3 transmembrane domains that forms a dimer 
(Figure 7.7b). Again, the N terminus o f 1 lp H S D l is localised to the cytosol with a 
helixA form ing the first putative membrane spanning region. The second 
transmembrane region is through a  helixE, and the third is through a helixF. In 
model 2, the active site o f  1 lp H S D l and the cofactor binding site are both located 
within the hydrophobic core o f the smooth ER membrane.
Model 3 also predicts that 11 pH SDl has 3 transmembrane domains (Figure 7.7c). As 
in models 1 and 2, the N  terminus is localised to the cytosol with the C terminus 
within the lumen o f the ER. a  helixA comprises the first putative transmembrane 
domain w ith a  helixE and a  helixF plus p strandF forming the second and third 
transmembrane domains, respectively. The active site is localised to the cytosol
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while the NADP(H) co-factor binding domain is localised to the lumen o f the ER. 
The protein is speculated to form homodimers at the third transmembrane domain 
with a potential intermolecular disulphide bond at Cys272 to stabilise the dimer.
To assess the validity o f each o f these 3 models, a number o f questions were 
generated, based on features that were deemed essential for 1 lpH S D l to be 
functional (Table 7.2). The questions asked o f each model were:
(i) Are Cys78, Cys2 i3 and Cys272 localised to the lumen o f the ER for intra- 
and inter-molecular disulphide bond formation respectively?
(ii) Are Asni23, Asni62 and Asn207 located in the lumen o f the ER for N- 
1 inked glycosylation?
(iii) Are the NADP(H) co-factor binding site and catalytic active site located 
on the same side o f the ER membrane?
(iv) Are Seri69 and Tyri83 within close proximity to form the catalytic site o f 
1 lpH SD l?
The intra-molecular disulphide bond proposed between Cys7g and Cys2i3 [Ozols 
1995] would be promoted in the oxidative environment o f the ER lumen, as would 
the inter-molecular bond (at Cys272) that is hypothesised to stabilise the dimer 
interface specifically for human 1 lpH S D l. In models 1 and 2, all 3 Cys residues are 
located within the lumen o f the ER, but in model 3, Cys2 i3 is localised within the ER 
membrane. This would render the possibility o f the formation o f an intramolecular 
disulphide bond in model 3 unlikely.
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1 lpH S D l is also known to contain 3 sites for N-linked glycosylation, which can 
only occur within the lumen o f the ER. Therefore each o f the Asn residues at 
position 123, 162 and 207 should be located within the lumen o f the ER. Model 1 is 
the only model that has all 3 Asn residues located within the lumen o f the ER. Model
2 has Asni62 within the cytosol, and model 3 predicts that Asni62 and Asn207 would 
be localised to the cytosol and hydrophobic core o f the smooth ER membrane 
respectively.
For 1 lpH S D l to be functional, both the catalytic site and co-factor binding site 
would need to be on the same side o f the membrane. Model 2 would orientate the 
catalytic site and the cofactor binding site on opposite sides o f the membrane. Model
3 would localise the active site within the ER membrane and the co-factor binding 
site to the lumen o f the ER. In contrast, Model 1 localises both the catalytic and 
cofactor binding site to the lumen o f ER.
The key catalytic residues o f Seri 69 and T yri83 o f the catalytic triad would need to be 
within close proximity for the active site to be functional [Tsigelny and Baker 
1995b]. Seri69 is necessary to decrease the pKa o f Tyng3 for catalysis. In Model 2 the 
Tyr and Ser residues would not be able to contact each other to form the key 
catalytic centre for cortisol-cortisone inter-conversion, such that Model 2 would 
almost certainly not produce a functional enzyme.
Taking all o f these data into consideration, Model 1, appears to fu lfil all criteria 
necessary for the 1 lpH S D l enzyme to be functionally viable. Therefore 1 lpH SD l 
appears to be a single transmembrane protein orientated with the extreme N terminus
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Figure 7.1 A : Visual alignment o f  primary sequences o f  1 lp H S D l from other 
mammalian species to human 1 lp H S D l
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Figure 7.1B: Primary sequence alignment o f  1 lp H S D l from different mammalian 
species using C LU STALW  database and subsequent alignment to the human enzyme 
in  order o f  evolutionary divergence
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........ R L. . .S...... R. . . .ST.GL. .---------
.......... IL . S . . LE . . G...... SLRH-..ME..T.N--------
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. . .D N.IL.S. .LK. .G. . .M. . . SLKK. . .E N-------
...D....GNLQ..P..LG..GKRLI...HLRKFDISKLV.N 
...D.M ...G.R.VPY.LG..G...M...SAAE..W .NVLSNEKLYGRWA
......... WS..PI.LG..G...M...SMK.FTF.KL.SS--------
..KD..... K.S..P..LG..G.R.M...SLR...R.L.VSN-------
..KS..... KLPL.PI.LG..G ...M ..FSLRY..K.M .VSN-------
217
1 10 20 30 40 50
11 beta HSD 1 Bos taurus ------------------------------------------- MAFMKKY
11 beta HSD 2 Bos taurus MESWPWPSGGAWLLVPARALLQLLRADLRLGRPLLAALALLAALDWLCQR
11 beta HSD 3 Bos taurus ---------------------------------------------- . .VL
11 beta HSD 1 Bos
11 beta HSD 2 Bos
11 beta HSD 3 Bos
60 70 80 90 100
LLP---ILGIFLAYYYYSANEEFRPEMLRGKR— VIVTGASKGIGREMAY
...PLAA.AVLA.TGWIVLSRLA..QR.PVATRA..I..CDSGF.NAT.K 
..T G..ALFFA..WDD.— .D.AS.H.A.— .LL..V.A...E .L..
110 120 130 140 150
11 beta HSD 1 Bos taurus HLARMGAHVVVTARSEESLKKVVSRCLELGAASAHYVAGTMENMTFAEQF
11 beta HSD 2 Bos taurus K.DT..FT.LA.VLDLN.PGALEL.ACCSSRLKLLQMDL.KPGDISRVLE
11 beta HSD 3 Bos taurus .Y..L.S.L.L ..HT.AL.QQ..GN.RK...PKVF.I.AD.ASPEVP.RV
11 beta HSD 1 Bos taurus
11 beta HSD 2 Bos taurus
11 beta HSD 3 Bos taurus
160 170 180 190 200
VAKAGELVGGLDMLILNH-IHYTPLGVFSNDIHLLRRTLEVNLLSYWLS 
FT.VHTPST..WG.VN.AGQNIFVADAELC PVAT F.TCM...FFGALEMT 
.QF.LDKL....Y.V ...-LGAA.A .TRVRSSQST.WLMQM.F....Q.T
11 beta HSD 1 Bos taurus
11 beta HSD 2 Bos taurus
11 beta HSD 3 Bos taurus
210 220 230 240 250
TAALPMLKQTNGSIWVSSIAGKIACPLVAAYSASKFALDGFFSSLRMEY 
KGL..L.RRSS.R..T...P..DMPF.CL...GT..A ..ALLMGNFSC.L 
SS. . .S.TDSK. .L LL . RVPTSFSSP . . .A S..... R.L
11 beta HSD 1 
11 beta HSD 2 
11 beta HSD 3
260 270 280 290 300
Bos taurus EATKVNVSIT LCILGLIDTDTAMKAVAGIFN---------------
Bos taurus LPWG.K...IQPACFKTESVK.VHQWEERKQQLLATLPQELLQAYGEDYI
Bos taurus DVQE...A.. M .V ...R.RAS.AEG.R..TR---------------
11 beta HSD 1 Bos
11 beta HSD 2 Bos
11 beta HSD 3 Bos
310 320 330 340 350
---------- AKASPKEECALEIIKGGTLRQD— EVYYDSS-ILTPLLL
EHLNGQFLHSLSQ.L.DLSPVVDA.TDAL.AAQPLRR..PGHGLGLIYFI 
---------- VR.A.GPKA..AV.R..ATRAS— G .F.PWR-FHLLC..
11 beta HSD 1 Bos
11 beta HSD 2 Bos
11 beta HSD 3 Bos
310 320 330 340 350
RNPGRKIMEFFFLKKYNMERFINN--------------------------
HYYLPEGLRQR..QSFFISPYVPRALQAGQPGLTSARDIAQDQGPRPDPS 
.SWMPHSRAW.VRQELNITTPAAA--------------------------
11 beta HSD 1 Bos taurus -----
11 beta HSD 2 Bos taurus PTAQ
11 beta HSD 3 Bos taurus -----
F igure 7.2: Primary sequence alignment o f  bovine 1 lp H S D l, 1 ipH SD 2 and 
llp H S D 3  using C LUSTALW  database.
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Figure 7.3: Predicted conserved regulatory sites o f  11(3HSD1. PTM = post-translational 
modification, N-m yr= myristoylation, CK2= casein kinase 2 phosphorylation site, diS= 
disulphide bond linkage, N-glyco=N-linked glycosylation sites, Amid=amidation.
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..................................... I . L    R . . .
..................................... I . L    . .   R . .R
........................................... L  R. .R
. . . L  T .  . M V . L  P. . . K,
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 .................... EQ.
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PTM
Kinase PKC PKC
diS N-Myr N-Myr N-Glyco.
C K2 C K2
Human 51 AYHLAKMGAHVVVTARSKETL Q KW SH C LELt AASAHYIAGTMEDMTFAE
Monkey
Pig
51
51 ........... R . . . E . . . K ____ S . . . . . S . S .  . V ............................
Cow 51 ...........R. . . E . S ^ K . . . R ____ ................. V ............ N .............
Sheep 51 ...........R. . . E . S . K . . . . R ____ ................. V .............N .............
Cat • • • • • • • ■ • . .N . K. I . . . . M . .
Rabbit 50 . F ................. • • • • .E . . A .  . . K .
Guinea 51 . . . . . . . . . . . A . . . A R . . , . ......................... S .....................
Hamster 51 ____S E . . . . . L . . . E . G .
Rat 47 ____S ____ . . L . . . E . G . ............R ...............................................................
Mouse 51 ____s ____ . . L . . . E . G . ............R ...............................................................
Site/
Domain NADP(H) Binding Site
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Kinase
Human
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Pig
Cow
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Rat
Mouse
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PKC
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 K . . E . V ................................ NY . P . R V . SN . . . L L . R . L . . . L ................
 K ................................................ . .M . . . SG.  . . 1 .  . R ...............................
. . . . K ................................................... A .  . M F . N N ..................... E .................................
E . A . E .  . N .................................. V L Y N R .T F . . G E . D N ............................H . F .  . .
. . . L K ..................................................Y . . M . F . R . E . . A L . . A  I  M
R.  . V E _____ L .................................. Q .T M S ......................S . .. R ...................................
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PTM
Kinase
N-Glyco
Rabbit
Guinea
Hamster
Rat
Mouse
PKC
Human 151 TVAALPMLKQSNGSI VVVS S LAGKVAY PMVAAY SAS K FAL DG F F SS IR K E
Monkey 151 . . . . M . .
Pig 151 S .............. o . . . M . N . L .  . P ............................... . . . T . .
Cow 151 S T ........... ____T T. . . I . C . L ....................................... . . L . M .
Sheep 151 S T ........... V . . . I . C . L A ..................................... . . L . T .
Cat S A T . . . . K. . . M . S . L I . P ............................... . . . .M.
Rabbit 150 • • • • • • • . . . . • • • • •  • • m m . . . . I . H . L I . P ............................... . A ____
Guinea 151 S . . . M . . . M . . Q. . . A . . . . V . . . I T .  . L I . P ............................... ■ T L . S .
Hamster 151 S .............. T . . . M . H . L . . S ............................... . . L . R .
Rat 147 S T .......... A l l .  . M. . . M T Q . L I . S .................................. . T ____
Mouse 151 S T ........... A . I .  . . . M T Q . . I . P .......................... . T . . T .
Site / 
Domain Catalytic Site
PTM
Kinase
Human 201
N-Glyco. diS N-Myr N-Myr 
CK2 PKC+CK2
YSVSRVNVSITLCVLGLIDTETAMKAVSGIVHMQAAPKEECALEIIKGGA
Monkey 201 . L M . E . . _____D. . . V
Pig 201 . . . T K . . _____D, . A .
Cow 201 . EATK. . _____D, . . . A . . F N A K . S ............................... . . T
Sheep
Cat
201 . E A T K . . _____D. . . . A . . Y N A E . S . . . . L * * _____
H . . A K I . . . I .  . . . N . D , N . I .  .
200
201
201
197
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E . . . K I D . KH A LTN ................     D .
F L .N K ...............  . 1 ....................... . 1 .  . T .  . . Y L G P . S .  .  .T
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HLM TK................   _  . . F    L . ET . . . IL S
L Y IT K .......................................................E l .  .  . I N A
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PTM diSAmid
K inase T y rK P K C  T y r K  P K C
Human 251 LRQEEVYY DS S LW T T LL IR N  P C R K ILE F LY S T S  YNMDRFINK 292
Monkey 251 . . R ................. L .  . . S ...................R . . . . S T . G L .  . 291
Pig 251 ............... . . . . I L . S . . LE . . G ..................SLRH . . . E . . T . N 292
Cow 251 . . . D . . ____ I L . P . . L . . . G . . . M . . F F L K K . . . E . . . . N 292
Sheep 249 . . . D . . . . N . I L . S . . L K . . G . . . M . . . S L K K . . . E . . . . N 290
Rabbit 250 . . . D . . . GNLQ. . P . . L G . . G K R L I . . . H L R K F D I S K L V . N 291
Guinea 251 . . . D. M . V G . R . V P Y . L G . . G . . . M . . . S A A E . . W. NVLSNEKLYGRWA 300
Hamster 251 .............. . . . WS. . P I . L G . . G . . . M . . . S M K . F T F . K L . S S 292
Rat 246 . . K D . . . . K . P . . P . . L G . . G . R . M . . . S L R . . . R . L . V S N 287
Mouse 251 . . K S . . . . K . P L . P I . L G . . G . . . M . . F S L R Y . . K . M . V S N 292
221
F igure  7.4: Secondary structure prediction fo r human 1 lp H S D l generated by PsiPred 
database based on PsiBLAST scores when compared to other proteins w ith in  the 
PsiPred database
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F igure  7.5: Hydropathy p lo t o f  aligned prim ary sequences fo r mammalian 1 lp H S D l 
enzymes. The K yte -D oo little  scale was used as a measure o f  hydrophobicity w ith  
positive values being more hydrophobic and negative values being less hydrophobic.
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Figure 7.6: Hydropathy p lot and transmembrane domain predictions for human 
l ip H S D l using TM AP , TopPred-KD (K yte -D oo little  scores), TopPred-GES, 
M E M S A T  2 and T M H M M  topology prediction methods.
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Figure 7.7a: Model 1 o f  secondary structure and topology w ith in  the ER membrane 
o f  human 1 lp H S D l |— ^
a-helix and p-strand (each drawn to scale); —  random coil
(not drawn to scale); pA-dB-Pirac = Rossmann fo ld  (site o f  N A D P (H ) binding); 
Pe-cif =  Catalytic site; m ■ ■ ■ dimerization interface; inter-molecular 
^ ^ lp h id e  bond (human 11 pH S D l only); site o f  intra-molecular disulphide bond; 
consensus N-linked glycosylation sequence.
CytosolCytosol
mm1 mmj
n~ j r
Figure 7.7b: Model 2 o f  secondary structure and topology w ith in  the ER membrane 
o f  human l lp H S D l
a-helix and p-strand (each drawn to scale); random coil
(not drawn to scale); Pa-cib-Pb-cic =  Rossmann fo ld  (site o f  N A D P (H ) binding); 
Pe-cif =  Catalytic site; dimerization interface; inter-molecular
|^ i lp h id e  bond (human 11 pH S D l only); site o f  intra-molecular disulphide bond; 
consensus N-linked glycosylation sequence.
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CytosolCytosol
Figure 7.7c: Model 3 o f  secondary structure and topology w ith in  the ER membrane 
o f  human llp H S D l
a-helix and p-strand (each drawn to scale); —  random coil
(not drawn to scale); pA-aB-pB-ac = Rossmann fo ld  (site o f  N A D P (H ) binding); 
Pe-(Xf = Catalytic site; £ ■ ■ ■ dimerization interface; inter-molecular 
^ ^ llp h id e  bond (human 11PHSD1 only); site o f  intra-molecular disulphide bond; 
consensus N-linked glycosylation sequence.
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Figure 7.8: Three-dimensional structures for the candidate structural
homologues of human lipH SD l
(a) Bacterial 3B/17BHSD
b) Thornapple Tropionine Reductase 1
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(c) Bacterial Glucose Dehydrogenase
d) Mouse Carbonyl Reductase
(e) Bacterial Sorbitol Dehydrogenase
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Rat 17BHSD type IV
(g) Human 17BHSD type I
(h) Porcine Carbonyi Reductase/20BHSD
231
(i) Bacterial 3aHSD
(i) Rabbit 20aHSD
232
Table 7.1: Table outlining homology to human lipH SD l primary sequence comprised 
of homology to whole sequence, N terminus before the catalytic region and C terminus 
following the catalytic region. Nd= not determined.
N-terminus 
(prior to conserved 
YSASK catalytic 
sequence)
C-terminus 
(conserved YSASK 
catalytic sequence and 
beyond)
WHOLE PROTEIN
Species # same aa % identity # same aa % identity # same aa % identity
Human 182 - 110 - 292 -
Monkey 173 95.1 92 83.6 265 90.8
Pig 154 84.6 84 76.4 238 81.5
Cow 148 81.3 82 74.5 230 78.8
Sheep 148 81.3 79 71.8 227 77.7
Cat Nd Nd Nd Nd Nd Nd
Rabbit 142 88.8 72 66.4 234 80.4
Hamster 151 83.0 79 71.8 230 78.8
Rat 158 86.8 74 67.3 232 79.5
Mouse 153 84.1 73 66.4 226 77.4
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Table 7.2: Summary o f  essential criteria to assess the functiona lity o f  each proposed 
model for the topology o f  human 1 lp H S D l.  Where the given structural arrangement 
would prevent to enzyme being functiona l it  is highlighted in  red bold text. Green text 
represents a specific orientation o f  an am ino acids or where a structural domain is 
consistent w ith  published data.
M odel I M odel II Model I I I
Number o f  putative transmembrane 1 3 3
domains (TM D s)
Model exhibits the T M D s1 as
predicted by:
TM AP - - YES
TopPred-KD2 - - -
TopPred-GES3 - YES -
M EM SAT2-V 1494 YES - -
M EM SAT2-R /E 1495 - YES -
T M H M M YES - -
Position o f  specific amino-acids:
M eti (N -term inus)6 Cytosol* Cytosol* Cytosol*
Cys787 Lum en* Lumen* Lumen*
Asn1238 Lum en* Lumen* Lumen*
Asni628 Lum en* Cytosol Cytosol
Asn2078 Lum en* Lumen* Membrane
Cys2i3? Lum en* Lumen* Membrane
CyS2729 Lum en* Lumen* Lumen*
Lys292 (C-term inus)6 Lum en* Lumen* Lumen*
Position o f  protein domains:
Pyridine nucleotide cofactor
binding domain Lumen Lumen Lumen
Catalytic site (Y x x x K ) Lumen Membrane Cytosol
Putative dimerisation
interface (he lix  aE) Lumen Membrane Membrane
Additional specifications:
(1) Are the nucleotide cofactor
binding domain and the catalytic
site o f  the enzyme on the same
side o f  the ER membrane? YES* YES* NO
(2) Is Ser!69 adjacent to T y r i83 such
that these residues can fo rm  a
catalytic reaction centre? YES* NO YES*
(3) Can the putative d im erisation
interface in he lix  aE fo rm  a 4-
helix bundle w ith  helices aF, aG
and aH? YES* NO NO
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Table 7.3: Summary of mGenTHREADER tertiary structure homology
Protein Organism
(Common
name)
PDB
ID
EC CATH SCOP Net
Score
E value Pairwise
E
Solv.
E
Align
Score
A
Len
D
Len
T
Len
3B / 17B-HSD
Comamonas
testosteroni
(Bacteria)
lhxh 1.1.1.51 3.40.50.720 0.972 0.00002 -1166.9 -15.0 697 250 253 292
Tropinone 
Reductase 1
Datura
stramonium
(Common
thomapple)
lael 1.1.1.236 3.40.50.720 0.972 0.00002 -1139.7 -14.7 657 240 245 292
Glucose
dehydrogenase
Bacillus
megaterium
(Bacteria)
lgco 1.1.1.47 3.40.50.720 0.972 0.00002 -1090.9 -17.8 783 254 261 292
.... M ......
Carbbnyl
reductase
Mus
musculus
(Mouse)
lcyd 1.1.1.184 3.40.50.720 0.972 0.00002 -1060.3 -14.4 642 240 242 292
Sorbitol
dehydrogenase
Rhodobacter
sphaeriodes
(Bacteria)
lk2w 1.1.1.14 None None 0.972 0.00002 -1058.0 -14.7 774 250 256 292
Estradiol 17B- 
dehydrogenase 
type 4
Rattus
norvegicus
(Rat)
lgz6 1.1.1.35 3.40.50.720 0.970 0.00002 -1047.7 -10.6 639 237 302 292
17BHSD type 
1
Homo
sapiens
(Human)
la27 1.1.1.62 3.40.50.720 0.968 0.00002 -950.7 -9.1 514 245 285 292
Carbonyl 
reductase / 
20BHSD
Sus scrofa
(Pig)
lhu4 1.1.1.53 3.40.50.720 0.965 0.00003 -957.5 -8.3 444 234 288 292
3aHSD
Comamonas
testosteroni
(Bacteria)
lfjh 1.1.1.50 3.40.50.720 0.960 0.00003 -797.2 2.2 410 205 236 292
20aHSD
Oryctolagus
cuniculus
(Rabbit)
lq5m 1.1.1.189 none none 0.364 8.378 -534.7 -13.9 66 215 322 292
to
u>
0 \
in the cytosol followed by a single transmembrane domain, and with the majority o f 
the protein and the extreme C terminus localised to the ER lumen.
7.3.6 Protein fold predictions for the lumenal domain o f human 11BHSD1 
Based on the output o f mGenTHREADER on 15 July 2004, 10 putative structures 
for the lumenal domain o f human 1 lpH S D l were isolated. These structures each had 
consistently high probabilities o f structural sim ilarity to 1 lpH S D l over 3 
consecutive interrogations o f the mGenTHREADER protein fold database (Table 
7.3). The number o f proteins identified with high fold homology to the lumenal 
sequence o f 11 pHSDl is unusually high. The proteins identified include a number o f 
members o f the SCAD enzyme family including human 17pHSD type 1, bacterial 
3p/17J3HSD, rat 17pHSD type 4 and bacterial 3aHSD (Figure 7.8). However, the 
protein rabbit 20aHSD had a low fold homology with an E score o f only 8.378 
(p>0.05 for homology to human 1 lpH S D l).
7.4 Discussion
This study aimed to generate and evaluate alternative models for the topology and 
secondary/tertiary structures o f 1 lpH S D l. Combining relevant literature, sequence 
alignment data, hydrophobicity plots, topology predictions for 1 lpH S D l and 
secondary structure predictions (based on homology to other folds within the PsiPred 
and mGenTHREADER databases) 3 models for the possible tertiary structure and 
topology o f 1 lpH S D l were generated. Each model was assessed by criteria that 
were known to be essential for lip H S D l function, or that had been proven by in
237
vitro studies o f 1 lpH S D l orientation in the ER membrane. Both Models 2 and 3 
predicted structures that would conflict with published experimental findings. 
Specifically, model 2 would localise Asni6 2 to the cytosol, however studies by Ozols 
[1995] have inferred that at least 1 Asn residue must be localised to the lumen o f the 
ER for N-glycosylation. Also, in Model 2, key residues o f Seri69 and Tyri83 would 
not lie within close enough proximity to form the catalytic triad required for 
functional enzyme activity as an oxidoreductase. Together, these findings render 
Model 2 an unlikely model for the topology and tertiary structure o f 1 lpHSD l 
within the ER membrane. Model 3 localised both Asn207 and Cys2 i3 to the 
membrane, and Asni62 to the cytosol, conflicting with data by reported Ozols [1995]. 
Model 3 also localises the active site o f 1 lpH SD l to the membrane, and the co­
factor binding site to the lumen o f the ER, therefore making Model 3 impossible for 
a functional enzyme.
Model 1 fulfils all o f the expected criteria for functional 1 lpH S D l. Published 
studies have hypothesised that 1 lpH SD l is a single transmembrane protein, with at 
least 2 sites for N-linked glycosylation, located in the lumen o f ER [Ozols 1995]. 
Model 1 is in accordance with these predictions. Moreover, in Model 1 both the 
catalytic site and residues Seri69 and Tyrm  forming the catalytic reaction centre are 
o f lumenal orientation with Seri69 able to adopt a position close to Tyr]83 . The 
Rossman fold for NADP(H) binding is located within the lumen o f the ER. The 
dimerisation interface is located within the lumen o f the ER and the helices forming 
the dimer can form a four helix bundle as predicted by Tsignely and Baker [1995b] 
with a-helixE, a-helixF, a-helixo and a-helixn.
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Although Model 1 upholds all structural requirements for 1 lpH S D l to be functional, 
there are still some unresolved problems with this Model. Firstly, exon 1 o f the 
HSD11B1 gene encodes the first 24 residues o f 1 lpH S D l, which almost certainly 
comprise the transmembrane domain o f the protein. When translation is initiated at 
exon 2, the 1 lpH S D l protein is still targeted to the smooth ER and is membrane- 
associated. Loss o f the N terminal amino acids, and transmembrane domain can be 
induced by site-directed mutagenesis, or physiologically, as is observed with 
U pH S D lB  [Mercer et al., 1993]. However, in vitro and in silico analysis have 
concluded that lip H S D l is a single transmembrane protein. Having excluded the 
possibility o f transmembrane domain membrane attachment, the association o f N 
terminally truncated forms o f 1 lpH S D l with the smooth ER membrane could reflect 
peripheral binding through myristoylation o f 1 lpH S D l. There are 5 predicted sites 
for myristoylation which could anchor 1 lpH S D l to the smooth ER membrane 
through one or more fatty acyl linkage (Figure 7.3).
In model 1, the consensus sequences for phosphorylation and the co-factor binding 
site both reside within the lumen o f the ER. This poses problems for the transport o f 
the pyridine nucleotides across the ER membrane. The lumen o f the ER is known to 
support an oxidative environment [Hwang et al., 1992] and is relatively impermeable 
to redox-active compounds including the pyridine nucleotides. It has been 
hypothesised that the oxidases and reductases that are anchored to the ER maintain a 
functional cooperativity to support this environment [Sawada and Carlson 1981; 
Kulkami and Hodgson 1982; Draper et al., 2003]. Hexose-6-phosphate
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dehydrogenase (H6PDH) has been speculated to be a key enzyme in maintaining the 
homeostasis o f the oxidative environment o f the ER through the production o f 
reducing equivalents o f the pyridine nucleotides. H6PDH is the microsomal 
counterpart o f the pentose phosphate pathway, utilising NADP+ as a cofactor and 
functioning to catalyse the first 2 reactions in the pathway. The supply o f substrate, 
glucose-6-phosphate, is ensured by the glucose-6-phosphate transporter [Clarke and 
Mason 2003]. The coupling o f H6PDH and 1 lpH S D l was in itia lly suggested based 
on cofactor requirements [Sawada and Carlson., 1991]. Recently it has been reported 
that co-segregating mutations in the genes encoding both 1 lpH S D l and H6PDH 
result in apparent cortisone reductase deficiency [Draper et al., 2003]. Moreover, a 
recent study by Banhegyi et al [2004] has revealed direct cooperativity between the 
activity o f H6PDH and 1 lpH SD l in rat liver microsomes. Specifically it has been 
proposed that H6PDH alters the redox state o f NADP within the lumen o f the ER 
highlighting a possible mechanism o f nucleotide support for 1 lpH S D l, and a 
possible mechanism for regulating 1 lpH SD l directionality, dependent upon the 
intra-lumenal environment. Therefore an increase in glucose-6-phosphate into the 
cell w ill increase the conversion o f glucose-6-phosphate to 6-phosphogluconate, 
which w ill increase the availability o f NADPH, thus favouring cortisone reduction 
by 1 lpH SD l [Atanasov et al., 2004].
The orientation o f the kinase phosphorylation sites o f 1 lpH S D l to the lumen o f the 
smooth ER questions the ability o f these kinase enzymes to directly phosphorylate 
the enzyme to regulate its activities. Numerous studies have shown that kinases and 
pharmacological stimulators and inhibitors o f protein kinase activity can regulate the
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activity o f 1 lpH S D l (Table 1.1). However, these studies show the need for further 
investigation into the mechanisms by which 1 lpH S D l is regulated.
Although the two hydrophobic regions that flank the active site o f 1 lpH S D l (Vali36 
-  Leu 158 and Ile i97 -  Thr22o) are unlikely to form transmembrane domains, these 
hydrophobic regions could act as potential binding sites for hydrophobic molecules. 
Since such ligands would be binding to the hydrophobic core o f the enzyme, 
adjacent to the active site o f 1 lpH S D l, this could provide a molecular mechanism 
whereby hydrophobic lipids could exert allosteric actions on enzyme activity. Such a 
mechanism could be hypothesised for the regulation o f 1 lpH S D l activity via 
progesterone and/or prostaglandins.
In conclusion, this study reveals that the previously predicted topology for 11 pHSDl 
within the ER is almost certainly correct. 1 lpH S D l does appear to be a single 
transmembrane glycoprotein, which forms homodimers and interacts with H6 PDH. 
The N terminal amino acids are localised to the cytosol, followed by a single 
transmembrane domain and a large globular C terminal domain that contains 
hydrophobic regions, and could be linked to the lumenal face o f the ER membrane 
through fatty acyl linkages. Although not fu lly resolved, the mechanisms o f 
regulation o f enzyme activity include effects on the intra-lumenal cofactor 
environment o f the ER, based upon the co-operativity between 1 lpH SD l and 
H6 PDH.
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Chapter Eight: General discussion
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Chapter 8: General Discussion
The goal o f this thesis was to elucidate the cellular mechanisms controlling 
glucocorticoid metabolism by 11 pHSD in the human ovary. This goal was achieved 
by addressing 5 different questions:
(i) What are the effects o f compounds comprising human follicular fluid on 
11 pHSD enzymes?
(ii) What are the effects o f local progesterone synthesis on the llpH S D  
enzyme(s) in human granulosa-lutein cells?
(iii) How does local eicosanoid synthesis affect the llp H S D  enzyme(s) in 
human granulosa-lutein cells?
(iv) Do eicosanoids mediate the stimulation o f ovarian 1 lpHSD enzyme(s) by 
hCG and IL - lp  in human granulosa-lutein cells?
(v) What are the structural topology, tertiary structure and mechanisms for 
regulation o f 11 pHSDl in the smooth ER?
The studies reported in this thesis utilised primary granulosa cell cultures for the 
study o f cellular mechanisms controlling glucocorticoid metabolism by 11 pHSD in 
the ovary. The limitations o f these in vitro granulosa cell cultures need to be noted. 
The granulosa cells were obtained from patients undergoing IVF-ET and so had been 
exposed to ovulatory doses o f gonadotrophins, pre-disposing the cells to assume a 
luteal phenotype [Richards 1994]. The culture o f isolated granulosa cells cannot take 
account o f processes that occur with ovulation and corpus luteum formation, such as 
tissue remodelling and vascularisation o f the follicle. However, primary granulosa
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cell cultures, as compared with granulosa cell lines, do retain functional responses 
and the ability to maintain steroidogenesis with the pattern o f steroid synthesis in 
vitro resembling the hormonal profile in vivo.
Results reported in Chapter 3 o f this thesis have demonstrated that there are 
hydrophilic stimulators and hydrophobic inhibitors o f NADP(H)-dependent 1 lpHSD 
activities in hFF. Under the conditions used in this study, these compounds have no 
effect o f NAD+-dependent cortisol oxidation. Moreover, the compounds present in 
hFF exert their effects on the NADP(H) dependent 1 lpH S D l activities without 
affecting protein expression. Although the identity o f the compounds remains 
unclear, the predominant hydrophobic inhibitor o f 11 PHSDl activities is not a 
known prostaglandin, steroid or cholesterol. Moreover, studies have shown that 
GALF is not a candidate for either the hydrophilic or hydrophobic modulators o f 
1 lpH SD l activity in human FF. A t present, based on biophysical properties, 
oxysterols and/or bile acids are the strongest candidates for the hydrophobic 
inhibitor(s) o f 11 PHSD human FF.
Limitations o f this study were that concentration-dependent effects o f the 
modulatory compounds in human FF on 1 lpH S D l activity were not determined. 
Also, the kinetic properties o f the modulatory hydrophobic components o f human FF 
were not determined. A kinetic study would enable a fuller understanding o f the type 
o f inhibition that the modulatory components exert on 1 lpH S D l activity.
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One potential mechanism by which the hydrophobic components o f human FF could 
inhibit the bi-directional activities o f 11 PHSDl is by binding to the active site o f the 
enzyme. Were this to be the case, then the inhibition o f enzyme activity would be 
competitive in nature. Hence, this possibility could be assessed by investigating 
whether the hydrophobic components o f human FF can increase the K m o f 1 lpHSD l 
for cortisol or cortisone, ideally in a cell-free system such as liver microsomes. The 
studies reported in Chapter 7 raised the possibility that hydrophobic compounds in 
human FF might inhibit 1 lpHSD l by allosteric actions. This could involve binding 
to the hydrophobic regions which flank the active site o f the enzyme.
In the studies reported in Chapter 4, inhibition o f endogenous progesterone 
production increased both the oxidative and reductive activities o f 1 lpHSD l in 
human granulosa-lutein cells, without affecting the expression o f 1 lpH SD l protein. 
Interestingly although progesterone appeared to inhibit basal 11 PHSD activities, it 
was notable in that in the studies reported in Chapter 6 , inhibition o f progesterone 
using AG has little impact on the stimulation o f 11 pHSD stimulated activities by 
hCG. Intuitively it would have been expected that hCG would have stimulated 
progesterone production which would have attenuated any stimulation o f 11 pHSD 
activities. I f  this were so, co-treatment with AG would be expected to enhance the 
stimulation o f enzyme activities by hCG. However this was not found to be the case, 
suggesting that elevation o f progesterone has no bearing on the endocrine 
stimulation o f 11 pHSD-mediated glucocorticoid metabolism in human granulosa- 
lutein cells.
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Limitations o f this study were that AG (an inhibitor o f P450CSCc) was used as a 
pharmacological tool to inhibit progesterone production. AG is known to non- 
specifically inhibit other P450 enzymes o f steroidogenesis such as aromatase [Santen 
and Misbin, 1981] and therefore could non-specifically affect the activity o f 
11 PHSD. However, co-treatment with AG has been shown to stimulate the activity 
o f 11 pHSD, which could be due to AG inhibiting the synthesis o f a regulator o f 
llpH S D , rather than through a direct effect o f AG itself on the activity o f the 
enzyme.
AG directly inhibits the conversion o f cholesterol to pregnenolone (the rate limiting 
step o f steroidogenesis). Pregnenolone is subsequently converted by 3pHSD to 
progesterone. Therefore the inhibition o f P450CSCc not only inhibits progesterone 
synthesis, but also pregnenolone synthesis. Thus pregnenolone could also be 
exerting an inhibitory effect on 11 pHSD activity that is removed by the presence o f 
AG. To investigate this, pregnenolone concentrations could be determined in the 
presence and absence o f AG, to confirm that AG does inhibit pregnenolone 
production. Also, pregnenolone and progesterone replacement experiments could be 
conducted in the presence o f AG, although there are limitations to these experiments 
as discussed in section 4.4. Moreover, due to progesterone being the major secretary 
product o f the CL it is likely that progesterone is the predominant inhibitor o f 
11 pHSD activity in hGL cells.
The cellular mechanisms by which progesterone could regulate the activities o f 
11 PHSD have been speculated on in Chapter 4. The simplest explanation is that
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progesterone could bind to the active site o f 11 PHSDl, thus competing with cortisol 
and/or cortisone. Alternatively the regulatory mechanisms could involve allosteric 
binding o f progesterone to hydrophobic interfaces in the structure o f 1 lpH S D l. The 
studies reported in Chapter 7 indicated that such regions exist on both sides o f the 
active site o f 11 pH SD l.
Studies reported in Chapter 5 have shown that inhibition o f endogenous 
prostaglandin synthesis using M A and NS-398 decreased 11 PHSD activities without 
affecting the expression o f 1 lpHSD l protein. These data suggest a role for 
endogenous prostaglandin synthesis in elevating the basal activities o f 11 pHSD in 
human granulosa-lutein cells. However, addition o f exogenous prostaglandins did 
not overcome the inhibition o f 11 PHSD activity induced by the addition o f M A and 
NS-398, calling into question the interpretation o f the initial finding. As conceded in 
Chapter 5 an alternative explanation o f these findings would be that other 
eicosanoids (e.g. leukotrienes) could have been non-specifically inhibited by NS-398 
and/or MA. Alternatively the inhibition o f prostaglandin synthesis may have re­
directed the flux o f AA  metabolism towards the epoxygenase and lipoxygenase 
pathways where products o f these pathways may have a negative effect on 11 PHSD 
enzyme activities. Findings in Chapter 5 also raise the possibility that exogenously 
administered prostaglandins may not exert the same actions as prostaglandins 
synthesised by PGHS2 within the lumen o f the smooth ER or within the nucleus o f 
the cell.
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The cellular mechanisms by which eicosanoids could regulate the activities of
I lpHSD could be through allosteric regulation o f 1 lpHSD. PGHS1 and PGHS2 are 
localised to the lumen o f the ER and to the lumenal side o f the nuclear envelope. 
Studies conducted in Chapter 7 are consistent with previous suggestions that the 
active site o f 1 lpH SD l is localised to the lumen o f the smooth ER, and have found 
the active site o f 11(3HSD1 to be flanked by hydrophobic regions. Therefore 
prostaglandins generated in the lumen o f the ER could act (without being secreted 
from the cell) allosterically within the lumen o f the ER to increase the activities o f
I I  (3HSD. Prostaglandins could also be acting in the more classical manner through 
paracrine and autocrine mechanisms via secretion from cells, and through the 
binding to cells surface GPCRs, activating second messenger signalling cascades and 
protein kinases. However, studies in Chapter 7 o f this thesis question the ability o f 
protein kinases to phosphorylate lip H S D l due to orientation o f the enzyme, with 
the consensus phosphorylation sequences present in the lumen o f the ER. Also, the 
addition o f exogenous PGs, which would be expected to act through a second 
messenger-protein kinase signalling cascade, does not overcome the inhibition o f 
1 lpHSD l observed when intracellular prostaglandin synthesis is inhibited using MA 
and NS-398.
A recent publication by Rae et al. [2004] has revealed a potential link between the 
expression o f PGHS2 mRNA and the expression o f 1 lpH S D l mRNA when hOSE 
cells are stimulated by IL - la . After 6  hours exposure to IL - la , PGHS2 mRNA 
expression was elevated, and after 12 hours exposure to IL - la , an increase in 
1 lpH SD l mRNA was also observed. The difference in time could be due to IL - la
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inducing an increase in 1 lpHSD l mRNA expression through increasing 
prostaglandin generation. These data are consistent with a model in which 
prostaglandins mediate the stimulation o f 1 lpHSD l activity and/or expression by 
hCG and IL-1. A  model whereby the effects o f hCG and IL - lp  on prostaglandin 
synthesis and 1 lpH SD l activities are causally linked (rather than independent) is 
logical. Were hCG and/or IL - lp  to simultaneously stimulate prostaglandin synthesis 
and the regeneration o f cortisol by 1 lpH SD l, cortisol may exert its anti­
inflammatory actions too rapidly, before prostaglandins have fulfilled their pro- 
inflammatory roles required for ovulation. A  model in which the elevation o f 
prostaglandins has to precede the stimulation o f lip H S D l would allow the 
prostaglandins to up-regulate MMPs and affect the vascularisation o f the follicle 
before local glucocorticoid synthesis limits further eicosanoid generation.
Studies reported in Chapter 6  have shown that M A and NS-398 can prevent hCG and 
IL - lp  from stimulating lipH S D  activities without affecting 1 lpH SD l protein 
expression. These data could imply a mediatory role for prostaglandins in the 
stimulation o f lipH S D  activities by hCG and IL -lp . However, it is also possible 
that, as previously discussed for Chapters 5 and 6 , the inhibition o f prostaglandin 
synthesis has favoured the generation o f epoxygenase and/or lipoxygenase products 
that inhibit the activities o f 11 pHSD in human granulosa-lutein cells.
To explore the possible involvement o f other eicosanoid products in hCG- and IL- 
lp - stimulated lipH S D  activities, inhibitors o f the lipoxygenase pathway such as 
NDGA (which inhibits the 5-, 12-, and 15-lipoxygenase pathways) could be used. I f
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co-treatment with NDGA inhibits the stimulation o f 11 (3HSD activities by hCG and 
IL -lp , it would be suggestive o f lipoxygenase products playing a mediatory role to 
increase 11 pHSD activities.
Since exogenous prostaglandins do not affect 1 lpHSD enzyme activities (Chapter 5) 
and the potential kinase regulatory sites o f 1 lpH SD l are orientated to the lumen o f 
the smooth ER (Chapter 7), it seems likely that the cellular mechanisms by which 
prostaglandins can regulate lipH S D  activities involve allosteric regulation. To 
investigate the possibility that prostaglandins are allosterically regulating 11 pHSD, 
studies using liver microsomes could be carried out. The microsomes could be used 
as a source o f 1 lpHSD l enzyme, and the direct effects o f prostaglandins could be 
assessed using radiometric conversion assays. A caveat to this study is that i f  no 
stimulation is seen, then this could be due to accessibility problems, as 
prostaglandins are normally generated on the lumenal side o f the ER (and nucleus) 
by PGHS, whereas exogenous prostaglandins would be added on the cytosolic face 
o f the microsomes. Therefore the addition o f exogenous prostaglandins might not be 
able to penetrate the microsomal membrane, as may be the case with the intact 
human granulosa-lutein cell system. Alternatively, binding studies could be carried 
out using liver microsomes or HEK-293 cells stably transfected with 1 lpH SD l. 
Tritiated prostaglandins could be added to the system, and bound verses free 
prostaglandins could be quantified. A control to this experiment would be to repeat 
the same experimental design with mock transfected HEK-293 cells.
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More sophisticated techniques could be used to further dissect whether 
prostaglandins can allosterically regulate 11 PHSD. For example, binding studies 
could also be carried out using affinity chromatography. A ffin ity  columns could be 
generated with prostaglandins and purified 1 lpH SD l protein could be loaded onto 
the column to assess binding o f the 1 lpHSD l to the immobilised prostaglandins. X- 
ray crystallography could also be used to determine whether prostaglandins interact 
with 1 lpH S D l. Crystals could be formed in the absence and presence o f 
prostaglandins and a conformational change in lip H S D l structure would be 
observed i f  the mechanism o f regulation was allosteric.
Further studies could be carried out to elucidate the mechanisms by which hCG and 
IL - lp  stimulate 1 lpHSD l activities. The signalling pathways through which the 
hormones are mediating the response could be dissected using pharmacological tools 
such as inhibitors and receptor agonists and antagonists and kinase 
activators/inhibitors. The use o f such agents would enable each step o f signalling 
pathways to be investigated starting from receptor, to second messenger generation, 
protein kinase activation, and initiation/inhibition o f transcription/translation.
A  mechanism o f emerging importance is that o f co-factor balance regulating the 
predominant direction in which the enzyme acts. As noted earlier, co-operativity is 
thought to exist between 1 lpHSD l and H6 PDH within the lumen o f the ER. H6 PDH 
catalyses the conversion o f hexose-6 -phosphate to 6 -phosphogluconate which 
requires NADP+ conversion to NADPH. Thus altering the co-factor balance o f the 
lumen o f the ER in favour o f 11KSR activity o f enzyme [Atanasov et aL, 2004;
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Banhegyi et al., 2004]. However, it is important to acknowledge that human 
granulosa-lutein cells are steroidogenic, and as such, have a high demand for 
NADPH in the lumen o f the smooth ER. This reductant co-factor is required for the 
activities o f steroidogenic cytochrome P450 and HSD enzymes such as CYP17, 
CYP19, and 17pHSDl. The combined activities o f these enzymes w ill result in the 
oxidation o f NADPH to NADP+, hence, increasing the NADP+:NADPH ratio within 
the lumen o f the smooth ER (Figure 8.1). The direction o f the enzyme has been 
questioned in steroidogenic gonadal cells with a predominant oxidative direction o f 
1 lpH SD l reported in both Leydig cells [Gao et al., 1997s; Ge et al., 1997; Ge and 
Hardy 2000] and human granulosa-lutein cells [Michael et al., 1997], suggesting that 
the co-factor balance may be different in steroidogenic cells. As suggested in Figure 
8 .1 , it seems likely that within steroidogenic cells, the activity o f steroidogenic 
enzymes increases the availability o f NADP+ to favour the oxidative activity o f 
lip H S D l, in much the same way as H6PDH can generate NADPH to favour the 
11KSR activity.
When comparing data obtained from each Chapter o f this thesis, it is noteworthy that 
each o f the regulatory compounds differentially regulate the activities o f 1 lpH SD l. 
The regulatory components o f human FF appear to regulate both the 11 pDH and the 
11KSR activities o f 1 lpHSD l with equal affinities. Inhibition o f progesterone and 
prostaglandins production appears to predominantly regulate the 11 KSR activity o f 
1 lpH S D l. Whereas, hCG and IL - lp  appear to predominantly increase the 1 lpD H
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Figure 8.1: Steroidogenic pathways utilis ing N A D P (H ) in  human granulosa-lutein cells
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activity o f 1 lpH S D l. These data remain un-reconcilable, and perhaps question 
whether the 1 lpD H  and the 11KSR activities reside in a single protein. However, the 
recent deposition o f the sequence for a third isoform o f lipH S D  in the NCBI 
database may resolve this quandary, and on publication o f the biochemical, and 
physiological data for llpHSD3, may provide a mechanism to reconcile these 
differences in the regulation o f 1 lpHSD l activity.
This thesis concludes that there are endogenous lipid regulators o f 11 PHSD activities 
but not expression in hFF and human granulosa-lutein cells. Hydrophobic factors 
contained in hFF can inhibit NADP(H)-dependent lip H S D  activities, without 
effecting 1 lpHSD l expression. Inhibition o f steroidogenesis using AG, inhibits 
progesterone production, which can suppress 11 pHSD activities in human granulosa- 
lutein cells. Inhibition o f endogenous progesterone secretion relieves this inhibition 
without effecting 1 lpH SD l protein expression. Both hCG and IL - ip  can increase 
prostaglandin synthesis in human granulosa-lutein cells. The increase in 
prostaglandin synthesis may mediate an increase in 1 lpH SD l activities, but not 
protein expression. This suggests a possible positive feedback mechanism by which 
inflammatory effectors o f ovulation such as cytokines and LH, through up-regulating 
PGHS2 and prostaglandin production can increase cortisol production, which may 
then lim it the inflammatory event o f ovulation (Figure 8.2).
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Figure 8.2 Proposed mechanism by which PGs and progesterone regulate 11HSD activities. Red arrows= thesis findings, Black 
arrows= hypothesised mechanisms
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Appendix I
A. 60% Percoll Density Gradient Solution
Reagent/Solution Volume per 15ml
Percoll 9ml
PBS 5ml
1.5M NaCl (filter sterilised) 1ml
B. PAS-Gelatin Buffer for Progesterone R1A at pH 7.0
Reagent Mass (g/1)
NaH2P04 .2H20 0 . 6
Na2HPO4 .12H20 2 . 2
NaCl 9.0
NaN3 1 . 0
Gelatin 1 . 0
C. Tris Buffer for Prostaglandin R1A at p f17.4
Reagent Mass (g/1)
Gelatin 1
Tris HC1 6.61
NaN3 0 . 2
Tris Base 0.97
D. Lysis Buffer for Rat Kidney Homogenate assay at pH 7.4
Reagent Mass (g/1)
Trizma Base 0 . 6
MgCl2 0.3
EDTA 0 . 6
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E. Lysis Buffer for Protein preparation for SDS-PAGE gel electrophoresis
Reagent Quantity
76.5mM Tris pH 6 . 8 83ml
SDS 2 g
Glycerol 1 0 ml
F. Transfer Buffer for Western Blot X I0
Reagent
390mM glycine
480nM Tris
0.375% (w/v) SDS
G. Transfer Buffer for Western Blot X I
Reagent Quantity
Transfer buffer X10 1 0 0 ml
Methanol 2 0 0 ml
dH20 700ml
H. TBST (Tris buffered saline-Tween) for Western Blot pH 6.7 X I0 
Reagent
500mM Tris
I.5M  NaCl 
0.2% Tween
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I. Samples Buffer for SDS-PAGE electrop loresis
Reagent Quantity
dH20 7.25ml
0.5M Tris HC1 (pH 6 . 8 1.25ml
Glycerol 1ml
(3-mercaptoethanol 0.5ml
SDS 0 .2 g
Bromophenol blue O.Olg
J. 10% resolving gel for reducing SDS-PAGE gel
Reagent Quantity
BDH Ultrapure water 19.8ml
30% Polyacrylamide 16.7ml
Tris-HCl (pH 8.4) 12.5ml
10% SDS (w/v) 500pl
10%(NH4)2S2O8 500pl
TEMED 2 0 pl
K. 4% stacking gel for reducing SDS-PAGE gel
Reagent Ouantitv
BDH Ultraoure water 1 2 .2 ml
30% Polvacrvlamide 2 .6 ml
Tris-HCl <t>H 6 .8 ) 5ml
10% SDS tw/v) 2 0 0 (ll1
1 0 % 125ul
TEMED 25 ul
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L. Stripping buffer for removal o f bound antibody from Western blots
Reagent Quantity
p-mercaptoethanol 700pl
SDS 2 g
62.5mM Tris-HCl (pH 6.7) 1 0 0 ml
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Type 1 11J3HSD : PROTEIN sequences 
Human ( 292 aa )
M A F M K K Y L L P  
G A S K G IG R E M  
L G A A S A H Y IA  
I T N T S L N L F H  
S N G S IV V V S S  
Y S V S R V N V S I  
C A L E I I K G G A
IL G L F M A Y Y Y
AYHLAKMGAH
G TM E D M TFA E
D D IH H V R K S M
LA G K V A YP M V
T L C V L G L I D T
LR Q E E V Y Y D S
S T S Y N M D R F I
Y S A N E E F R P E
V V V T A R S K E T
QFVAQAGKLM
E V N F L S Y V V L
A A Y S A S K F A L
E T A M K A V S G I
S L W T T L L IR N
NK
M L Q G K K V IV T
L Q K V V S H C L E
G G L D M L IL N H
TV A A LP M LK Q
D G F F S S IR K E
VHMQAAPKEE
P C R K IL E F L Y
M A F M K K Y L L P IL G L F M A Y Y Y Y S A N E E F R P E M L Q G K K V IV T G A S K G IG R E M A Y H L A K  
M G A H V V V T A R S K E T L Q K V V S H C L E L G A A S A H Y IA G T M E D M T F A E Q F V A Q A G K L M G G  
L D M L I L N H IT N T S L N L F H D D IH H V R K S M E V N F L S Y V V L T V A A L P M L K Q S N G S IV V V  
S S L A G K V A Y P M V A A Y S A S K F A L D G F F S S IR K E Y S V S R V N V S IT L C V L G L ID T E T A M  
K A V S G IV H M Q A A P K E E C A L E I IK G G A L R Q E E V Y Y D S S L W T T L L IR N P C R K IL E F L Y  
S T S Y N M D R F IN K
Squirrel Monkey (291 aa )
M A F M K T H L L P  
G A S K G IG R E M  
L G A A S A H Y IA  
I T N T S L N F F H  
S N G S I V I V S S  
Y L M S E V N V S I  
C A L E I I K G G V  
S T S Y S T D G L I
IL G L F M A Y Y Y
A YHLAKM GAH
G TM E D M TFA E
D D IH H V R K S M
V A G K V A Y P M I
T L C V L G L I D T
L R Q E E V Y Y D R
N
Y S A Y E E F R P E
V V V T A R S K E T
QFVAQAGKLM
E V N F L S Y V V L
S A Y S A S K F A L
D T A M K A V S G I
S L W T T L L L R N
M L Q G K K V IV T
LQ K V V S H C L E
G G L D M L IL N H
TVAAMPMLKQ
Y G F F S S IR K E
IK M Q A A R K E E
P S R K IL E F L R
M A F M K T H L L P IL G L F M A Y Y Y Y S A Y E E F R P E M L Q G K K V IV T G A S K G IG R E M A Y H L A K  
M G A H V V V T A R S K E T L Q K V V S H C L E L G A A S A H Y IA G T M E D M T F A E Q F V A Q A G K L M G G  
L D M L IL N H IT N T S L N F F H D D IH H V R K S M E V N F L S Y V V L T V A A M P M L K Q S N G S IV IV  
S S V A G K V A Y P M IS A Y S A S K F A L Y G F F S S IR K E Y L M S E V N V S IT L C V L G L ID T D T A M  
K A V S G I IK M Q A A R K E E C A L E I IK G G V L R Q E E V Y Y D R S L W T T L L L R N P S R K IL E F L R  
S T S Y S T D G L I N
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Pig ( 292 aa )
M A F M K K Y L L P  
G A S K G IG R E M  
L G A S S A H Y V A  
IT Q A F M T S V Y  
S N G S IV V V S S  
Y S V T K V N V S I  
C A L E I I K G A A
I L G I F L A Y Y Y
A YHLARM GAH
GTM E D M TFA E
D D IH L V R R S M
QAGKMANPLV
T L C I L G L I D T
L R Q E E V Y Y D S
Y S A N E E F R P E  
V V V T A R S E E T  
Q FVA K A G K LL  
E V N F L S Y V V L  
A P Y S A S K F A L  
D T A M T A V A G I  
S I L T S L L L E N  
IFT  NN
M L R G K K V IV T
L K K V V S H S L E
G G L D M L IL N H
SVA A LPM LK Q
D G F F S S IT K E
LN V Q P S P K E E
P G R K IL E F L S
M A F M K K Y L L P  I L G I  F L A Y  Y Y Y S A N E E F R P E M L R G K K V IV T G A S K G IG R E M A Y H L A R  
M G A H V V V T A R S E E T L K K V V S H S L E L G A S S A H Y V A G T M E D M T F A E Q F V A K A G K L L G G  
L D M L IL N H IT Q A F M T S V Y D D IH L V R R S M E V N F L S Y V V L S V A A L P M L K Q S N G S IV V V  
S S Q A G K M A N P L V A P Y S A S K F A L D G F F S S IT K E Y S V T K V N V S IT L C IL G L ID T D T A M  
T A V A G IL N V Q P S P K E E C A L E I IK G A A L R Q E E V Y Y D S  S I L T S L L L E N  P G R K IL E F L S
LR H Y N M E R FTN N
Cow ( 292 aa )
M A F M K K Y L L P  
G A S K G IG R E M  
L G A A S A H Y V A  
IH Y T P L G V F S  
T N G S I V V V S S  
Y E A T K V N V S I  
C A L E I I K G G T
I L G I F L A Y Y Y
A YH LAR M GA H
G T M E N M T FA E
N D I H L L R R T L
I A G K I A C P L V
T L C I L G L I D T
L R Q D E V Y Y D S
Y S A N E E F R P E  
V V V T A R S E E S  
Q F V A K A G E LV  
E V N L L S Y V V L  
A A Y S A S K F A L  
D TA M K A V A G I  
S I L T P L L L R N  
LFI NN
M L R G K R V IV T
L K K V V S R C L E
G G L D M L IL N H
STA A LPM LK Q
DG FFS S LRM E
FN A KA SPK EE
P G R K IM E F F F
M A F M K K Y L L P  I  LG IF L A Y Y Y Y S A N E E F R P E M L R G K R V IV T G A S K G IG R E M A Y H L A R  
M G A H V V V T A R S E E S L K K V V S R C L E L G A A S A H Y V A G T M E N M T F A E Q F V A K A G E L V G G  
L D M L IL N H IH Y T P L G V F S N D I H L L R R T L E V N L L S Y V V L S T A A L P M L K Q T N G S IV V V  
S S IA G K IA C P L V A A Y S A S K F A L D G F F S S L R M E Y E A T K V N V S IT L C I L G L ID T D T A M  
K A V A G I F N A K A S P K E E  C A L E I  IK G G T L R Q D E V Y Y D S  S IL T P L L L R N  P G R K IM E F F F  
L K K Y N M E R F IN N
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Sheep ( 290 a a )
M A F M K K Y L L P  I L G L F L A Y Y Y  
G A S K G IG R E M  AYH LAR M G A H  
L G A A S A H Y V A  G TM E N M TFA E  
IN Y T P L R V F S  N D I H L L R R S L  
T S G S I V V V S S  V A G K IA C P L A  
Y E A T K V N V S I  T L C I L G L I D T  
L E I I K G G A L R  Q D E V Y Y D N S I
Y S A N E E F R P E
V V V T A R S E E S
Q FV A K A G E LV
E V N L L S Y V V L
A A Y S A S K F A L
D TA M K A V A G I
L T S L L L K N P G
M L R G K R V IV T
LK K V V S R C L E
G G L D M L IL N H
STA A LPM LK Q
D G F F S S L R T E
Y NA E A S P K E E
R K IM E F L S L K
K Y N M E R F IN N
M A F M K K Y L L P IL G L F L A Y Y Y Y S A N E E F R P E M L R G K R V IV T G A S K G IG R E M A Y H L A R  
M G A H V V V T A R S E E S L K K V V S R C L E L G A A S A H Y V A G T M E N M T F A E Q F V A K A G E L V G G  
L D M L IL N H IN Y T P L R V F S N D I H L L R R S L E V N L L S Y V V L S T A A L P M L K Q T S G S IV V V  
S S V A G K I  AC P LA A A Y S  AS K F A L D G F F S S L R T E  Y E A T K V N V S  I T L C I L G L I D T D T A M  
K A V A G I Y N A E A S P K E E  L E I  IK G G A L R Q D E V Y Y D N S IL T S L L L K N P G R K IM E F L S L K  
K Y N M E R F IN N
Cat -  PARTIAL ( Partial = 193 aa )
. . . V IV T G A S K G IG E Q M A Y H L A K M G A H V V V T A R S K E N L K K IV S H C M E L G A A S A H Y I  
A G T M E N M T F A E Q F V A K A G K L M G G L D M L IL N H IT N T S M N L F S G D IH IV R R S M E V N F L  
S Y V V L S A T A L P M L K Q S N G S IV V V S S K A G K M A S P L IA P Y S A S K F A L D G F F S S IR M E H  
S V A K I N V S I T L C I L G L I N T D T A M N A I S G . . .
V I V T G A S K G IG E Q M
V V V T A R S K E N
G T M E N M TFA E
IT N T S M N L F S
S A T A LP M L K Q
A P Y S A S K F A L
T L C I L G L I N T
A Y H LA K M G A H  
L G A A S A H Y IA  
G G L D M L IL N H  
E V N F L S Y V V L  
K A G K M A S P L I  
H S V A K I N V S I
L K K IV S H C M E  
QFVAKAGKLM  
G D IH IV R R S M  
S N G S IV V V S S  
D G F F S S IR M E  
D T A M N A IS G .
303
Rabbit (291 a a )
A F M K K Y L L P L  
A S K G I G K E I A  
G A A S A H Y IA G  
T N A S L M F F N N  
N G S IV V V S S L  
A L T N V N V S I T  
A L E I I K G G A L
L G L F L A Y Y Y Y
FHLA KM G AH V
T M E D M TF A E Q
D IH H V R K E M E
A G K I A H P L I A
L C V L G L ID T D
R Q D E V Y Y G N L
S A N E E FR P E M  
V V T A R S K E T L  
FVAKAGKLMG  
V N F L S Y V V L T  
P Y S A S K F A L D  
T A M K E V S G K I  
Q W TP LLLG N P  
LVN N
L Q G K K V IV T G
Q E V V A H C L K L
G L D M L IL N H I
VAALPM LKQS
G F F S A IR K E H
DMKAAPKEEC
G K R L IE F L H L
A F M K K Y L L P L L G L F L A Y Y Y Y S A N E E F R P E M L Q G K K V IV T G A S K G IG K E IA F H L A K M  
G A H V V V T A R S K E T L Q E V V A H C L K L G A A S A H Y IA G T M E D M T F A E Q F V A K A G K L M G G L  
D M L IL N H IT N A S L M F F N N D IH H V R K E M E V N F L S Y V V L T V A A L P M L K Q S N G S IV V V S  
S L A G K IA H P L IA P Y S A S K F A L D G F F S A IR K E H A L T N V N V S IT L C V L G L ID T D T A M K  
E V S G K ID M K A A P K E E C A L E I IK G G A L R Q D E V Y Y G N L Q W T P L L L G N P G K R L IE F L H L
R K F D IS K L V N N
Guinea pig ( 300 aa
M A F L K K Y L L T  
G A S K G IG R E I  
L G A A S A H Y IA  
V L Y N R L T F F H  
S Q G S IA V V S S  
F L V N K V N V S I  
C A L E I I K G T A  
A A E Y N W D N V L
I L M V F L A Y Y Y
A YH LA K M G A H
G S M E D M T FA E
G E ID N V R K S M
V A G K I T Y P L I
T L C I L G L I D T
L R Q D E M Y Y V G
SNE K LY G R W A
Y P A N E K F R P E
V V V T A R S K E A
E FA A EA G N LM
E V N F H S F V V L
A P Y S A S K F A L
E T A I K A T S G I
SRW VPYLLGN
M L Q G K K V IV T
L Q K VV A R C LE
G G L D M L IL N H
SVAAMPMLMQ
D G F F S T L R S E
Y LG P A S P K E E
P G R K IM E F L S
M A F L K K Y L L T  I L M V F L A Y Y Y Y  P A N E K F R P E M L Q G K K V IV T G A S K G IG R E IA Y H L A K  
M G A H V V V T A R S K E A L Q K V V A R C L E L G A A S A H Y IA G S M E D M T F A E E F A A E A G N L M G G  
L D M L IL N H V L Y N R L T F F H G E ID N V R K S M E V N F H S F V V L S V A A M P M L M Q S Q G S IA V V  
S S V A G K I T Y P L I A P Y S A S K F A L D G F F S T L R S E F L V N K V N V S I T L C I L G L I D T E T A I  
K A T S G I  Y L G P A S P K E E  C A L E I  IK G T A L R Q D E M Y Y V G S R W V P Y L L G N  P G R K IM E F L S  
A A E Y N W D N V L S N E K L Y G R W A
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Hamster ( 292 a a )
M H FM K K YLL P  
G A S K G IG R E M  
L G A A S A H Y IA  
IT Y T S M N F F R  
S N G S IV V V S S  
H G V T N V N V S I  
C A L E I IK G G A
IL V L F L A Y Y Y
AYHLSEMGAH
GTMEDMTFAE
D E IH A L R K A M
IA G K M A H P L V
T L C V L G L IN T
LR Q E E V Y Y D S
Y S T K E E F R P E  
V V L T A R S E E G  
Q FV LK A G K LM  
E V N F IS Y V V M  
A S Y S A S K F A L  
E TA M K A TS G V  
W S W T P IL L G N  
:l i  SS
M L Q G K K V IV T
L Q K VA S R C LE
G G L D M L IL N H
SVA A LPM LK Q
D G F FS S L R R E
FN A P A S P K E E
P G R K IM E F L S
M H F M K K Y L L P IL V L F L A Y Y Y Y S T K E E F R P E M L Q G K K V IV T G A S K G IG R E M A Y H L S E  
M G A H V V L T A R S E E G L Q K V A S R C L E L G A A S A H Y IA G T M E D M T F A E Q F V L K A G K L M G G  
L D M L IL N H IT Y T S M N F F R D E IH A L R K A M E V N F IS Y V V M S V A A L P M L K Q S N G S IV V V  
S S IA G K M A H P L V A S Y S A S K F A L D G F F S S L R R E H G V T N V N V S IT L C V L G L IN T E T A M  
K A T S G V F N A P A S P K E E C A L E I IK G G A L R Q E E V Y Y D S W S W T P IL L G N P G R K IM E F L S
M K S F T F D K L IS S
Rat ( 287 aa )
M K K Y L L P V L V  
G IG R E M A Y H L  
S A H Y IA G T M E  
T M S L F H D D IH  
I A I I S S M A G K  
K V N V S I T L C V  
IK G T V L R K D E
L C L G Y Y Y S T N
S K M G A H VV LT
D M T F A E R F V V
S V R R S M E V N F
M T Q P L IA S Y S
L G F I D T E T A L
V Y Y D K S P W T P
EEFR PEM LQ G
A R S E E G LQ K V
EAG K LLG G LD
L S Y V V L S T A A
A S K F A L D G F F
K E T S G I I L S Q
L L L G N P G R R I
K K V IV T G A S K
V S R C LE L G A A
M L I L N H I T Q T
LPMLKQSNGS
S T IR K E H L M T
A APKQ E C A LE
M E F L S L R S Y N
M K K Y L L P V L V L C L G Y Y Y S T N E E F R P E M L Q G K K V IV T G A S K G IG R E M A Y H L S K M G A H  
V V L T A R S E E G L Q K V V S R C L E L G A A S A H Y IA G T M E D M T F A E R F V V E A G K L L G G L D M L  
IL N H IT Q T T M S L F H D D IH S V R R S M E V N F L S Y V V L S T A A L P M L K Q S N G S  I A I  IS S M A  
G K M T Q P L IA S Y S A S K F A L D G F F S T IR K E H L M T K V N V S IT L C V L G F ID T E T A L K E T S  
G I IL S Q A A P K Q E C A L E IK G T V L R K D E V Y Y D K S P W T P L L L G N P G R R IM E F L S L R S Y N
R D L F V S N
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Mouse ( 292 aa)
M A VM K N YLLP  
G A S K G IG R E M  
L G A A S A H Y IA  
I T Q T S L S L F H  
S N G S I A V I S S  
L Y I T K V N V S I  
C A L E I I K G T A
IL V L F L A Y Y Y
AYHLSKMG AH
G TM EDM TFAE
D D IH S V R R V M
L A G K M TQ P M I
T L C V L G L ID T
LR K S E V Y Y D K
Y S T N E E F R P E
V V L T A R S E E G
Q F IV K A G K L M
E V N F L S Y V V M
A P Y S A S K F A L
E T A M K E IS G I
S P L T P IL L G N
M L Q G K K V IV T
L Q K V V S R C L E
G G L D M L IL N H
S TA A LP M LK Q
D G F F S T IR T E
IN A Q A S P K E E
P G R K IM E F F S
LR YY N K D M FV  SN
M A V M K N Y L L P IL V L F L A Y Y Y Y S T N E E F R P E M L Q G K K V IV T G A S K G IG R E M A Y H L S K  
M G A H V V L T A R S E E G L Q K V V S R C L E L G A A S A H Y IA G T M E D M T F A E Q F IV K A G K L M G G  
L D M L IL N H IT Q T S L S L F H D D IH S V R R V M E V N F L S Y V V M S T A A L P M L K Q S N G S IA V I  
S S L A G K M T Q P M IA P Y S A S K F A L D G F F S T IR T E L Y IT K V N V S IT L C V L G L ID T E T A M  
K E I S G I I N A Q A S P K E E C A L E I I K G T A L R K S E V Y Y D K S P L T P I L L G N P G R K I M E F F S
LRYY N K D M FVS N
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Appendix III
Standard curve for a PGE2 radioimmunoassay
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Standard  curve for a  P G F 201 rad io im m unoassay
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Standard  curve for a  P rogesterone  rad io im m unoassay
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Personal communication with Huang, received on 16/06/04:
Dear Dr. Kim  Jonas,
I am very glad to hear from you.
Now I tell you some information about the gene 1 l-beta-HSD3.
This gene is homologous to HSD11B1 and HSD11B2. We have cloned this gene in 
human brain tissue designed SCDR10. its homolgs in Macaca fascicularis, Bos 
taurus, Gasterosteus aculeatus, Danio rerio, Gallus gallus and Oryzias latipes were 
also cloned.
We have studied gene SCDR10 in detail, including northern blotting, protein 
expression and purification ,enzyme activity assay, the mAb was also produced by 
immuning rabbit and the immunohistochemistry analysis was also done.
I am very regretful I could not tell you the detailed result at present Because we are 
writting a paper to report this gene. When our manuscript is accepted I w ill send you 
a copy in time.
I f  have chance we can cooperate. I am sure this gene is very important in human.
Best regards
Chaoqun Huang 
Department o f biochemistry 
and molecular biology 
Suzhou university 
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